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TDiscovery and Development of Novel Therapeutic Agents for Advanced
Melanoma
Abstract
Malignant melanoma is the most dangerous form of skin cancer and accounts for about 75% of skin
cancer deaths. Once diagnosed at the metastatic stage, it has a very poor prognosis with a median
survival rate of 6 months and a 5-year survival rate of less than 5%. In addition, melanoma has become an
important public health hazard owing to its rising incidence, which has been well documented over the
past 50 years. Currently there is no effective way to treat melanoma. It is highly resistant to existing
chemotherapy, radiotherapy, and immunotherapy. Over the past 30 years, only two drugs have been
approved by the Food and Drug Administration (FDA) for metastatic melanoma: dacarbazine (DTIC) and
interleukin-2 (IL-2). But even with these two drugs, fewer than 15% of patients have a favorable response
and fewer than 5% of patients reach complete remission. On the other hand, the toxicity associated with
DTIC and IL-2 is often significant, resulting in serious or life threatening side effects in many patients. In
recent years, great efforts have been made in fighting metastatic melanoma. But neither combinations of
DTIC with other chemotherapy drugs (e.g., cisplatin, vinblastine, and carmustine) nor adding interferonα2b to DTIC have shown a survival advantage over DTIC treatment alone. Extensive clinical trials with a
lot of antibodies and vaccines to treat metastatic melanoma have also failed to demonstrate satisfactory
efficacy. Therefore, developing more effective drugs for melanoma is urgently needed.
We started our efforts in finding new drugs for melanoma by screening a large compound library. The in
vitro cytotoxicity data on several melanoma cell lines led us to the discovery of three active structure
scaffolds: serine amides, serine amino alcohols, and arylthiazolidine-4-carboxylic acid amides (ATCAAs).
Because ATCAAs showed better selectivity between cancer cells and normal fibroblast cells, the chemists
in our group focused on this scaffold and performed extensive structure modifications for structureactivity-relationship (SAR) studies. The SAR results were then used to guide further synthesis in an effort
to maximize activity and selectivity. Two active compounds identified during the process were sent to the
U.S. National Cancer Institute for anticancer screening using 60 human tumor cell lines. Results showed
that these two compounds have extensive cytotoxic activity against all nine types of cancer cells with
IC50values ranging from 120 nM (leukemia, CCRF-CEM cell line) to 11 μM (colon cancer, HCC-15 cell line).
One compound showed particularly good activity against melanoma cells (IC50=130 nM~1 mM against
all eight melanoma cell lines). I then evaluated ATCAAs inhibitory effect on melanoma colony formation
and in vivo melanoma tumor growth. The in vivo data were very encouraging. One tested compound
significantly inhibited melanoma tumor growth at a dose of 10 mg/kg and showed higher efficacy than
did DTIC at a dose of 60 mg/kg. These findings built up a strong basis for the development of novel
chemotherapeutic drugs for advanced melanoma.
Furthermore, the chemists in our group also synthesized some new imidazole and imidazoline analogs by
focusing on the SAR studies of the central five-member ring. Although the current compounds displayed
lower potency when compared with our lead thiazolidine analogs, they may have the distinct advantage of
being more stable in vivo with the reduced necessity of chiral separations. Some of these new
compounds have activity similar to Sorafenib, an FDA-approved drug that has been tested clinically in
melanoma patients.
To further expand our understanding of SARs and to potentially identify new platforms for active
compounds, Dr. Li and Dr. Seibel explored a compound library from the University of Cincinnati’s Drug
Discovery Center. This library contains 342,910 small molecules. Based on the structure of our lead
molecule, two ligand-based virtual screening approaches were used: 1) similarity search based on atom
connectivity by using Scitegic Pipeline Pilot software and 2) similarity search based on molecular shape

by using Schrodinger software. Results showed that these two approaches are highly complementary and
lead to different active molecular structures. These structures are quite suitable for further structural
modification and provide new platforms for our anticancer drug discovery efforts.
Subsequently, further lead structure optimization led to the discovery of substituted methoxylbenzoyl-arylthiazole (SMART) compounds. To improve solubility and to circumvent the metabolic instability brought
by the thiazole ring, our team designed and synthesized a new series of analogs: 2-aryl-4-benzoylimidazoles (ABIs). These two classes of compounds showed great in vitro cytotoxicity against
melanoma, and the IC50 of the most active compound was below 10 nM. They also showed equal
potency against multi-drug resistant melanoma cells and the sensitive parent cells, indicating that these
compounds can effectively overcome multi-drug resistance, which is a major cause of cancer
chemotherapy failure. In vivo testing on C57BL/6 mice bearing B16-F1 melanoma allograft and on double
homozygous SCID (severe combined immunodeficiency) hairless outbred (SHO) mice or athymic nude
mice bearing A375 human melanoma xenograft showed these two classes of compounds significantly
inhibited melanoma tumor growth. Some compounds even showed substantially better activity than did
DTIC, the gold standard anti-melanoma drug. Meanwhile, preliminary toxicity studies suggested that mice
can tolerate tested compounds well at effective dose levels. No sign of acute toxicity was observed from
the experiments. More importantly, I identified the cellular target for ABI and SMART compounds through
a series of biotechniques and molecular modeling studies. Strong experimental evidence has shown that
these compounds bind to tubulin at the colchicine binding site in the α/β-tubulin heterodimers to disrupt
functional microtubule formation. In the meantime, I also tested the pharmacokinetic properties of some
active compounds in mice together with Mr. Chien-ming Li. With their good in vivo anti-melanoma activity
and their ability to overcome multi-drug resistance, these new classes of compounds have great potential
for melanoma therapy.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Pharmaceutical Sciences

Research Advisor
Wei Li, Ph.D.

Keywords
Melanoma, tubulin, inhibitor, multi-drug resistance, imidazole, thiazole

Subject Categories
Medicinal and Pharmaceutical Chemistry | Medicine and Health Sciences | Pharmaceutics and Drug
Design | Pharmacy and Pharmaceutical Sciences

Comments
Two year embargo expired May 2010

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/281

DISCOVERY AND DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS
FOR ADVANCED MELANOMA

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Doctor of Philosophy
From The University of Tennessee

By
Zhao Wang
May 2010

Portions of Chapter 2 © 2007, 2008, and 2009 by Elsvier Ltd.
Chapter 3 and portions of Chapter 4 © 2009 by American Chemical Society.
All other material © 2010 by Zhao Wang.
All rights reserved.

ii

DEDICATION
To
My parents,
My wife, Rui Zhu
And
My daughter, Sophia Z. Wang
For
Their endless love and continuous support

iii

ACKNOWLEDGMENTS
I could never have completed this daunting task without the help, support,
guidance and efforts from a lot of people. First and foremost, I would like to express my
deepest gratitude and sincere appreciation to my mentor Dr. Wei Li for providing me
with an opportunity to work in his lab and instilling in me the qualities of being a good
scientist. His co-operation and continued support have been major driving forces through
my graduate career at the University of Tennessee. I would also like to thank my
committee members, Drs. Miller, Slominski, Meibohm and Kim for their invaluable
suggestions, guidance and assistance over the years. I would like to especially
acknowledge Dr. Miller for providing me with the compounds and continuous
encouragement and support on the group meetings we held together. I am also very
grateful for Dr. Slominski in providing the initial training for me to start and the
following continuous support in biological studies. My dissertation work would not have
been possible without the kind help from all the committee members.
I would like to thank Dr. Yan Lu, Mr. Jianjun Chen and Dr. Veeresa Gududuru
for synthesizing compounds for my studies. Without their excellent work in synthesizing,
I will have nothing to discover. A special thank you to the members in Dr. Andrzej
Slominski’s group at the University of Tennessee, Drs. Blazej Zbytek, Zorica Janjetovic,
and Michael Zmijewski for their support, help and encouragement. I thank Dr. Meibohn
and Dr. Nageshwar Rao Budha for their great help in drug metabolic stability studies. I
thank Dr. David Hamilton for his warm help in the animal experiments. I thank Drs.
Vivian S. Loveless and Christina Barrett for their great help in the tubulin colchicine site
binding assay. I thank Dr. Bob M. Moore II and Dr. Steven Gurley for their help in taking
microtubule images. I thank Dr. George C. Wood, Mr. Vinayagan Kannan and Dr. Wen
Qu for their help in foumulation area. I thank Mr. Kui Zeng for his training in LC/MS. I
also thank Dr. David Armbruster at the University of Tennessee Health Science Center
library for his repeated and prompt editorial assistance during our publication efforts. I
thank the kind help from Dr. William Seibel for ligan-based virtual screening studies. I
also enjoy working with Chien-Ming Li in the PK studies and sharing the results of some
biological studies.
I acknowledge the support of the Alma and Hal Reagan Fellowship for the
academic years of 2007-2009. I really appreciate the College of Graduate Health
Sciences in the University of Tennessee Health Science Center for providing the students
with this fellowship as well as lots of travel awards which have supported us greatly in
attending important scientific meetings. I am especially grateful for Dr. Donald B.
Thomason who has promptly approved my applications for travel awards for several
times. I would also like to thank the University of Tennessee Health Science Center for
providing me with the opportunity to pursue graduate education.
A special thank you to my friends and colleagues, Feng Zhang, Guo Zhu, Dong
Wang, Fei Ma, Yi Zhang, Li Chen, Renuka Gupte, and Zhiyong Dong for their support
and wonderful company over all these years. I would also like to thank my colleagues
iv

who graduated before me including Wenwei Lin for their guidance and support. They
really made my stay in Memphis a memorable experience.
Last but not least, I would like to thank Drs. Larry Tague and Shirley Hancock for
their great help in format reviewing. Their adherence to perfectionism and great efforts
help our dissertation looks much more professional.

v

ABSTRACT
Malignant melanoma is the most dangerous form of skin cancer and accounts for
about 75% of skin cancer deaths. Once diagnosed at the metastatic stage, it has a very
poor prognosis with a median survival rate of 6 months and a 5-year survival rate of less
than 5%. In addition, melanoma has become an important public health hazard owing to
its rising incidence, which has been well documented over the past 50 years. Currently
there is no effective way to treat melanoma. It is highly resistant to existing
chemotherapy, radiotherapy, and immunotherapy. Over the past 30 years, only two drugs
have been approved by the Food and Drug Administration (FDA) for metastatic
melanoma: dacarbazine (DTIC) and interleukin-2 (IL-2). But even with these two drugs,
fewer than 15% of patients have a favorable response and fewer than 5% of patients
reach complete remission. On the other hand, the toxicity associated with DTIC and IL-2
is often significant, resulting in serious or life threatening side effects in many patients. In
recent years, great efforts have been made in fighting metastatic melanoma. But neither
combinations of DTIC with other chemotherapy drugs (e.g., cisplatin, vinblastine, and
carmustine) nor adding interferon-α2b to DTIC have shown a survival advantage over
DTIC treatment alone. Extensive clinical trials with a lot of antibodies and vaccines to
treat metastatic melanoma have also failed to demonstrate satisfactory efficacy. Therefore,
developing more effective drugs for melanoma is urgently needed.
We started our efforts in finding new drugs for melanoma by screening a large
compound library. The in vitro cytotoxicity data on several melanoma cell lines led us to
the discovery of three active structure scaffolds: serine amides, serine amino alcohols,
and arylthiazolidine-4-carboxylic acid amides (ATCAAs). Because ATCAAs showed
better selectivity between cancer cells and normal fibroblast cells, the chemists in our
group focused on this scaffold and performed extensive structure modifications for
structure-activity-relationship (SAR) studies. The SAR results were then used to guide
further synthesis in an effort to maximize activity and selectivity. Two active compounds
identified during the process were sent to the U.S. National Cancer Institute for
anticancer screening using 60 human tumor cell lines. Results showed that these two
compounds have extensive cytotoxic activity against all nine types of cancer cells with
IC50 values ranging from 120 nM (leukemia, CCRF-CEM cell line) to 11 μM (colon
cancer, HCC-15 cell line). One compound showed particularly good activity against
melanoma cells (IC50=130 nM~1 M against all eight melanoma cell lines). I then
evaluated ATCAAs inhibitory effect on melanoma colony formation and in vivo
melanoma tumor growth. The in vivo data were very encouraging. One tested compound
significantly inhibited melanoma tumor growth at a dose of 10 mg/kg and showed higher
efficacy than did DTIC at a dose of 60 mg/kg. These findings built up a strong basis for
the development of novel chemotherapeutic drugs for advanced melanoma.
Furthermore, the chemists in our group also synthesized some new imidazole and
imidazoline analogs by focusing on the SAR studies of the central five-member ring.
Although the current compounds displayed lower potency when compared with our lead
thiazolidine analogs, they may have the distinct advantage of being more stable in vivo
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with the reduced necessity of chiral separations. Some of these new compounds have
activity similar to Sorafenib, an FDA-approved drug that has been tested clinically in
melanoma patients.
To further expand our understanding of SARs and to potentially identify new
platforms for active compounds, Dr. Li and Dr. Seibel explored a compound library from
the University of Cincinnati’s Drug Discovery Center. This library contains 342,910
small molecules. Based on the structure of our lead molecule, two ligand-based virtual
screening approaches were used: 1) similarity search based on atom connectivity by using
Scitegic Pipeline Pilot software and 2) similarity search based on molecular shape by
using Schrodinger software. Results showed that these two approaches are highly
complementary and lead to different active molecular structures. These structures are
quite suitable for further structural modification and provide new platforms for our
anticancer drug discovery efforts.
Subsequently, further lead structure optimization led to the discovery of
substituted methoxylbenzoyl-aryl-thiazole (SMART) compounds. To improve solubility
and to circumvent the metabolic instability brought by the thiazole ring, our team
designed and synthesized a new series of analogs: 2-aryl-4-benzoyl-imidazoles (ABIs).
These two classes of compounds showed great in vitro cytotoxicity against melanoma,
and the IC50 of the most active compound was below 10 nM. They also showed equal
potency against multi-drug resistant melanoma cells and the sensitive parent cells,
indicating that these compounds can effectively overcome multi-drug resistance, which is
a major cause of cancer chemotherapy failure. In vivo testing on C57BL/6 mice bearing
B16-F1 melanoma allograft and on double homozygous SCID (severe combined
immunodeficiency) hairless outbred (SHO) mice or athymic nude mice bearing A375
human melanoma xenograft showed these two classes of compounds significantly
inhibited melanoma tumor growth. Some compounds even showed substantially better
activity than did DTIC, the gold standard anti-melanoma drug. Meanwhile, preliminary
toxicity studies suggested that mice can tolerate tested compounds well at effective dose
levels. No sign of acute toxicity was observed from the experiments. More importantly, I
identified the cellular target for ABI and SMART compounds through a series of
biotechniques and molecular modeling studies. Strong experimental evidence has shown
that these compounds bind to tubulin at the colchicine binding site in the α/β-tubulin
heterodimers to disrupt functional microtubule formation. In the meantime, I also tested
the pharmacokinetic properties of some active compounds in mice together with Mr.
Chien-ming Li. With their good in vivo anti-melanoma activity and their ability to
overcome multi-drug resistance, these new classes of compounds have great potential for
melanoma therapy.
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CHAPTER 1. LITERATURE REVIEW
1.1 Introduction
Melanoma is a cancer derived from melanocytes which produce pigment called
melanin. This cancerous transformation can be initiated from either localized pre-existing
nevi or de novo, arising from the single melanocyte that is located at the junction of the
epidermis (1). Under normal condition, melanocytes proliferation and migration are
regulated by keratinocytes through direct cell-cell contact or soluble growth factors (2).
Upon malignant transformation, melanoma cells initially have a superficial spreading
(radial growth phase), followed by tumor cells invading the dermis (vertical growth
phase). Then they can advance to a more aggressive metastatic phase in which the tumor
cells can metastasize lymphatically or haematologically to regional and distant sites in the
body (3).
Metastatic melanoma is the most dangerous form of skin cancer, accounts for
about 75% of skin cancer deaths (4). If detected at an early stage, cutaneous melanoma is
curable with complete surgical excision in most patients. But once the disease progresses
in regional or distant sites, it is very difficult to treat. And when disseminated, it is a
devastating illness. Metastatic melanoma has a very poor prognosis, with a median
survival rate of 6~10 months and a 5-year survival rate of less than 5% (5).
Melanoma has become an important public health hazard owing to its rising
incidence as this has been well documented over the past 50 years. There has been a 3 to
7% worldwide annual age standardized incidence increase over the past five decades. The
incidence of melanoma is rising steadily in Western populations. The number of cases
has doubled in the past 20 years. The current lifetime risk is 1.9% for men and 1.37% for
women (6). Melanoma is the fastest rising form of cancer among men and the second
fastest rising form of cancer among women. The overall mortality from melanoma has
increased because of the increase in incidence. Around 160,000 new cases of melanoma
are diagnosed worldwide each year, and it is more frequent in males and Caucasians (7).
According to a WHO Report, about 48,000 melanoma-related deaths occur worldwide
per year. Because melanoma affects young- and middle-aged individuals, the number of
years of life lost to this malignancy is high and exceeds all other adult solid tumors
except testicular carcinoma (8).
1.2 Current Treatment Agents for Metastatic Melanoma
According to the current 6th edition American Joint Committee of Cancer (AJCC)
staging system, melanoma can be pathologically classified to the following stages: 0, IA,
IB, IIA, IIB, IIC, IIIA, IIIB, IIIC, and IV. Stage 0 is in situ melanoma. Stage I and II are
growth phase of localized cutaneous melanoma with increasing thickness. Stage III has
regional involvement of lymph node. Stage IV means distant metastasis. Normally stage
III and IV melanoma are called metastatic melanoma. Localized melanoma is curable
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with complete surgical excision in most patients. But currently there is no effective way
to treat metastatic melanoma. Only two agents in current use have been approved by the
Food and Drug Administration (FDA) for metastatic melanoma: dacarbazine (DTIC) and
interleukin-2 (IL-2). But even with these two drugs, only less than 15% patients have
response and less than 5% patients can reach complete remission. On the other hand, the
toxicity associated with DTIC and IL-2 is often significant, resulting in serious or life
threatening side effects in many of the patients treated.
In this section, I will focus on the usage and performance of DTIC and IL-2 first.
Of cause surgery is often used as a treatment for melanoma whenever a surgical removal
is possible. Radiation therapy is often used after surgical resection for patients with
regionally advanced melanoma or for patients with unresectable distant metastases. But
these two strategies of treatment for metastatic melanoma are beyond the scope of this
review.
1.2.1 Chemotherapy Agent DTIC
Currently DTIC is the only FDA approved chemotherapy drug for metastatic
melanoma. This drug gained FDA approval in May 1975 as DTIC-Dome for the
treatment of metastatic melanoma. It was initially marketed by Bayer. The therapeutic
effect of DTIC is believed to be produced through alkylation of DNA. While its
anticancer mechanism of action is still not fully understood, DTIC is believed to be first
metabolically bioactivated through a series of reactions involving CYP450. Initial
demethylation to MTIC [3-methyl-(triazen-1-yl)imidazole-4-carboxamide] is followed
by formation of diazomethane, the active moiety of DTIC and a potent methylating
agent (9).
DTIC has produced response rates of from 15% to 25% in single-institution trials.
But the overall response rate has fallen over the years from 15% to 7% and less than 5%
of responses are complete in phase 3 trials. The median response durations to DTIC are
5 to 6 months. Long-term follow-up of patients treated with DTIC alone shows that only
<2% can be anticipated to survive for more than 6 years. In recent phase 3 trials that
used strict response assessment criteria, the response rates with single-agent DTIC did
not exceed 12% (10).
Over the past 30 years after its approval by the FDA, DTIC remains the only
currently used cytotoxic drug for the treatment of metastatic melanoma. Despite its low
single-agent activity, DTIC has remained the mainstay of many combination
chemotherapy regimens and evaluations of resistance-reversing agents. After more than
20 years of research, DTIC is still the standard against which most new chemotherapy
agents are compared (11).
As for the dose, it has been demonstrated that 850~1000 mg/m2 single dose of
DTIC is tolerated. This single dose administration appears to deliver clinical
improvements similar to those observed with multiple doses that provide the same total
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dose per cycle. This should be the reference standard for randomized trials comparing
new therapies with DTIC (12).
1.2.2 Immunotherapy Agent IL-2
In 1998, the FDA approved intermittent high-dose bolus IL-2 based on its ability
to mediate durable complete response in metastatic melanoma patients (13). IL-2 is a type
of cytokine immune system signaling molecule, which is a leukocytotrophic hormone
that is instrumental in the body's natural response to microbial infection and in
discriminating between foreign (non-self) and self. It’s a glycosylated 15,500 dalton
single protein molecule. IL-2 mediates its effects by binding to IL-2 receptors, which are
expressed by lymphocytes, the cells that are responsible for immunity. It is one of the
only two FDA approved agents for the treatment of metastatic melanoma. Although the
overall response rate is only about 15% and less than 5% of patients achieve complete
remission with IL-2, its performance on melanoma is better than DTIC.
One of the major immunologic effects of IL-2 upon the immune system is to
expand the total number of T-lymphocytes (CD4+ and CD8+) and to prevent lymphocyte
apoptosis. Another key role of IL-2 is to provide the appropriate cytokine milieu
necessary to overcome tumor-induced immune tolerance. But the exact molecular and
genetic mechanisms involved in this complex interaction between the tumor and the host
immune response is still largely unknown (14).
There is currently a wide spectrum of dosing schedules and regimens for IL-2
therapy, with the current standard used by most oncologists being 600,000 to 720,000
IU/kg/dose, given at 8 h intervals. Although the optimal dosing schedule resulting in the
best clinical response is currently unknown, previous data would suggest that the higher
dose regimens as well as the number of total doses received correlates best with clinical
response. Thus, several groups have begun to look at alternative dosing strategies to
achieve an increased drug tolerance and tolerability profile, such as the continuous
infusion of IL-2 (18 mIU/m2/day) over an extended period of 72 h (15). But the
multiorgan toxicity of many IL-2 regimens limits its use. In addition, the tumor-killing
cytotoxic T cells and natural killer cells, which are the presumed target cells for IL-2, are
frequently inefficient in the tumor environment, partly due to suppressive and apoptosisinducing signals from tumor-infiltrating mononuclear phagocytes (16).
1.3 Recent Research Efforts in the Treatment for Metastatic Melanoma
Because of effective treatment shortage, the prognosis for metastatic melanoma
patients remains very poor. Over the past 30 years, great efforts have been attempted to
search for better agents or strategies to fight this deadly disease. Hundreds of different
stages of clinical trials have been carried out. Although most of them have failed, some
did show very promising results. Some new treatment strategies have resulted in
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paradigm shift in our approach to therapy of melanoma patients. These shining examples
may markedly change our philosophy about melanoma treatment.
1.3.1 Chemotherapy
1.3.1.1 Temozolomide
Temozolomide (TMZ) is an orally active alkylating agent. It’s a prodrug of MTIC
and congener of DTIC. It has been available in the US since August 1999 and in other
countries since the early 2000s. The therapeutic benefit of temozolomide depends on its
ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions
of guanine residues. This methylation damages the DNA and triggers the death of tumor
cells. However, some tumor cells are able to repair this type of DNA damage, and
therefore diminish the therapeutic efficacy of temozolomide, by expressing an enzyme
called O-6-methylguanine-DNA methyltransferase (MGMT) or O-6-alkylguanine-DNA
alkyltransferase (17).
The single agent activity of TMZ in metastatic melanoma has been established in
several phase 1 and 2 studies (18). In a randomized trial of 305 patients with advanced
melanoma, TMZ showed efficacy at least equivalent to that of DTIC in terms of objective
response rate, time to progression, and overall disease-free survival (19). TMZ was
tolerated very well and showed an advantage in terms of improvement in the quality of
life. More patients showed improvement or maintenance of physical functioning at Week
12. That trial excluded patients who had brain metastases. Because the trial design was
intended to demonstrate the superiority of TMZ over DTIC, rather than equivalence, the
FDA did not accept the results of that trial as grounds for approving a melanoma
indication for TMZ. But in clinical practice, patients with metastatic melanoma often are
treated off-label with TMZ.
TMZ has demonstrated efficacy in the treatment of variety of solid tumors,
especially in brain malignancies, which is a manifestation of its far greater ability to
penetrate the central nervous system (CNS). Taking into account the high rate of CNS
recurrence as a site of failure after cytotoxic chemotherapy, TMZ may represent a viable
alternative to DTIC, which is ineffective against melanoma CNS metastases.
1.3.1.2 Sorafenib
Sorafenib (BAY43-9006, developed by Bayer Pharmaceuticals, West Haven CT,
trade name Nexavar) is an orally administered tyrosine kinase inhibitor that is a potent
inhibitor of the B-Raf kinase that is frequently mutated in melanoma, as well as an
inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor and other kinases.
It targets the adenosine triphosphate-binding site of the B-Raf kinase and inhibits both
wild-type and mutant B-Raf in vitro. Sorafenib was approved by the FDA in December
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2005 for use in the treatment of advanced renal cancer. Preclinical studies demonstrated a
significant retardation in the growth of human melanoma tumor xenografts with
Sorafenib. In a phase 1 study, the maximum tolerated dose of Sorafenib as a single agent
was established at 400 mg twice daily, and the most common toxicities were
gastrointestinal (mainly diarrhea), dermatologic (skin rash, hand-foot syndrome), and
fatigue (20).
But in further phase 2 clinical trials, Sorafenib had shown relatively little activity
in metastatic melanoma when using alone. In a phase 2 trial that was conducted in 20
patients with refractory metastatic melanoma, Sorafenib showed modest activity with 1
partial response and 3 patients who achieved stable disease (21). In another phase 2,
randomized, discontinuation trial, no objective responses were achieved, and 19% of
patients achieved stable disease (22).
Sorafenib combined with other chemotherapy drugs were also tested clinically.
In a phase 1 and 2 study that combined carboplatin and paclitaxel with escalating doses
of Sorafenib in 35 patients, a promising response rate of 31% was observed, and
another 54% of patients experienced stable disease that lasted longer than 3 months.
That study recently was updated to include 105 patients, and the current response rate is
27% (23). On this basis, 2 phase 3 trials have been launched to assess the efficacy of
carboplatin and paclitaxel plus Sorafenib versus placebo in chemotherapy-naive
patients and in previously treated patients. In December 2006, Bayer reported the
combinations failed to show significant improvement of progression-free survival in
melanoma patients (24).
1.3.1.3 Other Single Chemotherapy Agents
Cisplatin and carboplatin have shown modest activity as single agents in patients
with metastatic melanoma. Cisplatin as single-agent therapy induced a 15% response rate
with a short median duration of 3 months (25). A response rate of 19% has been reported
in 26 chemotherapy-naive patients with metastatic melanoma who received carboplatin.
In those patients, there were 5 partial responses, and thrombocytopenia was the doselimiting toxicity (26). In vitro studies suggested that oxaliplatin may be more active than
cisplatin or carboplatin. But a small phase 2 trial in 10 patients who had received and
failed prior chemotherapy produced no objective responses (27).
The nitrosoureas (carmustine, lomustine, and semustine) induce objective
responses in 13~18% patients. They can cross the blood-brain barrier. But at
conventional doses, little or no activity was observed against melanoma brain metastases
(28). Another drawback of the nitrosureas is they induce prolonged myelosuppression.
Despite these, they have been included frequently in multi-agent chemotherapy
combinations, presumably for their ability to penetrate into the CNS and lack of viable
alternatives for metastatic melanoma.
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The vinca alkaloids (vindesine and vinblastine) have produced responses in
approximately 14% of patients (29). The taxanes have produced responses in 16~17%
patients (30). All of these response rate data were obtained from phase 2 trials. None of
those drugs have been evaluated as single agents in phase 3 trials. Based on the
experience with DTIC, it is likely that the phase 3 trial objective response rates would be
less than the rates reported from phase 2 trials. All of these drugs are rarely used
currently as single-agent therapy in metastatic melanoma, but they frequently have been
incorporated into combination chemotherapy and biochemotherapy regimens.
1.3.1.4 Chemotherapy Drug Combinations
Theoretically drug combination should be based on laboratory or clinical evidence
of synergistic effect. But since single-agent chemotherapy regimens only provided
modest activity against metastatic melanoma and lack of viable alternatives, many
combination regimens have been evaluated in clinical trials. Initially two-agent
combinations were tested in which DTIC was combined with a nitrosourea, vinca
alkaloid, or platinum compound. In most of these trials, only 10~20% response rates were
observed. There was little evidence to suggest superiority of these combinations
compared with DTIC treatment alone (31-33).
In order to improve response rates, more aggressive multi-drug combinations
using 3 or 4 different drugs were also tested clinically. Two most widely studied
combinations are cisplatin, vinblastine, and DTIC (CVD) and the Dartmouth regimen.
The later is a 4-drug combination of cisplatin, DTIC, carmustine, and tamoxifen (also
called CBDT). Both combinations showed improved response rates that ranged from 30%
to 50% in single-institution phase 2 studies (34, 35). But in further randomized phase 3
trials which involved more patients, they all showed much lower efficiency: In a
randomized trial comparing CVD with single-agent DTIC that involved approximately
150 patients, the CVD arm produced a 19% response rate compared with 14% for the
DTIC arm, and there was no differences in either response duration or survival. In
another randomized phase 3 trial, the CDBT combination was compared with singleagent DTIC. That cooperative group trial involved 240 patients, and the response rate
was 10% for the DTIC regimen compared with 19% for the CDBT regimen (P=0.09).
The median survival was 7 months, with no significant difference between the 2
treatment arms (11).
The main reason for such discrepancies between the findings from singleinstitution studies and the findings from large, multicenter, cooperative trials probably is
selection bias. Differences in performance status, percentages of patients with visceral
involvement, and number of metastatic sites easily could account for some of the
observed differences. In fact, all of those factors are known to have an impact on both
response rate and survival (36).
Overall, controlled trials have produced no compelling evidence to support the
value of combination chemotherapy, with or without tamoxifen, in patients with
6

metastatic melanoma. Toxicity was substantially greater for the combination regimen,
with bone marrow suppression, nausea, emesis, and fatigue significantly more frequent
with CDBT than with DTIC (11). So it is difficult to justify the use of either CVD or
CBDT instead of single-agent DTIC or TMZ for the treatment of most patients with
metastatic melanoma.
1.3.2 Immunotherapy
1.3.2.1 Interferon α
Interferons (IFNs) are proteins made and released by the cells of most vertebrates
in response to the presence of pathogens or tumor cells. They allow communication
between cells to trigger the protective defenses of the immune system that eradicate
pathogens or tumors. IFNs belong to the large class of glycoproteins known as cytokines.
They are named after their ability to "interfere" with viral replication within host cells.
IFNs have other functions: they activate immune cells, such as natural killer cells and
macrophages; they increase recognition of infection or tumor cells by up-regulating
antigen presentation to T lymphocytes; and they increase the ability of uninfected host
cells to resist new infection by virus.
Based on the type of receptor through which they signal, human interferons have
been classified into three major types. The type I interferons present in human are IFN-α,
IFN-β and IFN-ω (37). High-dose IFN therapy using IFN-α was the first form of medical
therapy to be approved by the FDA for use in high-risk melanoma in the adjuvant setting.
Adjuvant normally means using IFN- α weeks after the surgical excision of the
melanoma tumor. Common treatment scheme is IFN-α2b at 20 million units
(MU)/m2/day intravenous injection 5 days a week for 4 weeks, then 10 MU/m2/day
subcutaneous injection 3 days a week for the next 48 weeks for a full year’s. But IFN-α2b
can also be used one month before definitive surgical lymphadenectomy. This is called
‘neoadjuvant’ treatment (38).
The first randomized comparison of high-dose IFN versus observation found the
median relapse-free survival was 1.72 years in the high-dose IFN arm versus 0.98 year in
the observation arm (P=0.0023) and the median overall survival was 3.82 versus 2.78
years (P=0.0237) respectively (39). But in a later pooled analysis of more patients in
more clinical trials, the relapse-free survival benefit was maintained but no overall
survival benefit was seen (40).
The exact mechanism of IFN IFN-α’s anti-tumor efficacy is still unknown. But it
was found that the STAT1/STAT3 expression ratios rose in association with IFN
treatment. The clinical effects of IFN-α2b in human melanoma are also found to be
inversely related to STAT3 expression (41). Induction of apoptosis has been shown to be
important in vitro, if not in vivo. IFN-α can induce apoptosis in transformed cell lines as
well as primary tumor cells (42).
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High-dose IFN is the standard of care for high-risk melanoma patients in the
adjuvant setting. However, it is associated with significant toxicity. The incidence and
severity of these adverse events is clearly dose-related. Consequently, there has been a
great deal of interest in intermediate- and low-dose regimens administered through
subcutaneous injection. However, none of the trials using intermediate or low dosing so
far have been able to demonstrate any reliable benefit in terms of relapse-free survival or
overall survival (43).
1.3.2.2 Anti-CTLA4 Antibodies: Ipilimumab and Tremelimumab
Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) also known as CD152 (Cluster of
differentiation 152) is a member of the immunoglobulin super family, which is expressed
on the surface of Helper T cells and transmits an inhibitory signal to T cells that
eventually shuts off the activated state. The rationale for involving this in treatment of
metastatic melanoma is to block the negative signal sending by CTLA4 by using antiCTLA4 antibodies, thus reduce the sensitivity of activated T cells to negative regulatory
signals and enhance the immune response of the host to tumor cells.
As of October 2007 there are two fully human monoclonal anti-CTLA4
antibodies in advanced clinical trials, one from Medarex, Inc. (Princeton, NJ) and BristolMyers Squibb (New York), called ipilimumab (MDX-010), and one from Pfizer (New
York), called tremelimumab (formerly ticilimumab, CP-675,206) (44). These antibodies
were produced using different types of mice with engineered immune systems, and are
thus fully human, with long half-lives of 2– 4 weeks.
Ipilimumab (MDX-010) is an IgG1 monoclonal antibody. Preclinical and early
clinical studies of patients with metastatic melanoma show that ipilimumab promotes
antitumor activity as monotherapy and in combination with treatments such as
chemotherapy, vaccines, or cytokines. The initial success with these antibodies has
encouraged the rapid development of new agonistic and antagonistic antibodies that alter
immune regulation, such as anti-PD-1, anti-4-1BB, anti-CD40, and anti-OX-40. On
December 10, 2007, Bristol-Myers Squibb and Medarex released the results of three
studies on ipilimumab (44). The three studies tested 487 patients with metastatic
melanoma. Short-term tumor progression prior to delayed regression has been observed
in ipilimumab-treated patients, and objective responses may be of prolonged duration. In
some patients clinical improvement manifests as stable disease, which may also extend
for months or years. One of the three studies failed to meet its primary goal of shrinking
tumors in at least 10% of the study's 155 patients. Overall the medication produced
weaker-than-anticipated efficacy on melanoma patients.
In the meantime, the side effect profile was high in the ipilimumab treated group,
with the generation of autoimmune-like effects, such as diarrhea, dermatitis and effects
upon the thyroid and pituitary glands. Several patients also experienced vitiligo,
indicative of anti-melanocyte autoimmunity. However, the majority of the side effects
were noted to be transient (except the vitiligo), improving or disappearing after the
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completion of therapy. Early clinical data suggest a correlation between these side effects
and response to ipilimumab treatment and most likely reflect the drug mechanism of
action and corresponding effects on the immune system (44).
Tremelimumab is an IgG2 monoclonal antibody produced by Pfizer. It blocks the
binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in
inhibition of B7-CTLA-4-mediated down-regulation of T-cell activation. Subsequently,
B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in
a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.
Tremelimumab is thought to stimulate patients’ immune systems to attack their tumors. It
has been shown to induce durable tumor responses in patients with metastatic melanoma
in phase 1 and phase 2 clinical studies (45).
On April 2, 2008, Pfizer announced that it has discontinued a phase 3 clinical trial
for patients with metastatic melanoma after the review of interim data showed that the
trial would not demonstrate superiority to standard chemotherapy (46). Studies for other
tumors are planned as of October 2009, namely for prostate cancer and bladder cancer.
1.3.2.3 Anti-Integrin Antibody: Etaracizumab
Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is
an IgG1 humanized monoclonal antibody directed against the αVβ3 integrin. αVβ3 is
essential for endothelial cell proliferation, maturation, and survival. When it is blocked,
proliferating endothelial cells undergo apoptosis and regress. In addition, αVβ3 is highly
expressed in melanomas and is associated with tumor growth and invasion. In preclinical
studies using αVβ3 antagonists, inhibition of melanoma tumor growth independent of its
antiangiogenic effects was reported (47). Etaracizumab has been investigated in 3 phase 1,
dose-escalation studies in patients with refractory melanoma. In the phase 2 trial, 57
patients received etaracizumab alone, and 55 patients received etaracizumab plus DTIC.
Etaracizumab with or without DTIC generally was well tolerated and was active in
patients with metastatic melanoma. The median survival was 12.6 months for the group
that received etaracizumab with DTIC and 9.4 months for the group that received
etaracizumab without DTIC (48). These results encouraged people to further test this
antibody in more clinical trials.
Early 2010, a study by the Etaracizumab Melanoma Study Group was reported. In
this study, 112 patients were randomized to receive etaracizumab alone or etaracizumab
plus DTIC. None of the patients in the etaracizumab alone study arm and 12.7% of
patients in the etaracizumab plus DTIC study arm achieved an objective response. Stable
disease occurred in 45.6% of patients in the etaracizumab alone study arm and 40.0% of
patients in the etaracizumab plus DTIC study arm. Despite a modest increase in survival,
12.6 months in the etaracizumab alone arm, versus 9.4 months in the etaracizumab plus
DTIC arm, the researchers concluded that the survival results in both treatment arms of
this study were considered unlikely to result in clinically meaningful improvement over
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DTIC alone (49). At the present time, clinical development of etaracizumab has been
interrupted
1.3.2.4 Vaccines Based on Tumor Cells: Canvaxin, Melacine, and MVax
The basic idea is to use tumor cell-based vaccine to stimulate and activate the host
immune system to recognize, contain and eliminate cancer cells. This effect may be
based on the following two pathways: direct migration of the tumor cells to the draining
lymph node basin after injection, or uptaking of apoptotic or necrotic tumor cells by host
dentritic cells located within the skin (50).
The most extensively studied tumor cell-based vaccine is a polyvalent, antigenrich whole cell vaccine called Canvaxin (CancerVax Corp., Carlsbad, CA). It is
comprised of three melanoma cell lines that contain over 20 immunogenic melanoma
tumor antigens, given intradermally every two weeks for 3 to 5 doses, followed by
monthly injections for the remainder of the first year. However, several small, singleinstitution phase 1 and 2 clinical trials of Canvaxin have not yielded a striking clinical
benefit in most patients when administered with BCG as an immunoadjuvant (51). But
the rare complete responder to Canvaxin therapy has prompted the initiation of two
multicenter phase 3 randomized trials of Canvaxin therapy in 1998. In these trials,
patients who have undergone complete resection of regional (stage III) or distant (stage
IV) metastatic melanoma receive postoperative adjuvant immunotherapy with Canvaxin
plus Bacillus of Calmette and Guerin (BCG) or BCG alone. In April 2005, CancerVax
announced the discontinuation of their phase 3 clinical trial of Canvaxin in patients with
Stage IV melanoma based upon the clinical funding that it was unlikely that the trial
would provide significant evidence of a survival benefit for Canvaxin-treated patients
versus those receiving placebo. On October 3, 2005, CancerVax announced the
discontinuation of another phase 3 clinical trial of Canvaxin in patients with Stage III
melanoma base on the similar reason (52).
The second tumor cell-based vaccine that has been well studied since 1988 is
Melacine. It is an allogeneic melanoma cell lysate combined with an immunologic
adjuvant which is composed of a mixture of detoxified endotoxin, cell wall cytoskeleton
and monophosphoryl lipid A. Early phase 1 and 2 clinical trials in 1987 and 1988
revealed some promising results, with one complete and three partial responses seen in 25
patients treated with Melacine. These results prompted the completion of seven openlabel phase 2 trials involving 139 patients with stage III/IV melanoma and a multicenter
phase 3 clinical trial of Melacine versus the Dartmouth regimen. The objective response
rates for all of the above studies have been between 5 and 10%. Based largely upon these
former results and the clinical results of other phase 3 trials, a phase 3 observation
controlled trial of Melacine in melanoma patients was conducted. But the results revealed
no evidence of a benefit from Melacine in patients with melanoma (53).
One very promising autologous cell vaccine is MVax which is now in active
phase 3 clinical trial sponsored by AVAX Technologies, Inc. This vaccine is derived
from autologous tumor cells that have been irradiated and then modified with the hapten
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dinitrophenyl (DNP) (54). In February 2004 the Journal of Clinical Oncology published
an article by Dr. David Berd on the treatment of 214 Stage IIIb and IIIc melanoma
patients that showed a five-year survival rate of 44%. Comparison to published results of
similar patients treated with surgery alone showed five-year survival figures of 22%. In
stage IV patients MVax has demonstrated significant response rates as a monotherapy
and in published reports MVax plus adjuvant IL-2 have reported response rate of 35%
(13% Complete Response, 22% Partial Response). This compares to published response
rates in low dose IL-2 of 3% (55).
In October 2006, AVAX obtained a Special Protocol Assessment (SPA)
agreement with the FDA for its phase 3 protocol. The SPA allows for the start of the
phase 3 registration clinical trial for MVax for the treatment of patients with metastatic
melanoma. In addition, the SPA addressed AVAX’s ability to use a surrogate endpoint as
a basis for accelerated approval. Based on this SPA, a phase 3 trial for stage IV
melanoma was started on May 2007. AVAX plans to enroll up to 387 patients who will
be assigned in a double-blind fashion at a 2:1 ratio to MVax or placebo vaccine. The
MVax arm will consist of an initial dose of MVax followed by cyclophosphamide and
then six weekly doses of MVax administered with BCG. Following vaccine
administration patients will receive a specific schedule of low dose IL-2. Patients
assigned to the control group will receive a treatment identical to the MVax group, except
that a placebo vaccine will replace MVax. The primary endpoints of the study are best
overall anti-tumor response rate and the percentage of patients surviving at least 2 years.
Secondary endpoints of the study will include overall survival time, response duration,
percentage complete and partial responses, progression free survival and treatment
related adverse events (56).
1.3.2.5 Vaccines Based on Peptides: MDX-1379, Astuprotimut-R, and Others
The identification of tumor antigens that are present on the surface of melanoma
cells is the basis for developing cancer vaccines that utilize peptide based immunotherapy.
There are several melanoma differentiation antigens known involved in the synthesis of
melanin and recognized by melanoma-reactive T cells, for example, gp100, MART1/Melan-A, tyrosinase, TRP-1 and TRP-2, NY-ESO-1and the melanoma-associated
antigen (MAGE) etc. One big advantage of peptide based-vaccination is that it has few
toxic side effects or adverse reactions. Data suggests that most tumor cell lines
established from fine needle aspiration biopsies of patients with metastatic melanoma
exhibit a relatively homogeneous co-expression of MART-1 and tyrosinase, with a much
more heterogeneous expression of other tumor antigens, such as gp100, NY-ESO 1 and
the MAGE antigens (57).
Rosenberg and his colleagues developed a with a peptide based-vaccine using
modified immunodominant peptide of the gp100 antigen, g209-2M. They used this agent
vaccinated stage IV melanoma patients subcutaneously every three weeks. Following two
immunizations, 10 of 11 (91%) of patients showed a consistently high level of
immunization against the native g209~217 peptide, but not against the control peptide
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g280~288. This study also demonstrated that the majority of patients immunized with the
g209-2M peptide in incomplete Freund’s adjuvant (IFA) consistently developed high
levels of circulating immune precursors reactive against the native g209~217 peptide.
Clinically, one of nine patients who received the g209~217 peptide in IFA experienced
an objective cancer regression that lasted 4 months. Three of the eleven patients exhibited
mixed responses with complete or partial regression of several lesions. However, all
patients eventually developed progressive disease (58).
MDX-1379 vaccine consists of two gp100 melanoma peptides. These peptides are
part of a protein normally found on melanocytes, or pigmented skin cells, and on
melanoma cells. These melanoma peptides are recognized by cytotoxic T cells in
melanoma patients that are positive for HLA-A2, a human immune system compatibility
antigen that is expressed in approximately half of the melanoma population. Phase II data
show limited evidence of MDX-1379's clinical activity although there is strong proof-ofconcept for therapeutic vaccines based on gp100 in melanoma. Medarex is currently
conducting a phase 3 clinical trial with ipilimumab and MDX-1379 combination therapy
in stage III and IV melanoma at multiple sites within the United States. Preliminary data
showed MDX-1379 plus ipilimumab induced a modest percentage of durable response in
stage IV melanoma. But autoimmune events could make the risk/benefit ratio for MDX1379 plus ipilimumab unfavorable (59).
Astuprotimut-R (also called recombinant MAGE-A3 antigen-specific cancer
immunotherapeutic GSK1203486A) is a cancer vaccine consisting of a recombinant form
of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with
potential immunostimulatory and antineoplastic activities. Upon administration,
astuprotimut-R may stimulate a cytotoxic T-lymphocyte response against tumor cells
expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumorassociated antigen (TAA) originally discovered in melanoma cells, is expressed by
various tumor types including melanoma, non-small cell lung cancer, head and neck
cancer, bladder cancer, with no expression in normal cells. MAGE-A3 protein has been
in-licensed by GlaxoSmithKline (GSK) from the Ludwig Institute for Cancer
Research. The proprietary immunostimulating adjuvant in this agent is composed of a
specific combination of immunostimulating compounds selected to increase the antitumor immune response to MAGE-A3. Using this vaccine as intramuscular
administration together with GSK’s two proprietary adjuvant systems, AS15 or AS02B,
they have developed a treatment regimen for cancer patients called Antigen-Specific
Cancer Immunotherapeutic (ASCI).
In 2008, GSK reported a randomized, open-label phase 2 study designed to
evaluate Astuprotimut-R. A total of 72 patients with measurable metastatic MAGE-A3positive cutaneous melanoma (unresectable or in transit stage III or stage IV M1a) were
randomized to receive immunization with MAGE-A3 protein combined with either AS15
or AS02B as first-line metastatic treatment. Patients were to receive a maximum of 24
immunizations over four years. Clinical activity is assessed by the Response Evaluation
Criteria In Solid Tumors (RECIST) criteria, the international standards for evaluation of
solid tumors. Complete response (CR) and partial response (PR) i.e., disappearance or
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significant reduction of tumor, were reported in 4 patients in the AS15 group (3 CR and 1
PR) with two of these ongoing for more than two years; in the AS02B arm, 1 patient
showed a partial response which lasted for 6 months. The safety profile was similar in
both groups with the majority of reported adverse events being mild or moderate local or
systemic reactions (60). Currently this agent still is under phase 2 clinical development
for progressive metastatic cutaneous melanoma.
Because melanoma tumors are heterogeneous in their antigenic profile, it is very
difficult to make vaccines that can elicit cytotoxic T-cell responses universally in all the
host immune systems. Rosenberg’s group analyzed 28 different peptide-based vaccines
utilized in stage IV melanoma patients. A total of 381 patients were treated with 370
patients showing no response, 9 patients showing a partial response and 2 patients with a
complete response, for an overall objective response rate of only 2.9%. This suggested
the lack of effectiveness with this single peptide based vaccination approach (61).
Next logical step is to make vaccines with multiple peptides to overcome tumor
cell antigenic heterogeneity. A recent randomized phase 2 trial was performed in 26
patients with metastatic melanoma, vaccinating with four melanoma peptides. Although a
high level of specific T-cell responses were noted (in 42% of the peripheral blood, 80%
of sentinel lymph nodes), only three patients had a clinical response (62).
Here is the biggest issue in this area, actually many peptide based-vaccinations
have resulted in a significant increase in the number of lymphocyte precursors reactive
against a variety of tumor differentiation antigens by immunization with native or
modified peptides. However, such immunological responses to peptide-based therapy
have not translated into meaningful clinical responses for the vast majority of patients. To
date, there is no study that has clearly shown a direct correlation between an
immunologic response to therapy (immune cell activation) and a clinical response
(regression of established tumor).
1.3.2.6 Vaccines Based on Dendritic Cells
In the normal human epidermis and dermis, dendritic cells (DC) are present as
relatively immature antigen presenting cells, exhibiting relatively low levels of class II
major histocompatibility complex (MHC) molecules and co-stimulatory molecules. But
these immature DC are quite capable of capturing various soluble protein antigens, such
as apoptotic and necrotic tumor cells and then cross-presenting such tumor-associated
antigens to cytotoxic CD8+ T cells. When relatively immature DC in the skin is triggered
to enter afferent lymphatic channels, this migrating pathway also initiates a phenotypic
conversion that has profound immunological consequences [30]. When the DC arrives in
the lymph node, it is characterized by an abundant levels of class II MHC antigens, as
well as high surface levels of costimulatory molecules, such as CD40, CD54, CD80,
CD83, and CD86. The matured DC is then capable of forming stable MHC class IIpeptide complexes available to activate antigen specific CD4+ T cells (63).
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To make the dendritic cell-based vaccine, the monocyte-derived, autologous DC
can be pulsed in vitro with either whole irradiated, autologous tumor cells or tumor cell
lysate. Once the tumor cells are “fed” to the DC in vitro, the apoptotic or necrotic cells
are then processed and tumor-specific peptide antigens are then transported to the surface
in both an MHC class I- and II-restricted fashion. Both immature and mature DC can be
administered to patients as vaccine safely with few adverse side effects. The
administration of DC via various routes of vaccination (intradermal, intranodal and
intravenous) is also feasible. The first published clinical trial of DC vaccination was in
1995 and has since been followed by 98 additional clinical trials describing more than
1,000 DC-based vaccines performed in 15 different countries. Twenty-eight trials focused
on patients with various advanced stages of melanoma. The safety profile was again
noted to be quite remarkable, however, despite the treatment of over 1,000 patients with
DC-based vaccines, the record of effectiveness have been disappointing (64).
One pretty successful DC-based trial for patients with advanced, metastatic
melanoma was reported by Nestle et al. He used plastic adherent monocytes matured
with a xenogenic-based 10% fetal calf serum, subsequently pulsed with either tumor cell
lysate or multiple HLA-matched peptides injected intranodally. This trial involved 16
patients who were immunized on an outpatient basis. Overall, 5 of 16 patients
experienced an objective response, 2 complete and 3 partial responses. The side effects
were noted to be minimal in all cases, with the development of vitiligo in a few patients.
One dramatic feature of this treatment was the durability of the clinical responses, with
the 2 complete responders remaining free of disease for over 15 months (65).
One phase 3 clinical trial about using DC-based vaccine to treat metastatic
melanoma was report by Schadendorf and colleagues recently. The trial was a
prospective, randomized trial that analyzed the therapeutic effects of an autologous
peptide-pulsed DC-based vaccine in patients with stage IV melanoma compared to
standard chemotherapy with DTIC alone. The results revealed that the overall response in
the vaccine group was 3.8% compared to 5.5% in the DTIC group, with no statistically
significant differences noted in response, toxicity, overall and progression-free survival
between the two groups. The median time to progression was 2.8 months versus 3.2
months respectively and the median survival was 11 months for the DTIC arm but only 9
months for the vaccine arm (66).
Although disappointed by many trials, several new avenues of DC-based
immunotherapy are actively being pursued and in various stages of development,
focusing on different ways to enhance the therapeutic efficacy of DC in combination with
various immunoadjuvants and other anticancer agents.
1.3.2.7 Individual Therapy Based on Activated T-Cells
One very promising approach to treat metastatic melanoma is to use fully
activated anti-tumor T-cells as warhead. This regimen involves the adoptive autologous
transfer of highly selective tumor-reactive T-cells directed against over-expressed self14

derived differentiation antigens after lymphodepleting chemotherapy. Rosenberg group
reported in 2004 a clinical trial using this method. Cancer regression in patients with
refractory metastatic melanoma with large, vascularized tumors was noted in a
remarkable 18 of 35 patients (51% response rate), including four patients with a complete
regression of all metastatic disease. Such results may stem from the ability to infuse a
large number of fully activated tumor infiltrating lymphocytes with anti-tumor activity
into a host that is depleted of regulatory T-cells (67).
1.3.3 Gene Therapy
The recent developments in the field of gene transfer have advanced the use of
gene therapy as a novel strategy against a variety of human malignancies. Because of its
unique set of characteristics, melanoma represents a suitable target for gene therapy.
Several strategies have been used by gene therapy to treat melanoma. First is to target
melanoma cells to introduce "suicide" genes. Second is to transfer tumor suppressor
genes. Third is to inactivate aberrant oncogene expression. Fourth is to introduce genes
encoding immunologically relevant molecules. Last is to target the host's immune cells to
redirect immune responses against melanoma. Clinical trials have shown the feasibility
and safety of gene therapy against malignant melanoma. Although no major successes
have been reported, the positive results observed in some patients support the potential
for gene therapy in the management of this disease. To make gene therapy as an effective
modality of treatment for malignant melanoma, better vector technology as well as
increased understanding of the "bystander effect" triggered by gene transfer approaches
are needed (68).
The gene therapy in our discussion is to introduce oligonucleotide or DNA
sequence into host body thus to stimulate immune response to tumor cells. So it is also
called DNA vaccination. This approach has been shown to induce long-lasting immunity
against infectious agents and protection from tumor outgrowth in several animal models
(69). Likewise, intramuscular injections of DNA (composed of naked DNA expression
plasmids) into humans have also resulted in the development of an immunologic response
(70). It is hypothesized that one mechanism of tumor antigen expression may involve the
DNA introducing the appropriate genes into dendritic cells for subsequent processing and
presentation to the host immune system. One of the obvious advantages of DNA
vaccinations is that they can be administered to patients regardless of HLA-phenotype
and without identifying immunogenic epitopes.
1.3.3.1 Anti-BCL2 Antisense Oligonucleotide Genasense
Genasense (Oblimersan sodium developed by Genta Inc. which is a
biopharmaceutical company based in Berkeley Heights, New Jersey) is a
phosphorothioate antisense oligonucleotide directed against the first six codons of the
Bcl-2 messenger RNA. Binding of the drug to the mRNA recruits RNAse H, resulting in
cleavage of the mRNA. As a result, further translation is halted and intracellular protein
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concentrations of Bcl-2 decrease with time. Melanoma cell lines having Bcl-2
overexpression have been shown to enhance activity of metastasis-related proteinases, in
vitro cell invasion, and in vivo tumor growth (71). Many in vitro studies have
demonstrated increased sensitivity of melanoma cells to chemotherapy when combined
with antisense Bcl-2 therapy (72). Genasense is the first oncology drug of its kind to
directly target the biochemical pathway (known as apoptosis) whereby cancer cells are
ultimately killed by chemotherapy. Genasense is believed to inhibit the production of
Bcl-2, a protein that is believed to be a fundamental cause of resistance to anticancer
therapy. By inhibiting Bcl-2, Genasense may greatly improve the activity of anticancer
therapy.
Encouraged by previous data, numerous clinical trials were started to evaluate the
addition of oblimersan to chemotherapy in various solid tumors, including melanoma.
Updated analysis from a randomized phase 3 trial, comparing DTIC combined with
oblimersan, with DTIC alone in 771 patients with Stage IV or unresectable Stage III
melanoma who had not previously received chemotherapy has shown a response rate of
12.4% in the former compared with 6.8% in the latter group (P=0.007) (73). Median
progression-free survival for the oblimersan group was 2.4 months as compared with 1.6
months for the DTIC group, with a relative risk reduction of 27% (P=0.0003). The
median survival was increased from 7.8 months in the DTIC arm to 9 months in the
oblimersan arm with a P value of 0.077, which became significant when the patients with
normal baseline LDH were analyzed. In terms of toxicity, no new or unexpected adverse
events were observed in this study, which had not been seen with DTIC alone.
However, in May 2004, a new drug application (NDA) based on 6-months of
minimum follow-up data from this trial failed to receive an affirmative vote for approval
by an advisory committee to the FDA. Genta subsequently withdrew that application, and
the Company has not yet made a decision regarding re-filing the U.S. application (74).
1.3.3.2 DNA Plasmid-Lipid Complex Allovectin-7
Allovectin-7 is a bicistronic plasmid formulated with a cationic lipid system
containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, which
together form a MHC1 antigen. Injection of Allovectin-7 directly into tumors is designed
to stimulate an immune response against both local and distant metastatic tumors.
Allovectin-7 is a novel gene therapy approach for cancer with a unique mechanism of
action that is fundamentally different from currently approved treatments. The following
three mechanisms were believed to play roles in this agent’s efficacy. Mechanism one, in
HLA-B7 negative patients, a vigorous allogeneic immune response may be initiated
against the foreign MHC class I antigen. Mechanism two, in all patients, ß2
microglobulin may reconstitute normal class I antigen presentation and/or increase tumor
antigen presentation to the immune system. Mechanism three, in some patients, an innate
pro-inflammatory response may occur that induces tumor responses following
intralesional injection of the DNA/lipid complex. The final outcome of all these
mechanisms is to initially cause recognition of the tumor at the local site to allow a then
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sensitized immune response to recognize un-injected tumors at distant metastatic sites
(75).
In 2001, Dr. Richards and his colleagues began a high-dose, 2 mg, phase 2 trial
evaluating the Allovectin-7 immunotherapeutic alone for patients with stage III or stage
IV melanoma, who have few other treatment options. The high-dose phase 2 trial
completed enrollment in 2003. The data showed that the trial had a total of 15 responders
among the 127 patients receiving the high dose (11.8%), with four of the patients having
complete responses and 11 having partial responses. The Kaplan-Meier estimated median
duration of response was 13.8 months. The Kaplan-Meier median survival was 18 months.
The safety profile was excellent with no reported Grade 3 or Grade 4 adverse events
associated with Allovectin-7 (76).
Allovectin-7 has been granted orphan drug designation for the treatment of
invasive and metastatic melanoma by the FDA’s Office of Orphan Products Development.
Orphan drug designation provides U.S. marketing exclusivity for seven years if
marketing approval is received from the FDA
Vical is conducting the AIMM (Allovectin-7 Immunotherapeutic for Metastatic
Melanoma) trial, a phase 3 pivotal trial of Allovectin-7 as first-line therapy in
approximately 375 patients with Stage III or IV recurrent metastatic melanoma in
accordance with a SPA agreement completed with the FDA. The trial is being conducted
at approximately 60 clinical sites worldwide. They designed the trial to include patients
most likely to benefit from our treatment, and specifically excluded patients with brain or
liver metastases, patients previously treated with chemotherapy, and patients with
elevated lactate dehydrogenase (LDH) levels.
In January 2010 Vical announced that the company has completed enrollment of
the planned 375 subjects in its multinational phase 3 trial of Allovectin-7 in patients with
metastatic melanoma. Allovectin-7®’s safety profile is excellent with no drug-related
serious adverse events reported to date in the phase 3 trial (75).
1.3.3.3 Herpes Simplex Virus Based OncoVEX
OncoVEX (GM-CSF) is an enhanced potency, immuneenhanced oncolytic herpes
simplex virus type 1 (HSV-1). It is deleted for infected-cell protein gene 34.5 (ICP34.5),
providing tumor selective replication, and ICP47 gene which otherwise blocks antigen
presentation. In addition, ICP47 deletion increases unique short region protein 11 (US11)
gene expression thereby enhancing virus growth and replication in tumor cells. The
coding sequence for human granulocyte-macrophage colony-stimulating factor (GM-CSF)
is inserted, replacing ICP34.5, to enhance the immune response to tumor antigens
released following virus replication.
OncoVEX is developed by BioVex (Woburn, MA). It is a first-in-class oncolytic,
or cancer destroying virus, that works by replicating and spreading within solid tumors
17

(leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the
immune system to destroy un-injected metastatic deposits. Both modes of action have
been clearly validated in the clinic, where multiple patients with metastatic disease
progressing at enrollment have been declared disease free.
BioVex recently concluded a 50-patient phase 2 trial for OncoVEX (GM-CSF) as
a stand-alone therapy in patients with Stage IIIc and Stage IV melanoma. The trial was
designed to measure overall objective response, which is defined as a complete response,
where disease is completely eliminated, or partial response, where there is a >50%
reduction in disease burden. 74% of patients who entered the study were progressing after
having failed prior therapy. 13 objective systemic responses (26% objective response rate)
were achieved including eight CRs, seven of which remain free of disease. 12 responses
have so far continued for more than 6 months (ranging from 6 to more than 29 months).
Responses were observed in patients with all stages of disease, including the complete
resolution of un-injected visceral deposits. Adverse effects were primarily limited to
transient flu-like symptoms (77).
In April 2009, BioVex Inc. announced that its OPTiM (OncoVEX Pivotal Trial in
Melanoma) phase 3 study with OncoVEX (GM-CSF) in previously treated patients with
Stage III and Stage IV melanoma had initiated. The study has commenced recruiting
patients in the U.S. and with sites in the United Kingdom, Germany and Australia. The
OPTiM trial is a multi-national, open label, randomized study designed to assess the
efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to
subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and
stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active
disease which includes any type of therapy including investigational drugs. A total of 360
patients will be enrolled (240 to the OncoVEX (GM-CSF) arm and 120 to the control
arm). The study design was agreed with the FDA under the special protocol assessment
process (78).
1.4 Possible Reasons for Failure
Despite an epic number of clinical trials to test a wide variety of anticancer
strategies, the average survival rate for patients with metastatic melanoma remains
unimproved during the past 30 years (41). Though constant clinical trials effort, although
some approaches showed promising intermediate results, still no any agents for
approaches have been granted a FDA approval for the treatment of metastatic melanoma.
There are several reasons that may be accountable for the extremely high resistance of
metastatic melanoma to current treatment modalities.
1.4.1 Reasons for Chemotherapy Failure
Melanoma cells are quite resistant to most chemotherapy reagents. This is
associated with the specific feature of melanoma cells. In nature, these cells have low
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levels of spontaneous apoptosis in vivo compared with other tumor cell types, and they
are relatively resistant to drug-induced apoptosis in vitro (4). The natural role of
melanocytes is to protect inner organs from UV light, a potent DNA damaging agent.
Therefore, it is not surprising that melanoma cells may have special DNA damage repair
systems and enhanced survival properties (79). Moreover, recent studies showed that,
during melanoma progression, it acquired complex genetic alterations that led to
hyperactivation of efflux pumps, detoxification enzymes, and a multifactorial alteration
of survival and apoptotic pathways. All these have been proposed to mediate the multidrug resistant phenotype of melanoma (80).
1.4.2 Barriers for Successful Immunotherapy
The major barrier is immunosuppressive effects activated by tumors. Tumor cell
can escape immune rejection and induce immunosuppression through the following five
major paths. Firstly, tumor cells may lose or down-regulate either the melanoma
associated antigens or MHC molecules. Secondly, tumor cells may produce a plethora of
immunosuppressive factors such as interleukin-10, VEGF and transforming growth factor.
These factors create an inherently unfavorable microenvironment that limits the host
immune response, in addition to tolerating the T-cell response to established tumor. Third
possible reason is intrinsic inefficiency of DC whereby the appropriate co-stimulatory
molecules are not being presented on the cell surface. Fourth possible reason is tumorrelated alterations in T-cell signaling and a skewing of the immune response from a Th1
(immunoactivating) to a Th2 response (immunotolerant). Lastly, the concept of tumor
cell escape and immune tolerance is an exceedingly complex process. We need to further
understand these mechanisms before we can have successful immunotherapy to
melanoma (14).
Specifically for cancer vaccines, there are some further barriers. First is the
characterization of vaccines potency and toxicity. This is especially important in the
transition from phase 2 to phase 3 trials. To select a meaningful and validated end point
for trials is a big challenge most of the time. Second barrier is selection of the maximum
tolerated dose of cancer vaccine, particularly compared with traditional anticancer agents.
Cancer vaccines are typically not very toxic. So the optimum dose often has to be based
on the immune response of patients. But if the patients have previously been heavily
treated with other anticancer agents, this can lead to a compromised immune system that
makes it difficult to detect an evoked immune response. The third barrier is appropriate
trial design and statistical data process. This is also a key part and can substantially affect
final trial outcome (54).
1.5 Future Directions
With the rapidly rising incidence and the high resistance to current therapeutic
agents, developing more effective drugs for metastatic melanoma is urgently needed. But
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before we can thoroughly understand all the major molecular pathological changes
associated with melanoma malignancy, it is very difficult to reach a cure for it.
Melanoma is an extremely complicated disease, with many gene mutation and
signaling pathway changes. Elevated signaling pathway in melanoma including mitogenactivated protein kinase (MAPK) pathway, phosphatidylinositol 3 kinase (PI3K)-AKT
pathway, Wnt-Frizzled-β-catenin pathway, JAK/Stat pathway and α-MSH-MC1R or
microphthalmia-associated transcription factor (MITF) pathway. The first two are crucial
pathway accounting for melanoma malignance. Gene mutation involved in melanoma
including the following oncogenes: B-raf, N-ras, akt3; tumor suppressors: CDKN2A,
PTEN, p53, APAF-1, p16, p15, p19; others: Cyclin D1, MITF etc (81).
The binding of growth factors to their respective receptors leads to activation of
RAS proteins. Ras will then activate Raf. Raf activate mitogen-activated protein kinase
(MEK), which then act on extracellular-related kinase (ERK). Phosporylated ERK
kinases (ERK-P) translocate to the nucleus and activate transcription factors, which
promote cell cycle progression and proliferation. The PI3K-AKT pathway mediates cell
survival signaling via growth factors. Phosphatase and tensin homolog (PTEN) inhibits
growth factor signaling by inactivating phosphatidylinositol triphosphate (PIP3)
generated by PI3K. Activated PI3K converts the plasma membrane lipid
phosphatidylinositol 4,5-bisphosphonate to PIP3, which acts as a second messenger
leading to the phosphorylation AKT and subsequent up-regulation of cell cycle, growth,
and survival proteins. AKT can also up-regulate mTOR (mammalian target of rapamycin),
S6K, and NFκb leading to cell growth and inhibition of apoptosis.
Knowing the huge complexity of melanoma, it’s easy to understand why so many
random trials of single agents or combinational treatment have failed. So targeted therapy
in a systemic way based on the understanding about melanoma molecular pathology
seems to be a reasonable way to fight this disease.
In learning from our efforts in the past, we must continue to challenge the current
paradigms of treatment as we forge new paths to more effective treatment options. This
will likely involve a multimodal approach to therapy utilizing all of the available tools in
our arsenal. Several agents given in unique combinations may then synergize with
standard chemotherapeutic regimens resulting in prolonged clinical responses and long
term survival. Like the example of Sorafenib, its failure maybe largely because of it only
blocked the Raf-MEK-ERK signaling pathway. Melanoma cells still can survive by
compensatory up-regulating other survival pathway like the PI3K-AKT pathway. Then it
can develop drug resistance with time by over expressing MDR gene. Ideally, if we can
use drugs to synergistically block all the major pathways for melanoma cell survival and
then educate our immune system to fight the tumor cells, we will have a very high chance
to conquer this deadly disease.
Individualized T-cell-based therapy is a very promising approach. If combined
with other suitable tumor killing agents, it maybe can improve the patient survival rate
and time. But the selective tumor-reactive T-cells isolated from the patients only can be
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used for themselves. Thus there is a pretty high cost associated with it. It may not be
available to all the patients in the near future.
Since all the combinational treatments are based on the performance of each
individual agent, developing more effective single agents is essential. In the next several
chapters, I will summary our efforts in identifying more active small molecule drugs for
melanoma. That’s the basis for our future treatment. It also can provide more choice for
combination treatment.
For the dissertation research, my overall hypothesis was by synthesizing novel
small molecule and further structure modification, we can find compounds that can
inhibit melanoma tumor cell growth both in vitro and in vivo. My experimental plan was
first establishing an in vitro method to test compounds activity in inhibiting melanoma
cell growth. Then I would use this method to screen a large compound library to identify
active lead structure. Next step was to further modify this structure to inpromve activity.
Finially I would test active compounds’ in vivo activity. In the meantime, compounds’s
pharmacokinetic properties would be also measured.
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CHAPTER 2. DISCOVERY OF NOVEL THIAZOLIDINE, IMIDAZOLE, AND
IMIDAZOLINE ANALOGS AS CYTOTOXIC AGENTS FOR MELANOMA*
2.1 Introduction
In a continuous effort in our laboratory, our team discovered that, by replacing the
glycerol backbone in lysophosphatidic acid (LPA, 1-acyl-sn-glycerol-3-phosphate), the
resulting 2-arylthiazolidine-4-carboxylic acid amides (ATCAAs) were potent cytotoxic
agents for melanoma (82-87). Two of earlier derivatives (2RS, 4R)-2-phenyl-thiazolidine4-carboxylic acid octadecylamide 1a and (2RS, 4R)-2-(4-acetamidophenyl)-thiazolidine4-carboxylic acid hexadecylamide 1b (Figure 2-1) were sent to the U.S. National Cancer
Institute for anticancer drug screen using 60 human tumor cell lines (NCI-60). The NCI60 screening data indicated that compounds 1a and 1b strongly inhibited the growth of all
nine types of cancer cells with IC50 values ranging from 120 nM (leukemia, CCRF-CEM
cell line) to 11 μM (colon cancer, HCC-15 cell line). 1b was very potent against
melanoma (IC50=130 nM~1 M against all eight tumor cell lines) and prostate cancer
(IC50=170~270 nM against two tumor cell lines). Based on these preliminary cytotoxic
screenings, extensive structure-activity relationship (SAR) and in vivo studies were
carried out. In this chapter, I will discuss the biological evaluation and SAR studies of
ATCAA analogues based on 1a and 1b for both melanoma. These analogs were further
assessed for their ability to inhibit melanoma colony formation. The in vivo efficacy of
compound 1b was tested in a xenograft model using human A375 melanoma tumors. This
class of compounds showed potent antitumor activity and selectivity, which could
represent the basis for their development into novel chemotherapeutic drugs.
2.2 Materials and Methods
2.2.1 Compound Library
Ninety-one compounds were selected to form a library for biological testing.
Their activity was compared with the existing drugs, Taxol and DTIC (Sigma-Aldrich,
Inc., St. Louis, MO). In addition, Sorafenib (Bay43-9006) has recently been used
extensively in clinical trials for advanced melanoma and is well tolerated in patients (22).
Hence, Dr. Wei Li also synthesized Sorafenib based on published procedures (88), and
*Portions of this chapter adapted with permission from the following:
1. Li W, Wang Z, Gududuru V, et al. Structure-activity relationship studies of arylthiazolidine amides as
selective cytotoxic agents for melanoma. Anticancer Res 2007;27:883-8.
2. Li W, Lu Y, Wang Z, et al. Synthesis and antiproliferative activity of thiazolidine analogs for
melanoma. Bioorg Med Chem Lett 2007;17:4113-7.
3. Chen J, Wang Z, Lu Y, et al. Synthesis and antiproliferative activity of imidazole and imidazoline
analogs for melanoma. Bioorg Med Chem Lett 2008;18:3183-7.
4. Lu Y, Wang Z, Li CM, et al. Synthesis, in vitro structure-activity relationship, and in vivo studies of 2arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem 2010;18:477-95.
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Figure 2-1. Structures of LPA and ATCAA.
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used its activity as a standard to assess our lead compounds. Thiazolidine analogues were
synthesized by Dr. Yan Lu. Imidazole and imidazoline compounds were synthesized by
Mr. Jianjun Chen. I worked for the biological part.
2.2.2 Cell Culture
SK-MEL-188 cells were derived from primary tumors and cultured in Ham’s F10
medium (Gibco Invitrogen, Inc., Grand Island, NY) plus 5% fetal bovine serum (FBS)
(Cellgro Mediatech, Inc., Herndon, VA) and 1% antibiotic/antimycotic mixture (SigmaAldrich, Inc., St. Louis, MO) (89). WM-164 cells were derived from metastatic tumors
and were a gift from Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA). A375
cells and B16-F1 cells were purchased from ATCC (American Type Culture Collection,
Manassas, VA). Both WM-164 and human dermal fibroblast cells (purchased from
Cascade Biologics, Inc., Portland, OR) were cultured in DMEM (Cellgro Mediatech),
supplemented with 5% FBS, 1% antibiotic/antimycotic mixture and bovine insulin (5
μg/mL; Sigma-Aldrich Inc., St. Louis, MO). Human dermal fibroblast (adult) cells
(HDFa) were used as a control to examine the effect of compounds on the stromal
environment. Thus, the effect of drugs on melanoma cells versus fibroblasts would
document their potential selectivity.
2.2.3 Sulforhodamine B Assay
Cells were seeded into 96-well plates at 5000 cells/well. After 12 h, media were
changed and serial dilutions of compounds were added (1 nM~100 M). Cells were
incubated with each compound for 48 h. Fresh media containing the testing compound
were changed every 24 h. Thereafter, total cell protein corresponding to cell numbers
(both viable and non-viable cells) was measured using the sulforhodamine B (SRB) assay
according to the manufacturer’s protocol (Sigma-Aldrich Inc., St. Louis, MO) (79, 90).
Briefly, cells were fixed with trichloroacetic acid, washed, and incubated with
sulforhodamine B for 30 min. After another wash, dye incorporated into the cells was
solubilized and measured using a plate reader at 565 nm.
2.2.4 Lactate Dehydrogenase Release Assay
SK-MEL-188 cells were seeded at a density of 5000 cells per well in 96-well flatbottom microtiter plates. Media were changed after 12 h, and the testing compound was
added at serial dilutions. Media were changed with fresh compound every 24 h. After
incubation for 48 h, supernatants were collected and transferred to a new plate. Lactate
dehydrogenase (LDH) in supernatants was measured using Cytotox 96 Non-Radioactive
Cytotoxicity Assay (Promega, Madison, WI). Briefly, substrate mix solution (containing
tetrazolium salt) was added to each well and incubated at room temperature for 30 min.
At the end of incubation, stop solution was added to each well and the plate was read at
490 nm. Cytotoxicity of compounds was calculated using the following formula: %
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cytotoxicity=(experimental LDH release/maximum LDH release). Experimental LDH
release was calculated by subtracting the absorbance corresponding to the media alone
from the absorbance corresponding to control or compound-treated cells. Maximum LDH
release was calculated by subtracting the absorbance corresponding to the media with
added lysis solution from the absorbance corresponding to cells lysed with lysis solution.
2.2.5 DNA Content Analysis
Flow cytometry analysis was performed as described elsewhere (91). Briefly, SKMEL-188 cells were seeded in 10 cm Petri dishes at a density of 106 cells per dish; at 12
h the medium was changed to 5% FBS with different concentrations (0, 6 and 60 M) of
the testing compound. Cells were incubated for 48 h and media with compounds were
changed every 24 h. Cells were trypsinized, washed with PBS, and fixed in ice-cold 70%
ethanol. Ethanol was removed by centrifugation and cells were incubated in phosphatecitrate buffer (0.2 M Na2HPO4, 4 mM citric acid, pH 7.8) for 1 h. Finally, cells were
centrifuged and 1 mL of propidium iodide solution (50 μg/mL) and RNAse (0.1 mg/mL)
in PBS was added (92). Samples were shaken for 30 min and analyzed with a FACS
Calibur cytometer (Beckton Dickinson, San Diego, CA). Data were analyzed and graphs
prepared using the Modfit 2.0 program (Verity Software House, Topsham, ME).
2.2.6 Cell Cycle Analysis
Flow cytometry analysis was performed to study cell cycle phase distribution.
Briefly, A375 cells (4106) were seeded in 10 cm dishes; Cells were synchronized using
0.5% charcoal-stripped DMEM medium for 72 h. After that, the medium was changed to
the media containing 10% FBS with different concentrations (0, 1, 5, 10 and 20 μM) of
testing compounds. Cells were incubated for additional 24 h. All cells were collected by
trypsinization. Cell pellets were washed by PBS. The supernatant was discarded, and the
pellets were fixed in ice-cold 70% ethanol at 4°C overnight. Ethanol was removed by
centrifugation and cell pallets were washed with PBS twice. 1 mL of PBS containing 100
μg/mL RNAase A was then added and cell pallets were incubated for 1 h. Cells were
centrifuged and re-suspended in 1 mL of PBS containing propidium iodide (50 μg/mL).
Cell cycle analysis was conducted with a FACS Calibur Autometer (Beckton Dickinson,
San Diego, CA). Data were analyzed and graphs were prepared using the Modfit 2.0
program (Verity Software House, Topsham, ME).
2.2.7 Colony-Formation Assay
To measure colony formation and growth of melanoma, A375 cells were plated
at a colony-forming density (2000 cells per well on 6-well plates). Cells were grown in
DMEM supplemented with FBS (Atlanta Biologicals, Lawrenceville, GA) and an
antibiotic–antimycotic solution (Sigma, St. Louis, MO) at 37°C in an atmosphere of 95%
air and 5% CO2 (93). Cells were treated with compounds 1b and 3ad at different
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concentrations (2, 20, and 100 M). Compounds were added to the medium from 1 mM
DMSO stock solutions, and corresponding dilution of DMSO was used as negative
(vehicle) control. Cells were grown for 14 days, and colonies were stained with 0.1%
crystalline blue for 30 min and rinsed with distilled water to remove excess dye. Plates
were photographed, and the number of colonies was measured by Artek 880 Automated
Colony Counter (Artek Systems Corporation, Farmingdale, NY).
2.2.8 In Vivo Evaluation of Anti-Melanoma Efficacy
Compound 1b was dissolved into a co-solvent system that was composed of 80%
Tween 80 (Sigma-Aldrich, St. Louis, MO) and 20% Captex 200 (Abitec Corporation,
Columbus, OH). Dacarbazine (DTIC) (Sigma-Aldrich, St. Louis, MO) was dissolved in
saline solution. Male athymic nude mice aged 4-5 weeks were purchased from Harlan
Laboratories (Harlan Laboratories, Indianapolis, IN). The laboratory housing the animals
met all Association for Assessment and Accreditation and Laboratory Animal Care
specifications. All of the procedures were conducted in accordance with the guidelines of
our Institutional Animal Care and Use Committee.
A375 cells in a logarithmic growth phase were prepared in FBS-free DMEM
medium (Cellgro Mediatech) at a concentration of 5×107 viable cells/mL and placed on
ice. The cell suspension was mixed with BD Matrigel (BD Biosciences, Waltham, MA)
at a 1:1 ratio. This cell suspension (100 L) was injected subcutaneously in the right
dorsal flank of each mouse. When tumor sizes reached about 150 mm3, about 7 days after
cell inoculation, all mice bearing tumors were divided into control and treatment groups
based on tumor size (n=8 per group). Each group had similar average tumor size. Mice in
control groups were injected intraperitoneally with 50 L vehicle solution only (negative
control) or DTIC at 60 mg/kg (positive control) once daily. Tumor volume was measured
twice weekly with a Traceable® electronic digital caliper (Fisher Scientific, Inc.,
Pittsburgh, PA) and calculated using the formula a×b2×0.5, where a and b represented the
larger and smaller diameters, respectively (94). Tumor volume was expressed as cubic
millimeters. Data were expressed as mean ± SE for each group and plotted as a function
of time. Percentage tumor reduction at the conclusion of the experiment (22 days after
initiating treatment) was calculated from the formula 100-100[(T-T0)/(C-C0)], where T
represents mean tumor volume of a treated group on a specific day, T0 represents mean
tumor volume of the same group on the first day of treatment, C represents mean tumor
volume of a control on a specific day, and C0 represents mean tumor volume of the same
group on the first day of treatment (95). Animal activity and average body weight of each
group were monitored during the entire experiment period to assess compound toxicity.
At the end of treatment, all mice were euthanized by CO2 followed by cervical
dislocation, and tumors were harvested for further studies.
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2.2.9 Statistical Analysis
Data are presented as mean ± SEM (n=6~8). IC50 (i.e., concentration that
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear
regression analysis (GraphPad Prism, San Diego, CA). Statistical analyses were
performed with the Student’s t-test (*p<0.05, **p<0.001).
2.3 Results and Discussion
2.3.1 Identification of Lead Structures for Melanoma
In the first step of lead identification, cells were exposed to each compound at 10
µM to identify those which are active for both SK-MEL-188 and WM-164 cell lines. The
IC50 values of the seven most active compounds with 50% or more growth inhibition at
10 µM were subsequently measured on both cancer cell lines and on the control cells
(fibroblast cells). Activities of several compounds with similar structures to the active
compounds were also measured in order to understand the structure-activity relationships
(SAR). Sorafenib, DTIC and Taxol were assayed in the same way for comparison and
served as internal quality controls in the different assay batches. The results for all three
cell types are summarized in Table 2-1.
Overall, three basic structures were found very active in inhibiting both melanoma
cell lines: (A) serine amides (e.g. VG-III-15), (B) serine amino alcohols (VG-II-197), and
(C) arylthiazolidine-4-carboxylic acid amides (ATCAA, e.g., VG-III-39) (Figure 2-2).
Analogs of (A) and (B) did not possess acceptable selectivity for cancer cells.
Thiazolidine derivatives (C) displayed the highest potency and selectivity with IC50
values in the nano-mole range for cancer cells (Table 2-1, VG-III-39). Not surprisingly,
data from this in vitro assay indicated that DTIC is inactive (IC50>100 µM) against both
cancer cell lines due to the lack of bio-activation. This is consistent with the currently
proposed mechanism of action for DTIC, as well as findings by Daidone and co-workers
(96). Clearly, in vivo assay is needed to assess the true activity of DTIC and similar
structures. While Taxol is outstanding in inhibiting cancer cell growth, it is not effective
in killing melanoma cells (cytostatic). In contrast, all the lead compounds from these
preliminary studies killed the cells completely at higher concentrations. The mechanisms
of action of our compounds are clearly different from that of DTIC and Taxol.
Sorafenib effectively killed all the melanoma cells at high concentrations, similar
to that of our lead compounds. When measured by IC50 values, VG-III-39 is about 10
times as potent as Sorafenib. Its selectivity, defined as the ratio of IC50 in fibroblast cells
over IC50 in melanoma cells, is moderate when compared with that of Sorafenib (10 vs.
larger than 3). Together with the clinical finding that Sorafenib has low toxicity and is
well tolerated by patients (22). The potency and selectivity of Sorafenib provide an
excellent standard to assess the activities of our compounds and represent the future goal
for optimization of our lead structures.
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Table 2-1. IC50 of the lead compounds, Sorafenib, DTIC and Taxol.
Structure

Name

IC50 (µM) (n=3)
SK-MEL-188

WM-164

HDFa

VG-II-189

>10

>10

ND

VG-III-15

4

3

3

VG-II-197

3

4

2

VG-II-201

3

4

3

VG-III-215

ND

>50

ND

VG-III-41

24

18

28

VG-III-149

40

>50

>50

10

13

28

VG-III-267

2

3

>10

VG-III-265

2

2

5

VG-III-271

3

6

>10

VG-III-39

570 nM

460 nM

6

Sorafenib
Taxol
DTIC

4
4 nM
>100

5
6 nM
>100

15
12 nM
>100
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Figure 2-2. Identified active lead structures for melanoma.
Several important SARs were revealed in examining the 91-member library.
Firstly, amides were less active than the corresponding alcohols (Figure 2-2A and B
respectively). Heteroatoms on the side chain substantially increased the potency (VG-III15), but unsaturation on the side chain had the opposite effect (VG-II-189). Secondly, an
alkyl amine (VG-II-197) was about equipotent to the un-substituted amine (VG-II-201),
suggesting that cyclization of the amine and alcohol may be possible. However, none of
the open chain compounds displayed acceptable selectivity against cancer cells. Thirdly,
the presence of the aromatic ring in the heterocyclic compounds improves selectivity and
cytotoxicity of structure C (Figure 2-2) (VG-III-215 vs. VG-III-149). Fourthly, the
potency of the compounds depended strongly on the chirality at C-4 position (VG-III-41
vs. VG-III-149), the substitution on the aromatic ring (VG-III-149 vs. VG-III-265), and
the chain length (VG-III-39 vs. VG-III-149). With a similar C18 chain, the S-isomer at
the C-4 position (VG-III-41) showed higher potency than the R-isomer (VG-III-149).
More electron donating substitutions on the aromatic ring progressively increased the
potency of analogs of structure C (VG-III-149 vs. VG-III-83, VG-III-267, and VG-III265). N-substitution with the C14 chain was much more potent and selective against
cancer cells than that of the C18 chain compound (VG-III-39 vs. VG-III-149). Clearly,
further structural optimization is warranted and will likely improve both potency and
selectivity for this class of compounds against melanoma.
It is interesting to compare the activity in melanoma with that in prostate cancer
for these compounds. In general, their activities are consistent in these two types of
cancer cells, demonstrating potentially broad anticancer properties for ATCAA analogs.
Compounds that are active or inactive in prostate cancer also displayed similar behavior
in melanoma, but there are a few exceptions. For example, although VG-III-149 (C18
chain length) showed excellent activity (IC50<3 µM) against prostate cancer cells, it was
not active in both melanoma cell lines (IC50>40 µM). In addition, for compounds which
are active in both cancer types, their relative potency and selectivity are not the same. For
example, in prostate cancer studies, a compound with a C14 side chain was found to be
slightly less active than that with a C18 chain. Substitutions on the aromatic ring with
mono-, di- or tri-methoxyl groups were found to be favorable in prostate cancer cell lines.
Both the potency and selectivity increased as more methoxyl substitutions were added to
the aromatic ring (82). In melanoma, however, methoxyl substitutions did not have
significant selectivity benefits when compared with nonsubstituted analogs (e.g. VG-III29

83 vs. VG-III-265). A C14 chain displayed much better activity and selectivity than C18
chain compounds (e.g. VG-III-39 vs. VG-III-265). Interestingly, Taxol behaves very
differently in prostate cancer cells and melanoma cells. While Taxol killed all the prostate
cancer cells, it only killed about half of the melanoma cells when compared with controls
based on our in vitro assay. This may suggest different oncogenic properties between
these two types of cancer.
2.3.2 VG-III-39 Induced DNA Degradation and LDH Release
To examine more closely the cell death induced by our compounds, I measured
lactate dehydrogenase (LDH) release by colorimetric assay and analyzed DNA content
by flow cytometry.
LDH is a stable cytosolic enzyme that is released upon cell lysis. Treatment of
cells with VG-III-39 resulted in a dramatic dose-dependent increase of LDH released to
the cellular environment (Figure 2-3A).
Analysis of the DNA content of control cells (Figure 2-3B) showed peaks
corresponding to the cells in G1/0-cell phase (62%), S-phase (32%) and G2/M-phase
(6%), a typical distribution of cells in culture (92). Treatment of cells with VG-III-39 at 6
μM and 60 μM led to the disappearance of peaks corresponding to viable, proliferating
cells and the appearance of single peaks corresponding to debris/degraded DNA.
2.3.3 Early Stage SAR Study of Thiazolidine Derivatives
The ability of thiazolidine derivatives to inhibit the growth of two melanoma
cancer cell lines and fibroblast cells is summarized in Table 2-2. Sorafenib (Velcade) has
been used extensively in clinical trials for melanoma. Hence I selected this compound
and DTIC as reference standards to assess the activity of our compounds. At this early
stage, all compounds were used as a diastereomeric mixture if they contain chiral centers
in order to select the most promising compounds for further development.
Examination of antiproliferative effects for a variety of substitutions on the
phenyl ring revealed the chain-length dependence for these compounds (1~5, 6~9, 10~13,
14~19). Short chain length such as a C10 chain (e.g., compound 2, 6, 10) displayed low
potency for both cancer cells and fibroblast cells. As chain length increased, potency
increased, as well as toxicity as measured on fibroblast cells except when the acetyl
amino group was substituted on the phenyl ring (compound 14~17). Both C15 and C16
chains with this substitution displayed both high potency and high selectivity against
cancer cells, with an IC50 for melanoma cells as low as 600 nM (compound 17). Further
chain increases, however, reduced potency and selectivity. At a chain length of C18
(compound 19), the IC50 value was higher than 10 M for all three cell lines.
Interestingly, adding either a cis- or trans- double bond in the C18 side chain restored
potency dramatically (compound 20Z and 20E), demonstrating that both length
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Figure 2-3. Compound VG-III-39 induced DNA degradation and LDH release.
SK-MEL-188 melanoma cells were incubated with VG-III-39 for 48 h. A: LDH released
from the cells after treatment was then analyzed. Data is presented as mean±SEM (n=8),
*p<0.05, **p<0.001. B: DNA content was analyzed using flow cytometry. Results are
representative of two separate experiments.
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Table 2-2. Cytotoxic activity of thiazolidine analogs, Sorafenib and DTIC.
Structure

S
R

N
H

CONR1R2

Compound
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20Z
20E
21
22
23
26
27

R1

R

R2

3,4,5-trimethoxyl
n-C8H17
H
3,4,5-trimethoxyl
n-C10H21
H
3,4,5-trimethoxyl
n-C12H25
H
H
3,4,5-trimethoxyl
n-C14H29
3,4,5-trimethoxyl
n-C16H33
H
H
3,4-dimethoxyl
n-C10H21
H
3,4-dimethoxyl
n-C12H25
3,4-dimethoxyl
n-C14H29
H
H
3,4-dimethoxyl
n-C16H33
3,4 -OCH2On-C10H21
H
n-C12H25
H
3,4 -OCH2On-C14H29
H
3,4 -OCH2O3,4 -OCH2On-C16H33
H
n-C12H25
H
NHCOCH3
NHCOCH3
n-C14H29
H
n-C15H31
H
NHCOCH3
n-C16H33
H
NHCOCH3
NHCOCH3
n-C17H35
H
n-C18H37
H
NHCOCH3
(Z)-Octadec-8-enyl H
NHCOCH3
(E)-Octadec-8-enyl H
NHCOCH3
H
H
n-C14H29
H
n-C16H33
H
H
OCH3
CH3
NH2
n-C12H25
H
NH2
n-C16H33
H
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IC50SEM (M) (n=3)
SK-MEL-188 WM-164
HDFa
171
201
2110
153
20
74
20
20
21
21
20
30
20
10
20
126
63
61
31
21
52
21
10
31
20
10
21
71
50
83
40
30
51
20
10
41
20
20
62
20
10
40
20
10
41
20
10
142
20
10
198
90
20
365
>60
223
121
10
10
111
30
10
184
21
10
30
20
10
20
>100
>100
>100
20
10
41
20
10
71

Table 2-2. (continued)
Structure

Compound

S
N
H

R

1 2

CONR R

S
R

N

CONR1R2

24
25
28
29

R1

R

3,4,5-trimethoxyl n-C14H29
NHCOCH3
n- C16H33
H
n-C14H29
3,4-dimethoxyl n-C14H29

R2
H
H
H
H

IC50SEM (M) (n=3)
SK-MEL-188 WM-164 HDFa
20
10
41
30
10
233
>50
>50
425
>50
192
4310

S
N
1 2
CH3 CONR R

R
S
R

N
C
O

O
C
N
S

R

30

NHCOCH3

n-C16H33

H

291

>100

>100
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3,4,5-trimethoxyl

N/A

N/A

>50

>50

>50

>100
51

>100
50

>100
151

DTIC
Sorafenib

NA: not available.
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and composition of the side chain are critical for their activity. There is no significant
difference in their activity between the cis- and trans- isomers.
Removing the acetyl amino group on the phenyl ring (compound 21 and 22)
resulted in the loss of selectivity, although potency was similar to those with this
substitution (compounds 15 and 17). Replacing the alkyl chain with a methoxyl group
completely abolished potency (compound 23). Changing the chirality from an R to S
configuration at the C4 position on the thiazolidine ring did not substantially affect either
potency or selectivity (compound 4 vs. 24 and compound 17 vs. 25). Selectivity has a
strong dependence on the substitutions in the phenyl ring. For example, with a C12 chain,
potency is similar for all the substitutions I studied (compounds 3, 7, 11, 14, and 26).
However, selectivity improves dramatically when proper substitutions are present
(compound 17 vs. compounds 5, 9, 13, 22, and 27).
When the amino group in the thiazolidine ring is substituted (compound 30) or a
double bond is introduced (compounds 28 and 29), the resulting compounds are largely
inactive with IC50 values above 20 µM. I also tested the intermediate compound in which
the amino group is protected by a Boc group, and that compound is inactive also (data not
shown). Furthermore, when Dr Yan Lu removed the aliphatic chain and the amino group
by synthesizing a dimer, she obtained an inactive compound (compound 31). These
results clearly demonstrate the importance of the amino group in the thiazolidine ring.
2.3.4 Further SAR Studies with New Thiazolidine Derivatives
The diastereomeric mixtures of compounds 3aa-15c were used to evaluate their in
vitro inhibitory activity and toxicity against two human melanoma cell lines (A375 and
WM-164), one mouse melanoma cell line (B16-F1), fibroblast cells (control cell line for
melanoma). Because preparing pure diastereomers was not easy to achieve, the IC50
values were obtained on diastereomeric mixtures to select the most promising
compounds. The standard sulforhodamine B (SRB) assay was used to evaluate the
antiproliferative activity of different compounds in melanoma cells. The results are
summarized in Table 2-3. Compound 1a and 1b were chosen as control compounds for
both tumor cell lines in these in vitro studies. Cisplatin (CDDP), DTIC, and Sorafenib
(Nexavar, Bay43-9006, which had been granted Fast Track designation by FDA to treat
advanced melanoma) were used as reference compounds for melanoma (97). The
antiproliferative data showed that all three melanoma cell lines were resistant to cisplatin.
DTIC was inactive because of the lack of bioactivation in vitro (98, 99). The average IC50
value of Sorafenib on three melanoma cell lines is 5 µM, and the selectivity of Sorafenib
between fibroblast cells and melanoma cells is 3-fold. Our purpose in modifying
chemical structure was to enhance the selectivity between tumor cells and control cells
and to increase or maintain antitumor potency. Thus, I used the average IC50 value of all
melanoma and prostate cancer cells for comparison. Selectivity is defined as the ratio of
IC50 values in the control cell line and the average in tumor cell lines. From Tables 2.3,
the most selective compound (3id) had a selectivity of 11.3-fold in melanoma cells
against fibroblast cells.
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Table 2-3. Cytotoxic activity of ATCAA on three melanoma cell lines and a fibroblast
cell line.
S
R1

ID

X

CON
3aa
CON
3ab
CON
3ac
CON
3ad
CON
3ba
CON
3bb
CON
3bc
CON
3ca
CON
3da
CON
3ea
CON
3fa
CON
3ga
CON
3ha
CON
3ia
CON
3ib
CON
3ic
3id
CON
CON
3ie
CON
3if
CON
3ig
CON
3ih
CON
3ii
CON
3jb
CON
3jc
CON
4
COO
5
CH2N
8a
CH2N
8b
CON
15a
CON
15b
CON
15c
CON
1a
CON
1b
DTIC
CDDP
Sorafenib

1

R

3, 4, 5-trimethoxy
3, 4, 5-trimethoxy
3, 4, 5-trimethoxy
3, 4, 5-trimethoxy
3, 4-dimethoxy
3, 4-dimethoxy
3, 4-dimethoxy
2-OMe
3-OMe
4-OMe
4-NMe2
2-NHAc
3-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
4-NHAc
H
H
4-NHAc
4-NHAc
H
4-NHAc
4-NHSO2CH3
4-NHCOCH2Cl
4-NHCONH2
H
4-NHAc

N
R4
2

R

XR2R3

3

4

IC50SEM (M) (n=3)

R R B16F1
n-C18H37
H H 60
(Z)-octadec-8-enyl H H 50
(E)-octadec-8-enyl H H 30
n-C16H33
H H 20
n-C18H37
H H 141
(Z)-octadec-8-enyl H H 30
(E)-octadec-8-enyl H H 30
n-C16H33
H H 40
n-C16H33
H H 30
n-C16H33
H H 20
n-C16H33
H H 71
n-C16H33
H H 80
n-C16H33
H H 20
n-C18H37
CH3 H 191
1-adamantanyl
H H 974
2-adamantanyl
H H 1085
9H-fluoren-2-yl H H 40
anthracen-2-yl
H H 60
4-biphenyl
H H 60
2-benzothiazolyl H H 553
(Z)-hexadec-9-enyl H H 20
nonadec-10-ynyl H H 20
(Z)-octadec-8-enyl H H 61
(E)-octadec-8-enyl H H 101
n-C16H33
H Ac 151
n-C16H33
H H 423
n-C16H33
H H 50
n-C16H33
H H 120
n-C16H33
H H 1142
n-C16H33
H H 934
n-C16H33
H H 61
n-C18H37
H H 161
n-C16H33
H H 20
>100
>100
50
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A375
50
20
20
10
70
20
10
30
20
20
20
91
20
212
1384
662
20
30
60
464
20
30
51
50
131
282
130
140
512
201
40
151
20
>100
>100
51

WM164
30
10
10
10
30
10
10
20
10
10
20
41
10
111
1283
643
20
10
40
>100
20
10
20
20
201
190
50
30
191
60
20
40
10
>100
>100
50

HDFa
50
50
40
20
201
181
161
70
30
81
213
284
60
>100
>100
>100
291
141
334
>100
141
70
121
121
581
>100
601
853
>100
251
70
302
163
>100
>100
151

2.3.4.1 SAR of Different Amide Chains and Chain Length of ATCAA
ATCAA molecules were designed from LPA structure, which contains a long
aliphatic chain. To examine whether the fatty chain played an essential role in
cytotoxicity, we explored the possibilities of mimic fatty chain with bulky ring or
aromatic systems such as adamantanyl, fluorenyl, and anthrancenyl. Although the
antiproliferative data showed that 1- or 2-adamantanyl amides and 2-benzothiazolylamide
(3ib, 3ic, and 3ig) had lower activity against most melanoma cells, introducing certain
aromatic bulky groups such as 9H-fluoren-2-yl (3id), anthrancen-2-yl (3ie), and 4biphenyl (3if) retained their proliferative activity. Of particular interest, while introducing
9-fluoren-2-yl (3id) showed a comparable IC50 value of 3 µM with 1b (2 µM) on
melanoma cells, the selectivity of 3id increased to 11 fold from 9 fold in 1b. This
structural modification provided us a new approach to optimize the drug-like properties
of ATCAA molecules, in which the hydrophobic fatty lipid chain could be modified with
other groups (100).
Hexadecyl chains (3ad) displayed both the highest potency and selectivity against
cancer cells among the examined chains, with an IC50=1 µM for WM-164 cells.
However, further increasing chain length (18 carbons, 3aa) reduced potency and toxicity.
Interestingly, adding either a cis- or trans- double bond in the C18 side chain restored
potency dramatically (cis- and trans-octadec-8-enyl), demonstrating that both length and
composition of the side chain are critical for their activity. Trans-octadec-8-enyl chain
(3ac, 3bc, 3jc) showed slightly better activity than did the cis-isomers (3ab, 3bb, 3jb)
against melanoma cells. Introducing a cis-double bond in the C16 fatty chain (3ih) or an
alkyne in the C18 chain (3ii) did not increase overall potency. Introducing a branched
aliphatic chain (3ia) decreased the potency in both melanoma cells (average IC50=17 µM,
9.3 fold decrease) compared with 1b (average IC50=2 µM).
2.3.4.2 SAR of Substitutions on 2-Phenyl of ATCAA
The antiproliferative effects indicated that when methoxy, 3, 4-dimethoxy, and 3,
4, 5-trimethoxy were introduced to 2-phenyl (3aa-3ea), potent activity was preserved or
increased compared with that of 1a. For example, (2RS, 4R)-2-(3, 4, 5-trimethoxyphenyl) thiazolidine-4-carboxylic acid octadecylamide (3aa) (average IC50=5 µM) was 3
fold more potent than was 1a (average IC50=12 µM). Subsequently, different groups were
introduced to the para-phenyl position. Replacements of 4-NHCOCH3 (1b) with 4-N
(CH3)2 (3fa) showed comparable activity on A375 (IC50=2 vs. 2 µM) and WM-164 cells
(IC50=2 vs. 1 µM) but slightly lower selectivity on fibroblast cells (IC50=21 vs. 16 µM).
Although 4-N (CH3)2 (3fa) substituted ATCAAs were more potent than was 1a
(average IC50=3 µM for 3fa, and 12 µM for 1a), they were less potent than 1b (average
IC50=2 µM and selective ratio=8.9 for 1b). Methanesulfonamide (15a) or 2chloroacetamide (15b) were less potent (IC50=6~114 µM) and less toxic (IC50= 25~>100
µM) on melanoma cell lines compared with 1b. Introducing an ureido, 4-NHCONH2
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(15c) instead of a 4-NHCOCH3 kept partial potency (average IC50=4 µM) but resulted in
loss of selectivity against melanoma cells (1.8-fold for 15c vs. 8.9-fold for 1b).
We also investigated the importance of o-, m-, and p- substitutions in the 2-phenyl
ring relative to acetylamino and methoxy groups. Interestingly, o-, m-, and p- isomers
showed different activities. P-Isomers (3ea, 1b) had the best selectivity and activity. MIsomers (3da, 3ha) had similar average IC50s against melanoma compared with pisomers, but their toxicity also increased on fibroblast (3 µM). o-MeO and o-NHAc
analogues (3ca, 3ga) showed slightly less potency and selectivity.
2.3.4.3 SAR of 4-Linkage of ATCAA and Thiazolidine Ring
To investigate the importance of amide linkage on C4 of ATCAA, the
carboxamide was replaced with an ester and amine. The isosteric replacement of the
amide by an ester resulted in 5 with markedly decreased activity against all cancer cell
lines. The amine derivatives 8a and 8b also failed to show any increased potency,
although they did show lower toxicity (60-85 µM) than did 1a (30 µM) and 1b (16 µM)
in fibroblast cells.
Thiazolidine-4-carboxylic acid has been reported to be effective for treating
advanced cancers (101, 102). To examine the importance of a central thiazolidine ring,
Dr Yan Lu synthesized 3-acetyl-thiazolidine compound 4 and a series of thiazolidine
ring-opened compounds 16a-16d. The structure of these ring-open and their relationship
is shown if Figure 2-4. Antiproliferative activity of 16a-16d against melanoma is
summarized in Table 2-4. When acetyl was introduced to 3-NH of thiazolidine, activity
decreased in both cancer cell lines (average IC50=16 and 10 µM against melanoma and
prostate cancer, respectively). Cleavage of both the C-S and C-N bond (16a) led to
substantial decrease in both potency (13~14 µM on melanoma cell lines) and toxicity (61
µM on the control cells) compared with 1b and 3ja (1~2 µM on cancer cells, 2~16 µM on
control cells). Opening the thiazolidine ring from the C-S bond (16b) caused a loss of
potency on both cancer and control cells (>100 µM). Cleavage of the C-N bond in the
thiazolidine ring (16c) also resulted in decreased activity (13~15 µM) and no
improvement on selectivity compared with 3ja. Removing the C-S bond (16d) reduced
the activity of 1b from IC50=1~2 µM to 10~12 µM. These results suggested that the
presence of the thiazolidine ring is critical for activity. Attempts to reduce the amide with
LAH or B2H6 resulted in the C-S bond cleavage in thiazolidine. A disulfanyl dimer,
which completely lost anticancer activity, was obtained, and this result is consistent with
the above finding that the thiazolidine ring played an essential role in ATCAA potency.
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Figure 2-4. Structure relationship of thiazolidine ring-open compounds.

Table 2-4. Cytotoxic activity of thiazolidine ring-open compounds against melanoma.
ID

IC50SEM (M) (n=3)
A375
WM-164
HDFa

16a
16b
16c
16d
3ja
1b

131
1095
151
121
ND
20

141
1455
132
111
10
10

ND: not determined
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614
>100
161
241
20
163

2.3.5 SAR Summary of ATCAA for Melanoma
After extensive chemical structure modification and in vitro activity studies on
melanoma cells, the overall SAR of ATCAA compounds on melanoma cells was
summarized in Figure 2-5. From the above studies, we generalized several important
SAR. Firstly, Thiazolidine ring and the free NH on the ring are very critical for the antimelanoma activity. The carbon 4 chiral center on the thiazolidine ring is not important for
activity because both isomers showed similar potency. Secondly, for the side chain,
aliphatic chain with a length of 16 carbons was best for activity. It also can be replaced
by 9H-fluoren-2-yl group. Thirdly, the link between the thiazolidine ring and the side
chain prefer amide to ester and amine. Lastly, for the substituents on the phenyl ring,
electron donating group (EDG) is better than electron withdrawing group (EWG), paraand meta- substitution are the same, ortho-substitution is slightly worse.
2.3.6 SAR of Newly Synthesized Imidazole and Imidazoline Analogs
I found that the chirality at position 4 in thiazolidine ring of ATCAA analogs is
not critical for their activity. However, the importance of chirality at position 2 is
unknown, because all our previous compounds were tested as diastereomers. Separation
of these stereoisomers by chromatographic methods turned out to be extremely difficult.
Dr. Li asked for assistance from scientists from Chiralcel Technologies who tried both
normal-phase and reverse-phase conditions with their nine chiral columns, but none of
the combinations could separate these stereoisomers satisfactorily.

a. Free NH and thiazolidine ring contribute to anticancer
activity; 4R and 4S isomers have similar potency
b. Fatty chains (C-16 optimum) and
9H-fluoren-2-yl are the best for activity

S
*
R1

N
R

4

*

R2R3

X

c. amide is better than ester and amine
d. Phenyl substitutions: EDG is better than EWG; para- and metasubstituents are comparable; ortho-substituents are slightly worse
Figure 2-5. SAR summary of ATCAA for melanoma.
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Converting the thiazolidine ring to an imidazoline or imidazole ring represents a
very productive approach. First, the nitrogen-containing ring would be very stable.
Imidazoline and imidazole rings are important biological building blocks and are present
in many existing drugs (103). Second, the imidazoline ring contains only one chiral
center, and the imidazole ring contains no chiral center at all. These attributes may
alleviate or even eliminate the need for future chiral separations. So Mr. Jianjun Chen
made the following modification to ATCAA: a) replacing sulfur with nitrogen or carbon
to understand the importance of the heteroatom in the ring, b) introducing one or two
double bonds in the ring (imidazoline and imidazole) to understand the importance of the
chiral centers, and c) introducing various spacers between the five-member ring and the
aromatic ring to understand the relative spatial arrangements for the two rings.
I examined the antiproliferative activity of these imidazoline and imidazole
analogs in two melanoma cell lines (human A375 cells and mouse B16 cells) and in a
fibroblast cell line. The ability of these new analogs to inhibit the growth of melanoma
cancer cell lines and fibroblast cells is summarized in Table 2-5.
In summary, none of the new analogs is as active as the lead compound. Although
they do not contain any chiral centers, analogs containing an imidazole ring (compounds
5-11) did not have activity at concentrations below 10 M. Replacing the imidazole ring
with an imidazoline ring slightly improved the activity in general (compounds 15-19),
with substantial improvement when trimethoxyl or amino acetyl substitutions were added
(compounds 20-21). The structure activity for the side chain was similar to that of the
thiazolidine analogs, with a saturated C14~C16 chain or an unsaturated C18 chain to be
optimal for activity against melanoma cells. Similarly, electronic donating substitutions
on the paraposition of the aromatic ring increased activity (compounds 20-21). Replacing
sulfur with carbon in the five-member ring produced an inactive compound (compound
30). Collectively, these results indicate that the thiazolidine ring is critical for the activity
of this series of compounds.
When a spacer was inserted between the imidazoline/thiazolidine ring and the
phenyl ring (compounds 22-29), there is no noticeable improvement in their activity
(compound 20 vs. compound 22). Increasing the size of the spacer by replacing one
hydrogen in the methylene group with a methyl group reduced the activity (compound 23
vs. 26, and compound 24 vs. 27). Both of these results seemed to indicate detrimental
effects of spacers for the activity. Finally, replacing the side chain with a fluorene group
resulted in complete loss of activity (compound 23 vs. 25). However, with proper
parasubstitution on the aromatic ring, the activity dramatically improved (compound 25
vs. compound 29) for this series of compounds. On the other hand, with a C16 side chain,
the substitution on the phenyl ring had the opposite effect (compound 23 vs. 26) in sharp
contrast to the non-chain analogs such as 29 and may indicate a different mechanism of
action when the long side chain is replaced by a conjugated ring system.
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Table 2-5. Cytotoxic activity of imidazolines, imidazoles and comparison with Sorafenib and the lead thiazolidine compounds.
Structure
H
N
NR1R2

N

R

O

O
N

R

NR1R2

N
H

H
H
H
H
H
H
H
H
H
H
H
CH3
H
H

A375
>30
>30
191
171
211
161
>30
70
100
541
80
>20
41
50

IC50SEM (M) (n=3)
B16-F1
>30
~30
382
402
>30
321
>30
70
60
511
120
>20
40
20

HDFa
>30
>30
432
281
471
241
>30
172
601
1114
253
>20
131
152

n-C16H33

H

40

40

162

n-C16H33
(E)-Octadec-8-enyl
2-Fluorene
n-C16H33
(E)-Octadec-8-enyl
n-C16H33

H
H
H
CH3
CH3
H

81
101
17411
131
211
19114

70
120
1188
120
171
17121

151
162
>100
567
23739
>100

29

140

120

472

Sorafenib

51

50

151

Compound

R

R1

R2

5
6
7
8
9
10
11
15
16
17
18
19
20
21

H
H
H
H
H
H
H
H
H
H
H
3,4,5-trimethoxyl
3,4,5-trimethoxyl
p-NHCOCH3

n-C10H21
n-C12H25
n-C14H29
n-C16H33
n-C18H37
(E)-Octadec-8-enyl
p-Bromophenyl
n-C14H29
n-C16H33
n-C18H37
(E)-Octadec-8-enyl
OCH3
n-C16H33
n-C16H33

22

3,4,5-trimethoxyl

23
24
25
26
27
28

H
H
H
H
H
p-NHCOCH3

O
R

H2
C

N

NR1R2

N
H

R

O

R2

H
N

C
H

S

NH
NH

O
N
H

R1

n-C16H33
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2.3.7 Flow Cytometry Analysis of Active ATCAA Compounds
Flow cytometry analysis was performed on human melanoma A375 to examine
the effect of the new synthetics on cell cycle progression. Analysis of the DNA content of
control cells (Figure 2-6, top graphs) showed typical distribution of peaks corresponding
to cells in G1/G0 phase (65.67~66.97%), S-phase (24.16~28.36%), and G2/M-phase
(5.97~8.87%). Upon treatment with compounds 3ad and 1b at 1, 5, 10, and 20 µM
concentrations for 48 h, flow cytometric analysis showed that these compounds
significantly induced apoptosis (sub-G1 phase) in cancer cells in a dose-dependent
manner. The accumulation of cells in sub-G1 phase became apparent at 5 µM.
2.3.8 ATCAA Inhibited Human Melanoma Colony Formation in Soft Agar
Cells grown in 96-well plates do not reflect many properties associated with
three-dimensional tumors. Human tumor colony formation assay (ex vivo soft agar colony
assay) has been suggested as an in vitro method to predict the response of an individual
patient's tumor to chemotherapeutic agents (104, 105). As a prelude to in vivo animal
experiments, I investigated the ability of compound 1b and 3ad to inhibit melanoma
colony formation by using a well-established method (93, 106, 107). I performed studies
with A375 human melanoma cells. Photos and quantified results are shown in Figure 2-7
and Figure 2-8. Compounds 1b and 3ad effectively inhibited A375 colony formation at 2
M, the lowest tested concentration. At a concentration of 20 M, compound 3ad almost
completely inhibited colony formation, while compound 1b inhibited colony formation
by 75%. At the highest tested concentration, 100 M, melanoma colony formation was
completely inhibited by both 1b and 3ad.
2.3.9 Antitumor Efficacy of ATCAA on A375 Xenograft Model
I chose human melanoma A375 cells to test efficacy in vivo because ATCAA
exhibited potency both in vitro assay and colony formation assay against A375 cells.
A375 xenograft tumors also exhibited faster tumor growth rate. While compound 3ad
was more potent than was 1b in inhibiting melanoma colony formation, it had much
poorer selectivity between melanoma cancer cells and fibroblast cells (2.0 fold for 3ad vs.
8.9 fold for 1b) as shown in Table 2-3. Therefore, I chose 1b for our in vivo studies
against A375 melanoma tumors. This compound was formulated with 80% Tween 80 and
20% Captex 200 because of its limited water solubility (108). I first determined the
maximally tolerated dose (MTD) in ICR (imprinting control region) mice. These mice are
less expensive than nude mice and are commonly used for toxicity testing. The MTD for
compound 1b was determined to be 42 mg/kg. Two nontoxic dosages (5 mg/kg and 10
mg/kg) were used. I also included DTIC (60 mg/kg) the gold standard for melanoma
treatment, as a positive control to assess the efficacy of compound 1b (109). Briefly, male
athymic nude mice were injected subcutaneously with 2.5×106 A375 cells. Treatment
began on day 7 after tumor inoculation, and 1b was injected once a day. Each group had
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Figure 2-6. Flow cytometry analysis of selected ATCAA compounds.
Sub-G1 phase accumulation was induced by tested compounds on melanoma A375 cells.
(This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of
Pharmacy, the Ohio State University).
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Figure 2-7. Human melanoma A375 cells colony formation in soft agar with ATCAA
treatment.
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Figure 2-8. Quantified results of colony formation assay with compounds 3ad and 1b
treatment.
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eight mice. The results are shown in Figure 2-9. Compound 1b at 5 mg/kg showed
moderate melanoma tumor growth inhibition. After 22 days of treatment, the percentage
of tumor reduction was 25%. At a higher dose of 10 mg/kg, compound 1b showed
significant melanoma tumor growth inhibition with 62% of tumor reduction. When
comparing with DTIC at a dose of 60 mg/kg, which inhibited tumor growth by 42% at
the end of treatment, compound 1b clearly showed superior activity in this human
melanoma xenograft model. All mice displayed normal activities, and no significant body
weight loss was observed during the experiment.
2.4 Conclusions
ATCAA analogs represent a novel class of potent and selective cytotoxic agents
for melanoma. Initial analysis indicated that the antineoplastic activity is attributed to
their ability to induce DNA break and LDH release in melanoma cells. These SAR
studies revealed that the potency of the compounds depends strongly on the chain length
and substitutions on the phenyl ring. Our current lead compound is highly potent and
moderately selective when compared with Sorafenib, a drug used extensively in clinical
trials for melanoma.
Dr. Yan Lu then synthesized a series of ATCAA compounds and thiazolidine
ring-opened analogues. Chemical modification and structure-activity relationship of
ATCAA compounds were investigated with different substituted 2-phenyl, thiazolidine
ring, 4-position linkage, and 4-carboxamide groups based on biological evaluation
against melanoma cells. Some compounds are very promising agents against melanoma.
Compounds 1b and 3ad effectively inhibited A375 melanoma colony formation.
Compound 1b at a dose of 10 mg/kg significantly inhibited melanoma tumor growth in
vivo and showed higher efficacy than did DTIC at a dose of 60 mg/kg. These compounds
did not seem to work via the LPA-GPCR pathway.
Mr. Jianjun Chen also synthesized new imidazole and imidazoline analogs, based
on our previous studies, by focusing on the structure activity relationship studies of the
central five-member ring. Although the current compounds displayed lower potency
when compared with our lead thiazolidine analogs, they may have the distinct advantage
of being more stable in vivo with the reduced necessity of chiral separations. Some of
these new compounds have activity similar to Sorafenib.
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Figure 2-9. In vivo anti-melanoma test of compound 1b on athymic nude mice (n=8 per
group) bearing A375 xenograft.
A: Tumor growth curve of control, compound 1b and DTIC treatment. DTIC was used as
positive control. B: Average body weight change in control and treatment groups.
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CHAPTER 3. IDENTIFYING NOVEL MOLECULAR STRUCTURES FOR
ADVANCED MELANOMA BY LIGAND-BASED VIRTUAL SCREENING*
3.1 Introduction
In our ongoing efforts to search for small molecules as potential therapeutic
agents for advanced melanoma, our team recently discovered a new series of thiazole
analogs that showed very potent activity against melanoma cells in vitro (110). One of
the best compounds in this series has an IC50 value below 60 nM. Screening results from
the National Cancer Institute (NCI-60 screening) for our lead compound, LY-1-100,
indicated nanomolar antiproliferative activity for all the cancer cell lines tested.
Preliminary mechanism of action studies on this series of compounds indicated that they
may interact with microtubules (110). In vivo testing with melanoma tumors showed
substantial growth inhibitory activity for this series of compounds. To further expand our
understanding of structure-activity relationships and to potentially identify new platforms
for active compounds, Dr. Wei Li and Dr. William Seibel explored a compound library
from the University of Cincinnati’s (UC) Drug Discovery Center, which contains
342,910 small molecules. All compounds are available to us for testing via an established
agreement. Usually, compounds are shipped within 2 days of request. Therefore, I can
obtain any compound I select easily for biological testing. Although other compound
libraries may have more entries than does the UC library, often availability of the
compounds is an issue. Therefore, I chose this library for our current studies.
In this chapter, I will discuss two ligand-based virtual screening approaches using
the structure of our lead molecule (Figure 3-1): 1) similarity search based on atom
connectivity using Scitegic Pipeline Pilot software (Accelrys Software, Inc., San Diego,
CA) and 2) similarity search based on molecular shape using Schrodinger software
(Schrodinger, Inc., New York, NY). Results showed that these two approaches are highly
complementary and lead to different active molecular structures. These structures are
quite suitable for further structural modification and provide new platforms for our
anticancer drug discovery efforts.
3.2 Experimental Methods
3.2.1 Validation of Connectivity Similarity Search
To validate the connectivity similarity search approach, Dr. Wei Li first
established a relatively small testing compound library. This library contains 22 known
compounds similar to LY-1-100, 10 known dissimilar compounds, and a diverse set of
2000 compounds pulled from the University of Cincinnati Drug Discovery Center
* This chapter adapted with permission from Wang Z, Lu Y, Seibel W, et al. Identifying novel molecular
structures for advanced melanoma by ligand-based virtual screening. J Chem Inf Model 2009;49:1420-7.

47

Figure 3-1. Structure and molecular surface of lead compound, LY-1-100.
This figure was prepared by Dr. Wei Li, Department of Pharmaceutical Sciences,
University of Tennessee Health Science Center.
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Compound Library (totally 342,910 compounds). These 2000 compounds were selected
to be “druglike” in that they adhered to Lipinski rules and were filtered from a wide
variety of functional groups. Dr. Wei Li seeded the known 32 compounds in the small
testing library so they could be evenly distributed through the database file. Then Dr.
Seibel conducted a connectivity similarity search for lead compound LY-1-100 against
the 2032 testing compound library. The small compound library was subjected to five
similarity filters in parallel using the ECFP2, ECFP4, ECFC6, FCFP4, and FCFP6
property sets and Tanimoto distances using LY-1-100 as the lead structure (111-113).
The top 400 compounds most similar to LY-1-100 from each of these operations were
ranked by calculated similarity; then an average rank for each compound across the
methods was calculated. The detailed algorithm of the search is shown in Figure 3-2.
3.2.2 Atom Connectivity-Based Virtual Screening
A protocol was designed within Accelrys’s Pipeline Pilot in the UC Drug
Discovery Center. The entire compound library was subjected to the same five similarity
filters in parallel as described in the validation process. Then an average rank for each
compound was also calculated. Our experience suggests that each of the property sets has
some inherent strengths and weaknesses with respect to any given structure, so we used
the above multiple, parallel similarity analysis to ensure that the optimal compounds by
any method were not missed. The detailed algorithm of the search is shown in Figure
3-2.
3.2.3 Validation of Shape Similarity Search
Dr. Wei Li also tested our shape-based virtual screening using the same test
database. The lead compound, LY-1-100, has a relatively rigid structure. So it has less
conformer than other molecules. Therefore, Dr Li chose its lowest energy conformer at
an environment of pH 7.4 as an active conformation, which is consistent with our
recently reported crystal structure of LY-1-100 (110).
All structures in this database were first prepared with the Ligprep software model
(Schrodinger, Inc., New York, NY). During this preparation step, hydrogen atoms were
explicitly added, all possible ionization states were generated between pH 5.0 and pH 9.0
using the Ionizer module, and the 3D molecular structures were minimized with
OPLS_2005 forcefield. Tautomers were also generated in this step. All structures were
then subjected to shape similarity search using the Phase software module. Each structure
was allowed to sample up to 100 conformers for which molecular shapes were calculated
and compared with that of LY-100. Similarity scores were ranked from most similar to
least similar.
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Figure 3-2. General protocol flowchart for virtual screening validation and virtual screening.
This figure was prepared by Dr. William Seibel, University of Cincinnati Drug Discovery Center, University of Cincinnati.
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3.2.4 Molecular Shape-Based Virtual Screening
To make the intensive computation of shape-based virtual screening manageable
for these 342,910 compounds, the database was first broken down into 17 smaller
databases. Each small database contained about 20,000 molecules and was subsequently
prefiltered to remove molecules containing reactive groups. Molecules in each small
database were then prepared by the Ligprep software module to generate proper 3D
structures with all possible ionization states between pH 5.0 and pH 9.0. Typically 30,000
to 50,000 structures were produced from this step for each database. Subsequently, 100
conformations were generated for each of the structures in the database, and the shape of
each conformation was then compared to that of LY-1-100. A normalized shape
similarity value was computed for each molecular conformation relative to that of LY-1100, with 0 the most dissimilar and 1 the exact same shape. Dr. Li set the threshold for a
hit as a shape similarity greater than 0.7 regardless of surface property to keep the
maximum hits. All hits were ranked down from the most similar hit. These calculations
were repeated for each small database for all the molecules in the original database.
3.2.5 Biological Assay and Data Processing
Hits from the two similarity searches were analyzed and their structures
examined. The top hits were requested from the UC Drug Discovery Center for a
subsequent two-step in vitro assay. The first step was a fixed drug concentration
screening assay on two melanoma cell lines. Compounds that killed at least 50% of both
cancer cells at 10 µM were selected for the second step, and their IC50 values on two
melanoma cell lines and one control cell line were determined. Human malignant
melanoma cells A375 and mouse melanoma cells B16-F1 were used to evaluate the
compounds’ in vitro anticancer activity. Both A375 cells and B16-F1 cells were obtained
from American Type Culture Collection (Manassas, VA). All cell lines were cultured in
DMEM media (Cellgro Mediatech, Inc., Herndon, VA), supplemented with 10% FBS
(Cellgro Mediatech, Inc.), 1% antibiotic/antimycotic mixture (Sigma-Aldrich, Inc., St.
Louis, MO), and bovine insulin (5 μg/mL; Sigma-Aldrich). Cultures were maintained at
37°C in a humidified atmosphere containing 5% CO2.
For the initial screening step, A375 and B16-F1 cells were seeded to 96-well
plates at a density of 4000~5000 cells/well, respectively. After cells adhered to the plate,
media were changed and test compounds were added together with media at a fixed
concentration of 10 µM in duplicate. After 48-h incubation, cell viability was evaluated
by using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (114). This
assay is based on the bioreduction of MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]. This tetrazolium dye can be
converted by living cells into a colored formazan product that is soluble in tissue culture
medium and, therefore, provides a sensitive readout of cell life or death that can be
monitored spectroscopically. After incubating cells with compounds for 48 h, 20 µL of
CellTiter 96 AQueous One Solution Reagent was pipetted into each well, which
contained the samples in 100 µL of culture medium. Plates were incubated for another
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1.5 h at 37°C in a humidified, 5% CO2 atmosphere. Absorbance was recorded at 490 nm
in a BioTek EL800 96-well plate reader (BioTek Instruments, Inc., Winooski, VT). Each
compound’s cell killing rate was normalized against a no-treatment control.
The second step was to further measure the IC50s of active compounds selected
from the initial step. I used the activity on fibroblast cells as a control to determine the
selectivity of these compounds between cancer cells and normal cells. Human dermal
fibroblast cells were purchased from Cascade Biologics, Inc., (Portland, OR) and cultured
in the same condition as the two melanoma cell lines. After cells were seeded on 96-well
plates, they were exposed to a wide range of eight concentrations of each compound in
quadruplicate to determine the IC50 values. Then the CellTiter 96 AQueous One Solution
Cell Proliferation Assay was used to measure cell viability. IC50 values were calculated
by nonlinear regression analysis using GraphPad Prism (GraphPad Software, San Diego,
CA) (115, 116). Each assay was repeated three times on different occasions.
3.3 Results and Discussion
3.3.1 Validation of Connectivity Similarity Search
Results from the connectivity search using the test database showed that the first
19 most similar compounds were from the 22 seeded similar compounds according to the
consensus score (average rank). The lowest rank of all seeded similar compounds was
31st in the search results. The highest ranking “dissimilar” compound was ranked at 131st.
This is approximately 6.5% of the way through the small 2032 compound database,
making it analogous to the 22,106th ranked compound from the original search of the
342,910 compounds library. This validation exercise clearly showed that similar
compounds are easily ranked higher than dissimilar compounds by the connectivity
indices-based methods we used.
3.3.2 Connectivity Similarity Search
The connectivity searches produced a combined total of 1292 compounds. To
illustrate that each property set identified somewhat different similar structures, only 13
compounds were in common among all five searches, 49 in common among four
searches, and 160 in common among three searches. Results were consistent with a
limited number of highly similar compounds and a fairly rapid digression to relatively
low-similarity compounds. Out of these 1292 compounds, I selected the top-ranked 110
compounds, middle-ranked 110 compounds, and bottom-ranked 110 compounds to
screen their activity on the two cancer cell lines: A375 and B16-F1. Our decision to select
compounds from the top-, middle-, and bottom-ranked compounds was not only to ensure
testing of any highly similar (and therefore likely to be active) compounds (top-ranked)
but also to search for active compounds of more divergent structure (middle- and lowranked compounds). Each of the 330 compounds was incubated with cells at a
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concentration of 10 µM for 48 h in duplicate. Percentages of cell death induced by these
compounds are shown in Figure 3-3. Three active compounds were identified from the
110 top-ranked compounds (UC-297549, UC-791794, and UC-791475), one active
compound from the 110 middle-ranked compounds (UC-406551), and four active
compounds from the 110 bottom-ranked compounds (UC-791814, UC-791792, UC792257, and UC-193691). IC50 values for these active compounds were subsequently
measured on A375, B16-F1, and fibroblast cells (Table 3-1). The best compound
identified, UC-297549, had an IC50 value less than 1 µM on A375 cells and good
selectivity between cancer cells and normal cells. Very interestingly, almost all of these
compounds contained a basic terminal amine group close to an aromatic ring. This
feature is different from the lead compound structure (LY-1-100), suggesting that adding
a properly positioned amine group may enhance the activity of LY-1-100. Another
important feature revealed from Table 3-1 is that a basic terminal amine group may help
increase selectivity. Among the identified eight active compounds, only one did not have
the basic terminal amine group (UC-406551). The selectivity of this compound was
worse than that of the lead compound. All other seven active compounds, which have the
basic terminal amine group, had better selectivity than our lead compound. Finally, a
basic terminal amine group is also expected to have the added benefit of a reduced logP
value and improved water solubility.
With this in mind, Dr. Yan Lu synthesized a new analog of LY-1-100 in which an
amino group was added to the para-position of the phenyl ring (compound LY-2-183H).
To our great satisfaction, LY-2-183H was more active and selective than LY-1-100 was
(Table 3-1). As expected, LY-2-183H had much better water solubility, which is an
important factor for future in vivo animal testing. Further optimization of this structure is
currently in progress.
3.3.3 Additional Analog Screening Based on Active Compounds Identified from
Connectivity-Based Screening
Encouraged by the structure of the initial connectivity screening and using the
same protocol as described above in combination with substructural analysis, I selected
an additional 40 compounds whose structures were close to the 8 active compounds.
When I tested the activity for these 40 compounds on A375 and B16-F1 cells, 4 active
compounds (10% hit rate, Figure 3-4) were identified (UC-792247, UC-792341, UC98514, and UC-831104). Their IC50 values against all three cell lines are shown in Table
3-2. While these four compounds were not as active as was UC-297549, they contained
more structural features than LY-1-100 and may provide more opportunities for further
structural modifications.
3.3.4 Validation of Shape Similarity Search
During the testing compound library preparation step, the Ligprep process
generated 6767 distinct structures from the original 2032 entries. Thirty-five ionization
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Figure 3-3. In vitro screening results for compounds identified from atom connectivitybased virtual screening.
Percentage of cell death resulted from compound treatment was normalized by nontreatment control. Each bar represents the average of two replications.
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Table 3-1. IC50 of lead compound, eight active compounds identified from atom
connectivity-based virtual screening, and newly synthesized compounds.
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Figure 3-4. In vitro screening results for compounds identified from further atom
connectivity similarity search based on previously identified active compounds.
All compounds were tested at 10 µM concentration on A375 and B16-F1 melanoma
cells. Each bar represents the average of two replications.
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Table 3-2. IC50 of active compounds identified from further atom connectivity similarity
search based on previously identified active compounds.
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IC50SEM (M) (n=3)
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states were generated for the 32 seeded molecules, including 24 similar structures
(protonated and unprotonated forms for both LY-2-103 and LY-2-84), and 11 dissimilar
structures (Figure 3-5, seeded similar structures are highlighted in yellow, and dissimilar
structures are highlighted in red). Validation search results for the seeded structures are
listed in Figure 3-5. From these results, I can see that the top 26 entries from this search
contained 20 of the 24 seeded similar structures (86% similar structures from 0.35% of
total database). The four remaining similar structures ranked at 107, 255, 281, and 1508.
Twenty-three out of 24 (96%) similar structures were found within the 4.2% of the total
structures in this sample database. The saturated thiazole ring and the amide bond in LY2-74 are responsible for its low similarity ranking of 1508, when compared with the
molecular shape of LY-100 (Figure 3-1). This structure also showed the worst similarity
rank in the connectivity-based similarity search (rank 31st). In contrast, the ranks for the
10 dissimilar structures spanned from 332 to 6712 out of the 6767 structures. In
summary, I found that this shape similarity search approach could identify similar
compounds, which provides reasonable validation for screening the entire database.
3.3.5 Shape Similarity Search
The classical concept of lock and key interaction between a receptor and its ligand
indicates that molecular shape is a critical factor for high binding affinity. Similarities in
connectivity and molecular shape have overlap but also have their own individual spaces.
To explore potentially new platforms based on the molecular shape of LY-1-100, Dr. Li
performed shape similarity searches against this database. These searches produced a
little over 5000 structures that had a similarity score larger than 0.7 and did not contain
any reactive groups. I selected the 88 top-ranked compounds and performed an initial
single concentration screening (Figure 3-6). Two active compounds (UC-521092 and
UC-398535), which are very close analogs, were identified, and their IC50s are shown in
Table 3-3. The tight criterion (similarity score must be at least 0.7) was likely responsible
for limiting greater variations for identified structures.
Although still not as active as LY-1-100, these two compounds were more potent
than compounds identified from connectivity-based virtual screening, with IC50 values in
the nanomolar range. One important hint revealed from this search was that a properly
constructed amide linkage between the five-member ring and the trimethoxyphenyl ring
may be very beneficial to anticancer activity. Previously, Dr. Lu made one compound
(LY-2-30) containing an amide bond that was not active. Based on results of this
screening, Dr. Lu prepared another analog in which the direction of the amide bond was
reversed to directly connect the carbonyl group to the trimethoxyphenyl ring (LY-2173b-OTs). The activity of this compound was greatly improved (Table 3-3).
The high activity of compounds identified from this shape similarity search likely
resulted from the very close structural features to LY-1-100. Obviously, this similarity
also limited their structural variations; therefore, a dramatically different scaffold from
LY-1-100 will be difficult to obtain. Hence, at least for this database, shape similarity
search will not provide completely new molecular structures. On the other hand,
60

Figure 3-5. Seeded structures in validation testing library with shape similarity ranks.
Seeded similar structures are highlighted in yellow. Dissimilar structures are highlighted
in red.
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Figure 3-5. (continued)
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Figure 3-5. (continued)
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Figure 3-6. In vitro screening results for compounds identified from molecular shapebased virtual screening.
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Table 3-3. IC50 of active compounds identified from a shape similarity search, one
inactive compound, and one newly synthesized compound based on the information get
from shape similarity search.
UC number
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depending on the criteria of the connectivity search, completely novel structural features
and new molecular platforms could be identified, but loss of activity may be expected.
These two approaches are therefore highly complementary.
3.3.6 Comparison of Two Similarity Search Methods
Generally speaking, the connectivity similarity search gave us more diverse
structure scaffolds that are bioactive than did the shape similarity search. For example, I
got eight bioactive compounds in the first round of whole-library connectivity similarity
search and four bioactive compounds in the further search. I obtained highly varied
scaffolds such as compound UC193691, in which I found the lead compound
trimethoxyphenyl ring replaced by an isothiourea group; in compound UC98514, I found
the lead compound phenyl right replaced by the amidine group. But in the shape
similarity search, I only got two bioactive compounds, and they both shared very close
features with the lead compound. On the other hand, the shape similarity search gave us
more bioactive compounds than did the connectivity search. The two hits from the shape
similarity search had IC50 values on melanoma cell lines in the nanomolar range, while
hits from the connectivity search were mostly in the micromolar range. The reason for
this difference was largely to the result of the inherent algorithm difference of these two
screening approaches.
We did not choose receptor-based virtual screening because we did not confirm
the target for this new class compounds at the initial stage. Later mechanism of action
studies revealed that the target is the tubulin colchicine binding site.
3.4 Conclusions
Using both connectivity- and shape similarity-based virtual screening against a
large database, I identified 14 new molecules from the UC compound library that are
active against melanoma cells. These molecules provide several new functional groups
and structure features compared with the lead structure. In summary, the novel
pharmacophoric elements identified through these virtual screening exercises include a) a
terminal basic amine group can improve activity and selectivity; b) a properly constructed
amide linker between the five-member ring and the trimethoxyphenyl ring is beneficial to
bioactivity; c) the thiazole ring in the lead compound is not necessary for bioactivity, and
it can be replaced with an N-methylene hydrazine linker; d) an isothiourea group can
replace the lead compound trimethoxyphenyl ring; and e) an amidine group can replace
the phenyl ring of the lead compound.
This information is helpful for understanding the structure-activity relationship
and for further improving compound activity. While the shape similarity search did not
provide diverse active structures, the active compounds identified were generally much
more active than those identified by the connectivity search. Combining both
connectivity and shape similarity search techniques was complementary for our ligand67

based drug discovery efforts. Further modification of the lead compound is in progress
based on the information obtained from these virtual screenings.
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CHAPTER 4. DISCOVERY AND BIO-EVALUATION OF 4-SUBSTITUTED
METHOXYBENZOYL-ARYL-THIAZOLE AS NOVEL ANTI-MELANOMA
AGENTS*
4.1 Introduction
Microtubule is composed of - and -tubulin dimmer, which plays an important
role in cell mitosis, motility and organelle distribution (117). The formation of
microtubule from tubulin is a dynamic process that involves the polymerization and
depolymerization of - and -heterodimer. These dynamic behaviors are crucial to cell
mitosis, which is the process of chromosomal division to form new cells (118).
Interference with tubulin-microtubule dynamics may be one of the attractive potential
strategies in developing an anticancer drug (119, 120). There are some antitubulin agents
developed with great potency, which may achieve low nano-molar range in the inhibition
of cell proliferation by inducing cell cycle to be arrested in G2/M phase and subsequently
the inhibition of cell division (121, 122).
Tubulin heterodimer has three major known pharmacologic sites, including taxane,
vinca, and colchicine site. Vinca and colchicine domain ligands destabilize and inhibit
microtubule formation. Taxane–site agents stabilize and promote the formation of
microtubules, having the opposite effects of vinca and colchicine domain ligands. Some
of the antitubulin agents have been successfully developed for clinical use, such as
paclitaxel on taxane domain, and vincristine, vinorelbine, vinblastine on vinca domain.
However, they are substrates of P-glycoprotein and have drug resistance issues (123, 124).
Although no clinical application colchicine-domain binding drugs yet, there are some
agents which are on the phase I or II stage of development (125, 126). To address the
drug resistance of antitubulin agents for each binding-domain, many new generation
antitubulin agents are developed to overcome the issue caused by over expression of Pglycoprotein and/or the MDR1 (127-130).
I have been actively engaged in searching novel anticancer agents that target on
tubulin. More recently, a series of 4-Substituted Methoxylbenzoyl-Aryl-Thiazole
(SMART) has been developed in our laboratory (100). This series compounds was
developed from 2-aryl-thiazolidine-4-carboxylic acid amides (ATCAA) which I
discussed in chapter 2. SAR studies of ATCAA indicated that replacement of the lipid
chain with a bulky aromatic ring in the 4-amide position of ATCAA attached to the
thiazolidine ring still kept the anti-proliferative activity. This finding afforded us a new
point to replace the fatty amide chain with a number of aromatic groups, which would
maintain the cytotoxicity. With further investigation of ATCAA analogues, structure
modifications were made on thiazolidine ring and 4-carboxylic amide linker. Thus,
substituted methoxylbenzoyl-aryl-thiazole (SMART) compounds were discovered.
*Portions of this chapter adapted with permission from Lu Y, Li CM, Wang Z, et al. Discovery of 4substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and
structure-activity relationships. J Med Chem 2009;52:1701-11.
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The general structure of SMART agents with as showed in Figure 4-1. The
SMART agents have a structure containing three conjugated aromatic rings (A, B and C
rings, respectively) with a ketone linkage between B and C rings. Thiazole was
introduced in B ring instead of thiazolidine ring in ATCAA. The linker between B and C
rings was modified from an amide to carbonyl group. The C ring was characterized by
the presence of differently-substituted phenyl groups, in particular, the 3, 4, 5-trimethoxy
substituted phenyl at C ring played an important role of antiproliferative activity against
melanoma.
According to the study, I characterized the biologic effect using three
representative SMART compounds: SMART-100, SMART-45, and SMART-211.
SMART-100 and SMART-45 are the most potent SMART compounds in our laboratory;
however, they exhibit poor solubility. SMART-211 was synthesized to increase solubility
by adding a hydroxyl- group on the A-ring, and it still remained potent cytotoxicity with
IC50 value of 120 nM on several melanoma cell lines. I examined these SMARTs on cell
proliferation in a variety of cancer cell lines including MDR-positive cell lines and
summarized the SAR. I determined the binding site to tubulin, the ability of inhibition on
tubulin polymerization. Together with Mr. Chien-ming Li, I determined pharmacokinetic
parameters on mice, and developed a formulation for the improvement of the poor
solubility of SMARTs. I also examined the anticancer efficacy using nude mice bearing
human melanoma A375 xenograft.
4.2 Materials and Methods
4.2.1 Compounds and Reagents
All the SMART compounds were synthesized by Dr. Yan Lu. Paclitaxel, vinblastine, and colchicine were obtained from Sigma-Aldrich. Ethanol was obtained from Decon
labs, Inc. Cremophor ELP was obtained from BASF, Inc. CellTiter 96® AQueous One
Solution Reagent was obtained from Promega.
4.2.2 Cell Culture and Cytotoxicity Assay
The A375 and B16-F1 melanoma cancer cells were obtained from American Type
Culture Collection (Manassas, VA). WM-164 cells were derived from patient metastatic
melanoma tumors and were a gift from Dr. Meenhar Herlyn (Wistar Institute,
Philadelphia, PA). Human Dermal Fibroblast (adult) cells (HDFa) were obtained from
Cascade Biologics. This cell line was used as control to determine selectivity. The P-gp
overexpressing multi-drug resistant cell line MDA-MB-435/LCC6MDRI and matching
sensitive parent cell line were kindly provided by Dr. Robert Clarke (Georgetown
University, Washington, DC). Cells were grown as monolayers by using standard cell
culture conditions. All cells were cultured in DMEM (Mediatech, Inc., Manassas, VA),
supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1%
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R = 4-H, SMART-100
R= 4-F, SMART-45
R= 4-OH, SMART-211

antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO), and bovine insulin (5
µg/mL) (Sigma-Aldrich, St. Louis, MO).
Cultures were maintained at 37°C in a humidified atmosphere containing 5%
CO2. 1000 to 5000 cells were plated into each well of 96-well plates depending on
growth rate and exposed to different concentrations of a test compound for 48 h in three
to five replicates. Cell numbers at the end of the drug treatment were measured by the
MTS assay. Absorbance was recorded at 490 nm in a BioTek EL800 96-well plate reader
(BioTek Instruments, Inc., Winooski, VT). Percentages of cell survival versus drug
concentrations were plotted and the IC50 (concentration that inhibited cell growth by 50%
of untreated control) values were obtained by nonlinear regression analysis using
GraphPad Prism (GraphPad Software, San Diego, CA).
4.2.3 Cell Cycle Analysis
Flow cytometry was performed to study cell cycle phase distribution. A375 cells
were cultured in growth media until the confluence was about 70%, and then cells were
starved in 0.5% charcoal-stripped serum (CS-FBS) for 48 h before the experiment. A375
then were treated with 0, 10, 50, 200, and 1000 nM of SMART-100, -45, and -211 for 24
h in growth media. The cellular DNA was stained with PBS containing 100 g/mL
propidium iodide, and 100 g/mL RNase A. Flow cytometry assay was used to determine
the distribution of a population of cells to different stages of cell cycle.
4.2.4 In Vitro Microtubule Polymerization Assay
Bovine brain tubulin (0.4 mg) (Cytoskeleton, Denver, CO) was mixed with 10
M of test compound and incubated in 120 L of general tubulin buffer (80 mM PIPES,
2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9 and 1 mM GTP). The absorbance of wavelength
at 340 nm was monitored every 60s for 20 min by the SYNERGY 4 Microplate Reader
(Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set at 37C for tubulin
polymerization.
4.2.5 Tubulin Colchicine Competition Assay
[3H]colchicine competition-binding scintillation proximity assay (SPA)
(Cytoskeleton Inc, Denver, CO) was used to evaluate SMART compounds that bind to
the colchicine binding site on tubulin. Biotin-labeled tubulin (0.5 g) was mixed with
[3H]colchicine (0.08 µM) (Perkinelmer LLC., Shelton, CT) and varies concentrations of
SMARTs. Streptavidin-labeled SPA beads (80 g) (GE-healthcare Bio-Sciences Corp.,
Piscataway, NJ) are added, and co-incubated in 200 L binding buffer [80 mM PIPES
(pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2, and 1 mM GTP] for 45 min at 37°C.
IC50 values (concentrations that inhibited 50% of tritiated colchicine binding) were
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determined by nonlinear regression analysis with GraphPad Prism (GraphPad Software,
San Diego,CA).
4.2.6 Microtubule Imaging Using Fluorescence Microscope
In order to get a visually appreciable proof of SMART compounds interacting
with tubulin inside the cells, I examined microtubule arrangement in human melanoma
WM-164 cells upon treatment with different compounds. I selected the Cellomics
Cytoskeleton rearrangement kit (Thermo Scientific, Rockford, IL) which is widely used
for such studies and followed the instructions from the manufacturer. WM-164
Melanoma cells were treated with each compound for 18 h in duplicate using a collagencoated 96-well plate (Becton Dickinson Labware, Bedford, MA). Then cells were fixed
with 4% paraformaldehyde (Thermo Scientific, Rockford, IL) and permeabillized using
permeabilization buffer supply from the kit. Primary antibody for tubulin and
fluorescence labeled secondary antibody were subsequently added to the cells. Cell nuclei
were stained by DAPI. Whole Cell Stain Green was also applied to all cells. All images
were acquired with an Olympus IX71 inverted fluorescence microscope (Olympus
Corporation, Tokyo, Japan) with overlays from separate images of tubulin (red), nuclei
(blue) and whole cells (green). For comparison, I also included paclitaxel, colchicine
along with SMART compound.
4.2.7 Pharmacokinetic Studies in Mice
Male ICR mice 6 to 8 weeks of age were used to perform pharmacokinetic study.
Drug solutions were dissolved in DMSO/PEG300 (80/20) and administrated by a single
i.v. injection into the tail vein. For SMART-100, 5 and 15 mg/kg of body weight were
administrated. For SMART-45, 15 mg/kg of body weight was administrated. Blood
samples were obtained via cardiac puncture under isoflurane anesthesia at 2, 5, 15, and
30 min, 1, 2, 4, 8, 16, and 24 h after administration, using 3-4 animals per group. Sodium
heparin (5 L of 1,000 USP units/mL per sample) was used as an anticoagulant. Blood
samples were collected on ice, and separated by centrifuging at 3000g for 10 min to
obtain plasma. All samples were stored at -20ºC until analysis.
Protein precipitation method was used for sample preparation. Plasma samples
were thawed at room temperature.150 µL of acetonitrile (ACN) containing an internal
standard, a SMART analog, was added to 100 µL of plasma sample, and then was
thoroughly vortexed for 15 s. After centrifugation at 14,000 RPM for 10 min at 4°C, the
supernatant was transferred into high-performance liquid chromatography vials and
directly used for LC-MS/MS analysis.
Plasma concentration-time data were analyzed by non-compartmental analysis
using WinNonlin 5.2 (Pharsight Corporation, Mountain View, CA). The area under the
plasma concentration-time curve from time 0 to infinity (AUCinf) was calculated by the
trapezoidal rule with extrapolation to time infinity. The terminal half-life (t1/2) was
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calculated as 0.693/λz, where λz is the terminal phase rate constant. The plasma clearance
(CL) was calculated using the equation CL=Doseiv/AUCinf, iv, where Doseiv and AUCinf, iv
are the IV dose and corresponding area under the plasma concentration-time curve from
time 0 to infinity, respectively. Volume of distribution based on terminal phase (Vz) was
calculated using Vz=Doseiv/(λz*AUCinf, iv). The peak plasma concentration (Cmax) and the
time when it occurred (tmax) in the IP group were obtained by visual inspection of the
plasma concentration-time curves. Clearance after IP (CL/F) was calculated as
Doseip/AUCinf, ip. Volume of distribution after IP (Vz/F) was calculated as
Doseip/(λz*AUCinf, ip). IP bioavailability (F) was calculated using F=(AUCinf,ip*
Doseiv)/(AUCinf, iv *Doseip), where Doseip, Doseiv, AUCinf, iv, and AUCinf, ip are the IP and
IV dose and the corresponding areas under the plasma concentration-time curves from
time 0 to infinity, respectively.
4.2.8 LC-MS/MS Method for Measuring SMART Compounds
Sample solution (10 µL) was injected into an Agilent series HPLC system
(Agilent 1100 Series Agilent 1100 Chemstation, Agilent Technology Co, Ltd). SMART100 and SMART-45 were separated on a narrow-bore C4 column (Varian Inc, 2.1×150
mm, 5 µm, Palo Alto, CA). Gradient mode was used to achieve the separation of analytes
using mixtures of mobile phase A (5% acetonitrile containing 0.1% formic acid) and
mobile phase B (95% acetonitrile containing 0.1% formic acid) at a flow rate of 300
L/min. Mobile phase A was used at 100% from 0 to 1 min followed by a linearly
programmed gradient to 100% of mobile phase B within 3 min, 100% of mobile phase B
was maintained for 1 min before a quick ramp to 100% mobile phase A. Mobile phase A
was continued for another 8 min towards the end of analysis.
A triple-quadruple mass spectrometer, API QtrapTM (Applied Biosystems/MDS
SCIEX, Concord, Ontario, Canada), operating with a TurboIonSpray source was used.
SMART-100 and SMART-45 were infused into the mass spectrometer at 1 mg/L and 10
L/min to optimize the instrument parameters used for LC-MS/MS. The Q1 full scan
spectrums of SMART-100 and SMART-45 were first obtained to identify [M+H]+ ion as
the precursor ion to generate product ion scans for selecting the most distinctive
precursor-product ion pair. For the most sensitive quantitative analysis, the mass
spectrometer was operated in the multiple reaction monitoring (MRM) mode, which
includes m/z 356.2→ 188.2 for SMART-100, 374.2→ 206.2 for SMART-45, and m/z
434.0 → 266.0 for an internal standard, which is analog of SMART compound. Dwelling
time was set to 100 ms for each analyst, and 50 ms for the internal standard. Detection
limit is 0.2 ng/mL for SMART-45, -100, and -211.
The spraying needle voltage was set at 5000 V for positive mode. Curtain gas was
set at 10; Gas 1 and gas 2 were set at 50. Collision-Assisted-Dissociation (CAD) gas at
medium, and the source heater probe temperature at 500C. DP, EP, CXE were set at 16,
10, and 15 V, respectively. Data acquisition and quantitative processing were
accomplished using AnalystTM software, Ver. 4.0 (Applied Biosystems).
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4.2.9 Antitumor Efficacy on A375 Xenografted Athymic Nude Mice
A375 cells (5107/mL) were prepared in phenyl red free DMEM media
containing 10% FBS, and mixed with 1:1 of Matrigel (BD Biosciences, San Jose, CA).
Tumors were established by injection 100 L of mixture (2.5106 cells per animal, s.c.
into low flank of mice) to 6-8-week-old male athymic nude mice. Treatments were
initiated when tumor reached a mean group size of 150 mm3. Tumor volume (mm3) was
measured with calipers and determined by the formula, π/6  L  W2, where length (L)
and width (W) are in mm. The formulation of Tween80/Captex200 (80/20) were used to
prepare SMART-100 (20 mg/kg), and SMART-45 (15 mg/kg). Mice were administrated
by i.p. daily for 34 days (10 mice per group).
4.3 Results and Discussion
I studied the structure-activity relationship (SAR) in our laboratory and selected
three potent SMARTs to perform the mechanism of action. SMART-100 has no
substitution on the A-ring. SMART-45 and SMART-211 have fluorine (-F) and hydroxy
(-OH) on the A-ring, respectively. SMART-45 and -100 have poor solubility; however,
SMART-211 is a water-soluble compound. The effects of SMART-100, -45, and -211 on
the proliferation of melanoma cancer cells (B16-F1, A375, and WM-164) and normal
fibroblast cells are summarized in Table 4-1. SMARTs inhibit the proliferation of
prostate and melanoma cancer cells with IC50 values in the low nano-molar range.
Overall, the potency of SMART-45 is similar to SMART-100, and greater than SMART211.
4.3.1 SAR Studies
4.3.1.1 SAR of the B Ring
Please see Figure 4-1 for the designation of A, B, and C ring of SMART
compounds. In the previous ATCAA compounds, I found the thiazolidine ring, which
contained a free NH at its 3-position, was important for cytotoxicity. Once the B ring
thiazolidine moiety was replaced by a thiazoline ring, the antiproliferative activity
decreased sharply from 600 nM to over 50 µM on WM-164 cell lines (83). The ATCAA1 fatty amide derivatives that were most effective against melanoma cell lines were
examined and shown to have an IC50 2 μM (Table 4-2). Replacement of the long fatty
chain with a certain aromatic bulky subsistent such as fluorene (ATCAA-2) showed
inhibitory activity on both cancer cell lines (IC50=2~4 μM). The fluorene group in 4carboxylic amide position was also replaced by 3, 4, 5-trimethoxylphenyl group (2a and
2b), but the potency against both cancer cell lines was lost. The subsequent B ring
modification from saturated thiazolidine compound 2a to unsaturated thiazole 5 did not
show any cytotoxicity against either cancer cell line tested. But thiazoline enantiomers 4a
and 4b (R-isomer and S-isomer, showed similar antiproliferative activities) showed
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Table 4-1. Cytotoxic activity comparison of representative SMART compounds with
other anticancer drugs.
Compound name

IC50SEM (nM) (n=3)
A375

B16-F1

WM-164

HDFa

SMART-100

285

555

646

405

SMART-45

2911

4321

416

407

SMART-211

9311

1136

9910

28992

Paclitaxel

123

172

183

123

Vinblastine

10

51

10

31

Colchicine

203

295

102

182

Bortezomib

81

242

81

262

Table 4-2. In vitro cytotoxic activity of modified ATCAA compounds.
X

IC50SEM (M) (n=3)

C

S B N

A ring

B ringa

C ringb

X

p-NHAc-Ph
p-NHAc-Ph
Ph
3,4,5trimethoxyPh
Ph
Ph
Ph
Ph

TZD
TZD
TZD

C16H33
9H-fluoren-1-yl
3,4,5-trimethoxyl-Ph

TZD
TZL
TZL
TZ
TZ

B16-F1

A375

CONH
CONH
CONH

20
40
>100

20
20
>100

3,4,5-trimethoxyl-Ph

CONH

>100

>100

3,4,5-trimethoxyl-Ph
3,4,5-trimethoxyl-Ph
3,4,5-trimethoxyl-Ph
3,4,5-trimethoxyl-Ph

CONH
CONH
CONH
CO

383
303
>100
555 nM
295 nM

232
141
>100
285 nM
203 nM

A

ATCAA-1
ATCAA-2
2a
2b
4a(4R)
4b(4S)
5
8f
Colchicine
a

TZD=thiazolidine, TZL=thiazoline, TZ=thiazole
For ATCAA-1, C position contains a lipid chain.

b
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improved activity (IC50=14~38 μM) compared with 2a, 2b and 5. When the amide CONH
linkage between B ring and C ring was replaced by a carbonyl linker, the mixtures of
thiazoline/thiazole ketone 8f were obtained instead of desired thiazoline ketone, because
the auto-dehydrogenation between thiazoline and thiazole occurred. Surprisingly,
introduction of the carbonyl group linker and thiazole led to a significant enhancement of
growth inhibition of examined cancer cell lines with a low nanomolar level (8f,
IC50=21~71 nM), which is comparable to the natural anticancer agent colchicine. Thus a
series of the SMART compounds with B as a thiazole ring were designed and synthesized
based on the discovery of 8f and their anticancer activity was evaluated against
melanoma.
4.3.1.2 SAR of the C Ring
We started our investigation of the C position of the SMART by introducing
different substituted phenyls or alkyl chain. Variation of the phenyl substituents has a
remarkable change in effect on potency. The in vitro assay as shown in Table 4-3 gave us
an interesting result but only 3, 4, 5-trimethoxylphenyl in C ring (8f) showed excellent
inhibition against all cancer cells (IC50=28~55 nM). Compound 8g, with a 3, 5dimethoxyphenyl group, showed 6-fold average cytotoxicity lower than 8f. Modifications
of 8f by removal of one methoxy at meta-position (8e) or two methoxy groups (8b, 8c
and 8d) from 8f led to a dramatic loss in activity (IC50>20 M). Although orthosubstituted monomethoxy compound 8d exhibited weak activity against a certain cell
lines compared with meta-/para-MeO substituted 8c/8b and dimethoxyphenyl compound
8e, none of them showed significant potency in inhibition compared with 8f. Similar
trends were also seen in 8h and 8j with 2-fluorophenyl and hexadecyl in C ring
modifications.
4.3.1.3 SAR of the A Ring
In SAR studies of the ATCAA compounds, I found that the electronic properties
of substituents of the phenyl ring in the 2-positioin of the thiazolidine ring strongly
affected the anticancer activity in ATCAA compounds  electron-withdrawing groups
(EWG) on 2-phenyl gave higher activities than those with electron-donating groups
(EDG). Dr. Lu also introduced different para-substituted EWG and EDG on A phenyl
ring of the SMART molecules. From the IC50 value against these cancer cell lines,
electronic effects of A ring phenyl substituents did not show clear influence on
antiproliferative activity. Introduction of a weak EWG (4-F in 8n, IC50s: 33~43 nM) or
weak EDG (4-CH3 in 8k, IC50s: 11~21 nM), both increased the potency compared with 8f
(see Table 4-4). The replacement of para- position with strong EWG such as NO2 (8p),
CN (8q), CF3 (8t) or introducing strong EDG (3, 4-dimethoxy) to A phenyl ring (8o)
exhibited comparable antiproliferative activity.
To compare the effects of ortho-, meta- and para- substitutions, a fluoro atom was
introduced to different positions of A phenyl ring (8l, 8m and 8n). The various o-, m-, p77

Table 4-3. In vitro cytotoxic activity of SMART compounds with C rings modification.
Compounds

Ph
4-Methoxy-Ph
3-Methoxy-Ph
2-Methoxy-Ph
3, 4-Dimethoxy-Ph
3,4,5-Trimethoxy-Ph
3, 5-Dimethoxy-Ph
2-Fluoro-Ph
Hexadecyla

8a
8b
8c
8d
8e
8f
8g
8h
8j

O
C
S

C Ring

N

IC50SEM (M) (n=3)
B16-F1
A375
>100
>100
>100
>100
>100
>100
7033
5921
>100
>100
555 nM
285 nM
17010 nM
35020 nM
>100
>100
16  15
1918

a

Compound 8j has a lipid chain at C ring position.

Table 4-4. In vitro cytotoxic activity of SMART compounds with A rings modification.
Compounds

O

OCH3
OCH3

S

N
A

OCH3

A Ring
8f
8k
8l
8m
8n
8o
8p
8q
8t
8u
8v
8x
8y
8z
10

Ph
4-Methyl-Ph
2-Fluoro-Ph
3-Fluoro-Ph
4-Fluoro-Ph
3, 4-Dimethoxy-Ph
4-Nitro-Ph
4-Cyano-Ph
4-Trifluoromethyl-Ph
4-Bromo-Ph
4-Ethyl-Ph
4-Pyridine
2-Pyrimidine
2-Thienyl
Ha

a

Compound 10 has a proton at A ring position.
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IC50SEM (nM) (n=3)
B16-F1
A375
555
285
2110
115
2711
309
28736
30425
4321
3314
16129
3410
5612
389
5924
5316
9216
235
325
132
708
172
>100000
>100000
2300860
4100740
3815
207
>100000
>100000

substituents did not exhibit equal activities. o-fluoro substituted 8l showed the lowest
IC50s (27~30 nM) against melanoma cells. 8n has similar average IC50s (33~43 nM)
against melanoma compared with 8l. Meta-substituted compound 8m showed lowest
activity on melanoma cells (IC50s: 287~304 nM).
Turning to the effects of steric hindrance group on the A phenyl ring substituents,
I found that p-bromo (8u, IC50s: 13~32 nM) caused a slightly decrease in antiproliferative
activity relative to p-fluoro position (8n, IC50s: 6~12 nM). Reduced activity against both
cancer cell lines is obvious when p-methyl (8k, IC50s: 11~21 nM) was replaced with a pethyl group (8v, IC50s: 17~70 nM).
To investigate if phenyl played an essential role at A ring in cytotoxicity, Dr. Lu
also removed phenyl at 2-thiazole position and compound 10 was obtained. This
modification caused a total loss of activity compared with 8f. The replacement of the A
ring by pyridine (compound 8x) had the same effect. Moreover, substituting 2-pyrimidine
in A ring (compound 8y) also caused a significant loss of activity (IC50s: 2~4 µM).
However, introducing the thiophene replacement of phenyl (8z) into A position slightly
improved the potency (IC50s: 20~38 nM) compared to 8f (IC50s: 28~55 nM).
4.3.1.4 SAR of Pharmaceutically Acceptable Salt Groups to the SMARTs
Most of the SMART compounds have good solubility in organic solvents such as
CHCl3, CH2Cl2 and DMSO. But they show poor water-solubility. Dr. Lu designed and
synthesized water-soluble salts of the SMART by introducing a hydrophilic group such
as NH2 (8w) and COOH (8r) into A ring and generated the HCl or sodium salt. Another
modification is replacing A/C rings in 8a with pyridine (8i, 8x, 8y) or pyrimidine rings,
which could also be converted into HCl salts. These modifications reduced the calculated
LogP values (LogP=3~4) compared with 8a and 8f (LogP=4, See Table 4-5). Introducing
p-amino to A phenyl (8w) is the only case to increase the antiproliferative activity (HCl
salt, IC50s: 11~29 nM) compared with 8f against all cell lines. Although replacing phenyl
with pyrimidine (8y) kept partial activity against both cancer cells, the potency range was
markedly reduced from nano-molar to micromolar compared with 8f. Unfortunately
introducing COOH to para- phenyl A ring and pyridine to A or C rings (8i, 8r, 8x) all
resulted in the total loss of the anticancer activity. A total loss of potency was seen in the
methyl ester 8s of acid 8r against both cancer cell lines. Demethylation of compound 8f
afforded water soluble 3, 4, 5-trihydroxyphenyl at C ring compound 11, but this
demethylation results in complete loss of antiproliferative activity against all tested
cancer cells, which also points out the importance of 3, 4, 5-trimethoxyphenyl at C
position.
4.3.1.5 SAR Summary
The general SAR of SMART compounds on melanoma cells was summarized in
Figure 4-2. Present SAR studies revealed that 3, 4, 5- trimethoxyphenyl was the essential
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Table 4-5. In vitro cytotoxic activity of SMART compounds containing hydrophilic
group.
Compounds

O
C

8i

IC50SEM (nM) (n=3)
B16-F1
A375

Structure
N

N

S

8iHCl
O

CLogPa

>100000

>100000

4

>100000

>100000

-

>100000

>100000

4

>100000

>100000

4

>100000

>100000

3

>100000

>100000

-

O
O

8r

N

S

O

COOH

O

O
O

8s

S

N

O

COOCH3
O
O
O

8x

S

N

O

N

8xHCl
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Table 4-5. (continued)
Compounds

IC50SEM (nM) (n=3)
B16-F1
A375

Structure

CLogPa

O
O
O

8y

O

N

S

2300860

4100740

3

2910

112

-

>100000

>100000

3

>100000

>100000

5

555

285

4

N

N

O
O
O

8wHCl

O

N

S

NH2HCl
OH
O
OH

11

OH

N

S

O
C
N

S

8a

O
O
O

8f

a
b

S

N

O

Calculated LogP data using Chemoffice 2005, Chemdraw Ultra 9.0 software.
LogP value were calculated based on free base.
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(d). Ketone C=O linkage significantly improved the potency compared with
CONH linker.

X
S B N
A
R1

C

R2
(c). C ring is specific for 3, 4, 5-trimethoxyl
substituted phenyl

(b). Thiazole ring kept potency, thiazoline
and thiazolidine ring lost potecy

(a). A ring: No obvious electronic effect. p-F-Ph,
p-CH3, p-NH2-Ph is helpful for potency.

Figure 4-2. SAR summary of the SMART compounds.
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group in the C ring to keep excellent antitumor potency. p-Fluoro, p-NH2 and p-CH3
substituents in A ring will increase the activity, with no clear difference in effect on
activity between EWG and EDG when A are substituted phenyl rings. The carbonyl
linkage between B ring and C ring played an important role for the high potency.
4.3.2 SMARTs Overcome Multi-Drug Resistance on Drug Resistant Melanoma Cells
MDA-MB-435/LCC6MDRI cells over-express P-gp, and were used to test
whether SMARTs were substrates of P-glycoprotein comparing to its parental cell line,
MDA-MB-435. I demonstrated that paclitaxel, vinblastine, and colchicine were more
resistant against MDR-positive cells than those with the parent sensitive cells. Please see
Figure 4-3 for selected dose-response curves and Table 4-6 for summary of results. The
resistance indexes were 69.3, 27.5, and 65.8 respectively. In the meantime, SMARTs did
not show significantly difference on those two cell lines. The resistance indexes were
around 1. This strongly suggested that SMARTs were not substrates for P-glycoprotein.
4.3.3 SMARTs Target Tubulin on Colchicine Binding Site
The strategy I used here to find out the cellular target of SMART compounds is
the same as I described for ABI compounds in Chapter 5. I first did a cell cycle analysis
for A375 cells after treatment with SMART-100, -45, and -211 (0, 10, 50, 200, and 1000
nM) for 24 h prior to staining with propidium iodide and cell cycle analysis. The
proportion of cells in G2/M phase increased when treated with 50 nM of SMART-100
and -45, and SMART-211 showed the effect until the concentration was 200 nM. Some
representative cell cycle distribution graphs were shown in Figure 4-4. Quantified
representation of all results was shown in Figure 4-5. SMART-100 and SMART-45 had
no effect on cell cycle distribution below 50 nM. About 16% of untreated cells were
observed in G2/M phase, whereas the cells treated with more than 50 nM of colchicine or
SMART compounds showed a greater proportion of cells in G2/M phase. The increase in
G2/M phase cells was accompanied by a decrease in G1 populations, relative to control.
In vitro tubulin polymerization assay was used to identify the target of SMART
compound on tubulin. This experiment was performed by my colleague Mr. Chien-Ming
Li. He demonstrated that SMART-100 inhibited tubulin polymerization in a doseresponse manner in the previous study (15). In the current study, 10 M of SMARTs
were used to examine the inhibition of tubulin polymerization. In Figure 4-6, all three
SMART compounds inhibited tubulin polymerization, indicating that SMARTs did target
on tubulin. SMART-100 showed similar inhibitory ability as SMART-45, and greater
than SMART-211. In vitro tubulin polymerization could be blocked by SMARTs, and the
ability of inhibition on tubulin polymerization was also related to their IC50 values on cell
anti-proliferation. 10 M of substrates were examined in this study because high
concentration of tubulin (4 mg/mL) was used to form microtubule.
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O

O
C

O
O

SMART‐183H
R=0.9

S

N

SMART‐293
R=1.2

O

S

N

OMe
OMe
OMe

HN

NH2HCl

Colchicine
R=65.8

Paclitaxel
R=69.3

Figure 4-3. Dose response curves showed SMART compounds overcome multi-drug
resistant for melanoma compared with colchicine and paclitaxel.
R: resistance index, this value were calculated by dividing IC50 values on multi-drug
resistant cell line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive
parent cell line MDA-MB-435.
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Table 4-6. SMART compounds showed equal potency against multi-drug resistant
melanoma cells and parent sensitive cells.

Compounds

IC50SEM (nM) (n=3)
MDA-MB- MDA-MB-435
435
/LCC6MDRI

Structure

Resistance
index (R) *

O
O
C

SMART-293

S

N

O
O

91

112

1

122

111

1

101
41
400100
pM

65850
27741

66
69

111

28

HN
O
O
O

SMART-183H

S

N

O

NH2HCl

Colchicine
Paclitaxel
Vinblastine

*Resistance indexes were calculated by dividing IC50 values on multi-drug resistant cell

line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive parent cell
line MDA-MB-435.
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Control

Colchicine (50nM)

SMART-100 (50nM)

SMART-45 (50nM)

Figure 4-4. Cell cycle analysis showed SMART compounds and colchicine arrested
A375 cells in G2/M phase after incubation for 24 h.

100
Colchicine
SMART-45

Percentage of G2/M Phase

80

SMART-100
SMART-211

60

40

20

0
0

10

50

200

1000

Compound Concentration (nM)

Figure 4-5. Quantified cell cycle analysis results showed SMART compounds and
colchicine arrested A375 cells into G2/M phase in a dose dependent manner.
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Control
0.625 uM
2.5 uM
5 uM
10 uM
20 uM

0.3

O.D. (340 nM)

0.25
0.2
0.15
0.1
0.05
0
0

5

10

15

20

min

Figure 4-6. SMART-100 inhibited in vitro tubulin polymerization in a dose dependent
manner.
This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of
Pharmacy, the Ohio State University.
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[3H]colchicine competition-binding assay was used to confirm that SMART bind
to tubulin at the colchicine binding site. In the meantime, I also measured the relative
binding affinity. Binding graph (Figure 4-7) showed that: 1), SMART compounds can
competitively bind to tubulin colchicine binding site. As concentration of these three
testing compounds increased from 0.1 µM to 100µM, more and more tritiated colchicine
were competitively stripped away from tubulin. Thus gave out lower and lower SPA
counts. 2), SMART compounds have relatively high binding affinity to the tubulin
colchicine binding site. Table 4-7 Showed that software calculated IC50 value for binding.
SMART-100 has the highest binding affinity among the three tested compounds. Its
value is close to colchicine, although a little bit higher than that. 3), the binding affinity
was positively correlated with in vitro anti-melanoma activity. The higher of the binding
affinity, the higher is the anti-melanoma activity. In our experiment, the D value is 0.08
µM, the Kd value is around 1 µM according to literature (131). So the IC50 is very close
to Ki value. Our result is quite comparable with literature reported Ki value for colchicine
binding to tubulin. On the binding graph, some data point is a little bit below 0. That is
caused by experimental variation. Theoretically, the maximum inhibition is 0.
Microtubule images (Figure 4-8) showed that all four tested compounds results in
cytoskeleton rearrangements. There is a significant difference between paclitaxel and
other two compounds (Colchicine and SMART-100). Treatment with paclitaxel resulted
in condensation of microtubules nice surrounding the nuclei compared with control,
consistent with its mechanisms of action for stabilizing microtubules. On the contrary,
treatment with colchicine or SMART-100 all has similar effect on microtubules, and
result in some degree of microtubule fragmentations, consistent with their common
mechanism of action for destabilize microtubules.
In summary, our data clearly showed that SMARTs triggered several molecular
events, which include binding to colchicine site of tubulin, inhibiting on tubulin
polymerization, arresting cells in G2/M phase and resulting microtubule fragmentation.
4.3.4 Pharmacokinetic Properties of SMART-100, SMART-45 and SMART-211
I first examined SMART-100 at a dose level of 5 mg/kg (Figure 4-9). The plasma
concentration-time profiles of SMART-100 after single IV and IP administration are
shown in panel A and B of Figure 4-9. The derived pharmacokinetic parameters are
shown in Table 4-8. The formulation I used for both injections were DMSO/PEG300
(80/20). SMART-100 appeared rapidly in plasma after IP injection with peak level (Cmax)
observed in less than 2 min after administration. This suggested a rapid absorption of the
compound from the injection site. The compound was distributed extensively in the body
with a volume of distribution of 112 L/kg. A very high clearance of 223 mL/min/kg
indicates extensive metabolism and rapid elimination. The high clearance resulted in a
relative short terminal half-life of 349 min after IV and 358 min after IP administration
despite of the huge volume of distribution. The IP bioavailability is only 31%. I thought
the poor bioavailability was largely due to the poor water solubility of the compound and
too simple formulation.
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SMART-45
SMART-100
SMART-211
Paclitaxel
Colchicine

25

0

control

Normalized SPA counts of control

100

0.1

1

10

100

Drug Concentration (M)

Figure 4-7. Tubulin binding assay showed SMART compounds competitively bound to
tubulin colchicine binding site in a concentration dependant manner.
As concentration of these compounds increased from 0.1 µM to 100µM, more and more
tritiated colchicine were competitively stripped away from tubulin. Thus gave out lower
and lower SPA counts. The negative control paclitaxel just gave out a flat line because it
didn’t bind to the colchicine binding site on tubulin. Each data point represents an
average of three replicates.
Table 4-7. Comparison of tubulin binding affinity and in vitro cytotoxic activity between
SMART compounds and known tubulin interacting drugs.
IC50SEM (n=3)
For tubulin binding (µM) On A375 (nM)
SMART-100
73
285
SMART-45
224
2911
SMART-211
382
9311
Colchicine
10
203
Paclitaxel
N/A
123
Compounds
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Paclitaxel (0.5µM)
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Figure 4-8. Microscopic images of immunofluorescence labeled microtubules inside
WM-164 melanoma cells showed microtubule modality was dramatically changed after
compounds treatment for 18 h.
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Figure 4-9. Measured plasma concentration-time profiles (mean±SD) after bolus
administration of 5 mg/kg SMART-100 to ICR mice (n=3 per group).
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation,
DMSO:PEG300=80:20 (v/v).
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Table 4-8. Pharmacokinetic parameters of SMART-100, SMART-45, and SMART-211.
Route

Compound and dose

IV

SMART-100 5 mg/kga
SMART-100 15 mg/kga
SMART-45 15 mg/kga
SMART-211 15 mg/kga

IP

SMART-100 5 mg/kga
SMART-100 15 mg/kga
SMART-100 15 mg/kgb
SMART-45 15 mg/kgb
SMART-211 15 mg/kgb

AUCinf
AUClast
Clearance
Vz
Vss
Bioavailability
t1/2
(min) (ng·min/mL) (ng·min/mL) (mL/min/kg) (mL/kg) (mL/kg)
(%)
349
22434
22159
223
112311 24803
140
115336
115221
130
26274
4926
141
134340
134051
112
22643
6588
334
168759
151526
95
45954
5420
358
308
123
182
208

7038
17645
55842
72001
122578

6771
17189
55760
71719
122440

a

Compound was formulated with DMSO:PEG300=80:20 (v/v).
Compound was formulated with Tween80:Captex200=80:20 (v/v).

b
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710
850
269
208
122

366859
378339
47507
54674
36700

31
15
48
54
73

I then examined SMART-100 at a dose level of 15 mg/kg and compared two
different formulations for IP injection. One is DMSO/PEG300 (80/20), one is
Tween80/captex200 (80/20). The later formulation was one of the self-emulsifying drug
delivery systems (SEDDS), which contained a mixture of oil (captex200) and surfactant
(Tween80), and improved the solubility of our lipophilic SMARTs (132). The plasma
concentration-time profiles of SMART-100 after single IV and IP administration are
shown in panel A, B, and C of Figure 4-10. The derived pharmacokinetic parameters are
shown in Table 4-8. Compared different dose of SMART-100 with the same
DMSO/PEG300 (80/20) formulation, higher dose (15 mg/kg) gave lower bioavailability
(15% vs. 31%). This may be due to higher concentrated SMART-100 in DMSO/PEG300
(80/20) precipitated out more after IP injection. Thus more compounds became
unavailable for absorption. Absorption of SMART-100 after IP injection with
Tween80/captex200 (80/20) formulation was slower than DMSO/PEG300 (80/20). The
former one had a tmax of 15 min vs. the later one of 1 min. That’s because the former
formulation delayed the release of compound. With the help of this new formulation, the
bioavailability was increased from 15% to 48%. 15 mg/kg of SMART-100 had 5.1-fold
area on under the curve (AUC) than the dose with 5 mg/kg. The other parameters like t1/2,
volume of distribution, and clearance also changed dramatically along with dose change.
This suggested that SMART-100 may have non-linear kinetics.
I next examined SMART-45 and SMART-211 at a dose level of 15 mg/kg with
the new formulation for IP injection. The plasma concentration-time profiles of SMART100 after single IV and IP administration are shown in panel A and B of Figure 4-11 and
Figure 4-12. The derived pharmacokinetic parameters are shown in Table 4-8. The IP
bioavailability of SMART-45 and –SMART-211 were 54% and 73% respectively. This
confirmed the new formulation’s ability to increase bioavailability. I then used this
formulation for our further in vivo xenograft studies, and no toxic effects were found in
the vehicle group of A375 xenograft models, suggesting that this formulation was safe to
use for long-term (more than one month) xenograft studies.
With the same dose of 15 mg/kg of SMART-45 and SMART-100, the parameters
of AUC (min•ng/mL), t1/2 (min), Vz (L/kg), and CL (mL/min/kg) were very close to each
other. That can be understood by their similarity of chemical structure and lipiphilicty.
SMART-211 has relative lower clearance and thus its terminal half life was relatively
longer. But overall SMART compounds exhibited high clearances and short half-life.
Once-daily regimen was designed to improve compounds exposure and treatment
efficacy for our xenograft studies.
The calculated clearances of SMART compounds are much higher than the mouse
hepatic blood flow rate. There maybe three reasons account for this. First, this may be
due to expetimental error. Especially when drug concentration is close to detection limit,
the measurement error is relatively large. Second, this may be due to incomplete tail vein
injection. The drug amount actually got into the vein may be is less then what we planned.
Third, SMART compounds may have extra-hepatic metabolism. For example, the
enzyme in the blood, speen, heart or other organs may be can metablize these compounds.
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Figure 4-10. Measured plasma concentration-time profiles (mean±SD) after bolus
administration of 15 mg/kg SMART-100 to ICR mice (n=3 per group).
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation,
DMSO:PEG300=80:20 (v/v). C: i.p. injection, formulation, Tween80:Captex200=80:20 (v/v).
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Figure 4-11. Measured plasma concentration-time profiles (mean±SD) after bolus
administration of 15 mg/kg SMART-45 to ICR mice (n=3 per group).
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation,
Tween80:Captex200=80:20 (v/v).
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Figure 4-12. Measured plasma concentration-time profiles (mean±SD) after bolus
administration of 15 mg/kg SMART-211 to ICR mice (n=3 per group).
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation,
Tween80:Captex200=80:20 (v/v).
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4.3.5 Antitumor Efficacy of SMARTs on A375 Xenograft Model
I examined 20 mg/kg of SMART-100 and 15 mg/kg of SMART-45 treatments on
A375 human melanoma xenograft model. Nude mice were administrated i.p. every day
for consecutive 32 days when the tumor size was ~150 mm3. As shown in Figure 4-13,
SMART-100 and SMART-45 exhibited significant inhibition of tumor growth. Summary
of the data was presented in Table 4-9. The average tumor size in control group increased
by about 13 folds. I obtained 4.8-fold and 4.2-fold tumor increases in SMART-100
treated (20 mg/kg) and SMART-45 treated (15 mg/kg) groups, respectively. SMART100 reduced tumor growth rate with a %TGI of 70% (20 mg/kg treatment), and SMART45 inhibited 72% (15 mg/kg treatment). I also calculated %T/C for our efficacy study.
With 20 mg/kg treatment of SMART-100 and 15 mg/kg treatment of SMART-45 on
A375 xenograft, I observed %T/C values of 36% and 33%, respectively. The data
indicated that SMART-100 and -45 were pretty active in inhibiting A375 xenografts
growth on athymic nude mice.
In the mean time, the general activities of mice in all groups were normal during
the treatment period. At the conclusion of the experiment, the group average body weight
increased by 3.1g for control group, 2.2g for SMART-45 treated group, and 2.4g for
SMART-100 treated group. Corrected by group average tumor weight, which were 1.3g
for control group, 0.6g for SMART-45 treated group, and 0.6g for SMART-100 treated
group, the net group body weight gain were 1.8g for control group, 1.6g for SMART-45
treated group, and 1.8g for SMART-100 treated group. One mouse in control group, one
mouse in SMART-100 treated group, and two mice in SMART-45 treated group died
during the experiment period. I also observed big hard lumps in the injection sites of dead
mice. So I guess the death of the mice was due to injection, not the toxicity of compounds
treatment. No any other acute toxicity phenomenon was observed.
4.4 Conclusions
We have discovered a new class of simple synthetic compounds based on a 2aryl-4-(3, 4, 5-trimethoxylbenzoyl)-thiazole molecular skeleton, which was derived from
thiazolidine ring modification of ATCAA structures. Chemical modification of different
substituted aryl in A and C rings and structure-activity relationship of the SMART were
investigated based on biological evaluation against melanoma cells in vitro. I have
demonstrated that SMARTs are very potent in inhibiting melanoma cell proliferation in
vitro. In the meantime, our data also showed SMARTs overcame multi-drug resistance in
drug resistant melanoma cell line, suggesting they are not substrates for P-gp. Mechanism
of action studies showed these compounds bound tubulin at the colchicine binding site
thus inhibit tubulin polymerization. The in vivo efficacy studies showed that SMARTs
significantly inhibited A375 melanoma tumor growth on nude mice xenograft models.
The dramatic biologic effect of SMARTs suggested that it has great potential for
melanoma chemotherapy.
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Figure 4-13. In vivo efficacy of SMARTs on nude mice bearing A375 melanoma
xenograft tumor (n=10 per group).
A375 cells (2.5106) were injected s.c. on the right flank. The compounds were given by
i.p. daily when tumor size was 150 mm3.
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Table 4-9. Summary of mice number, mice body weight change, and tumor size change
during in vivo efficacy experiment.

Groups
Vehicle
control
SMART-100,
20 mg/kg
SMART-45,
15 mg/kg

Number of
animals
Start End

Body weight (g)
Mean±SEM
Start
End

Tumor size (mm3)
Mean±SEM
Start
End

TGIa T/Cb

10

9

19±2

22±3

165±11

2183±279

N/A

10

9

19±2

21±2

160±15

775±107

70% 36%

10

8

19±2

21±3

164±12

722±135

72% 33%

a

N/A

TGI (tumor growth inhibition) were measured on the final day for drug-treated
compared with vehicle-treated mice and calculated as 100× {1-[(Treated, final Treated,day1)/(Control, final - Control, day1)]}.
b
T/C were generated from the mean-treated tumor volume on the final day divided by the
mean control tumor volume on the final day times 100.
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CHAPTER 5. NOVEL IMIDAZOLES TARGET TUBULIN POLYMERIZATION
AND OVERCOME MULTI-DRUG RESISTANCE IN METASTATIC
MELANOMA
5.1 Introduction
I have previously dicussed the discovery of substituted methoxylbenzoyl-arylthiazole (SMART) compounds that showed good anti-melanoma activity both in vitro
and in vivo (100). But poor solubility and fast metabolism were two major problems
associated with these compounds. After a thorough structure-activity relationship (SAR)
study and extensive lead compound modification, we discovered a new class of
compounds: 2-aryl-4-benzoyl-imidazoles (ABIs). The general structure of this class of
compounds is shown in Figure 5-1. Mr. Jianjun Chen used an imidazole ring to replace a
thiazole ring for the following two reasons: (a) To increase water solubility. The
imidazole ring has a lower LogP value and a higher pKa value compared with the
thiazole ring. Thus, imidazole compounds are more hydrophilic and more basic. It is also
easier to make them into salt, thereby further increasing water solubility. (b) To increase
metabolic stability. The thiazole ring is liable to oxidation, so it can make the whole
molecule unstable to cytochrome enzymes (133).
To our great satisfaction, I have identified experimentally two advantages of ABIs
over SMART compounds: (a) slightly increased in vitro activity. The IC50s of some ABIs
were in the low nanomolar range on several melanoma cell lines. (b) I have discovered
that the trimethoxyphenyl substituent can be replaced by a metabolically more stable pfluorophenyl ring and retain good anticancer activity. In this chapter, I will summarize
more findinga about ABIs such as their effect on MDR melanoma cells, effect on
melanoma colony formation, and in vivo anti-melanoma efficacy. I also will explain how
we identify the cellular target of ABIs.
5.2 Materials and Methods
5.2.1 Compounds and Reagents
Compound ABI-270 {IUPAC name: (4-Fluoro-phenyl)-[2-(4-methoxy-phenyl)1H-imidazol-4-yl]-methanone}, compound ABI-274 [IUPAC name: (2-p-Tolyl-1Himidazol-4-yl)-(3,4,5-trimethoxy-phenyl)-methanone], and compound ABI-288 {IUPAC
name: [2-(4-Chloro-phenyl)-1H-imidazol-4-yl]-(4-fluoro-phenyl)-methanone} were
synthesized by Mr. Jianjun Chen in our lab. Bortezomib was obtained from Millennium
Pharmaceuticals, Inc. (Kansas City, MO) through a material transfer agreement.
Compound ABT-751 was synthesized by Dr. Yan Lu. Paclitaxel, vinblastine, colchicine,
dimethyl sulphoxide (DMSO), and Tween 80 were obtained from Sigma-Aldrich (St.
Louis, MO). Captex 200 was obtained from ABITEC Corporation (Paris, IL). CellTiter
96® AQueous One Solution Reagent was obtained from Promega Corporation (Madison,
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Figure 5-1. Structures of SMART, ABI, and three representative ABI compounds: ABI270, 274, and 288.
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WI). DTIC for injection, USP (a formulation for human use), was obtained from APP
Pharmaceuticals, LLC (Schaumburg, IL).
5.2.2 Cell Culture
The A375 and B16-F1 melanoma cancer cells were obtained from American Type
Culture Collection. WM-164 cells were derived from patient metastatic melanoma
tumors and were a gift from Dr. Meenhar Herlyn (Wistar Institute, Philadelphia, PA).
The P-gp overexpressing multi-drug resistant cell line MDA-MB-435/LCC6MDRI and
matching sensitive parent cell line were kindly provided by Dr. Robert Clarke
(Georgetown University, Washington, DC). Cells were grown as monolayers by using
standard cell culture conditions. All cells were cultured in DMEM (Mediatech, Inc.,
Manassas, VA), supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA),
1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO), and bovine insulin (5
µg/mL) (Sigma-Aldrich, St. Louis, MO).
5.2.3 In Vitro Antiproliferative Activity Assay
The CellTiter 96® AQueous One Solution Cell Proliferation Assay was used to
determine the activity of each compound (please see reference Chapter 3 Section 3.2.5
Biological Assay and Data Processing, for details).
5.2.4 Colony Formation Assay in Soft Agar
B16-F1 melanoma cells were plated at a colony-forming density (2000 cells per
well on six-well plates) on top of 0.8% base agar. Cells were grown in 0.4% agar together
with DMEM medium supplemented with fetal bovine serum and an antibioticantimycotic solution at 37°C in an atmosphere of 95% air and 5% CO2 (93). Cells were
treated with compounds ABI-270, -274, and -288 at different concentrations (20, 100,
and 500 nM). Compounds were added to the media from 1-mM DMSO stock solutions,
and a corresponding dilution of DMSO was used as control. Cells were grown for 14
days. Plates were photographed, and the number of colonies was measured by Artek 880
Automated Colony Counter (Artek Systems Corporation, Farmingdale, NY).
5.2.5 Animals
Female C57BL/6NHsd mice, age 7-8 weeks, were obtained from Harlan
Laboratories, Inc. (Indianapolis, IN). Male double homozygous SCID hairless outbred
(SHO) mice, age 6-8 weeks, were obtained from Charles River Laboratories International,
Inc. (Wilmington, MA). The laboratory housing the animals met all Association for
Assessment and Accreditation and Laboratory Animal Care specifications. All of the
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procedures were conducted in accordance with the guidelines of our Institutional Animal
Care and Use Committee.
5.2.6 In Vivo Antitumor Study
For C57BL/6 mice, logarithmic growth phase B16-F1 (5×105) cells were injected
subcutaneously (s.c.) in the right dorsal flank. For SHO mice, logarithmic growth phase
A375 (5×107/mL) cells were prepared in phenyl red-free, FBS-free DMEM media and
mixed at 1:1 ratio with Matrigel (BD Biosciences, San Jose, CA). Tumors were
established by injecting 100 L of this mixture subcutaneously in the right dorsal flank of
each mouse (2.5106 cells per mouse). When the tumor reached a mean size of 100~150
mm3, mice were randomized into 4 groups for C57BL/6 mice and 3 groups for SHO mice
and treatments were started. The formulation of Tween80/Captex200 (80/20) was used to
prepare the compound solution. ABI-288 at 15 and 45 mg/kg was used for C57BL/6 mice
with intraperitoneal (i.p.) injection once daily for 13 days. ABI-288 at 25 mg/kg was used
for SHO mice with i.p. injection once daily for 31 days. Injection volume was 30 L. The
control group was given only a vehicle solution injection at the same frequency. DTIC
was reconstituted with sterile water according to drug usage instructions, and 100 L of
this solution was given i.p. to each mouse.
Tumor volume was measured three times a week with a Traceable® electronic
digital caliper (Fisher Scientific, Inc.) and calculated by using the formula a×b2×0.5,
where a and b represented the larger and smaller diameters, respectively (94). Tumor
volume was expressed as cubic millimeters. Data were expressed as mean±SD for each
group and plotted as a function of time. Tumor growth inhibition (TGI) at the conclusion
of the experiments was calculated from the formula 100-100*[(T-T0)/(C-C0)] where T
represented mean tumor volume of a treated group on a specific day, T0 represented
mean tumor volume of the same group on the first day of treatment, C represented mean
tumor volume of a control on a specific day, and C0 represented mean tumor volume of
the same group on the first day of treatment (95, 134). Animal general activity and
average body weight of each group were monitored during the entire experiment period
to assess compound acute toxicity. The statistical significance of observed differences
between growth curves was evaluated by Student’s t test. At the end of treatment, all
mice were euthanized by CO2, and tumors were harvested for further study.
5.2.7 Cell Cycle Analysis
Flow cytometry analysis was performed as described elsewhere to study cell
cycle phase distribution (95). A375 cells were cultured in 10 cm tissue culture dishes
until the confluence was about 80%, and then cells were treated with 0, 10, 50, 200, and
1000 nM of colchicine, ABI-270, -278, and -288 for 24 h in growth media. Cellular DNA
was stained with PBS containing 50 g/mL propidium iodide and 100 g/mL RNase A.
The cell cycle was determined using a BD LSR-II cytometer (BD Biosciences, San Jose,
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CA) with 10,000 cells scored. Data were analyzed and graphs were prepared using the
Modfit 2.0 program (Verity Software House, Topsham, ME).
5.2.8 In Vitro Tubulin Polymerization Assay
Bovine brain tubulin (0.4 mg) (Cytoskeleton, Denver, CO) was mixed with 10
M of tested compounds and incubated in 120 L of general tubulin buffer (80 mM
PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9, and 1 mM GTP). The absorbance of
wavelength at 340 nm was monitored every 60 s for 15 min by the SYNERGY 4
Microplate Reader (Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set
at 37C for tubulin polymerization.
5.2.9 Molecular Modeling
Dr. Li selected the crystal structure of N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine) in tubulin complex (PDB code: 1SA0) which has been
most widely used for modeling approaches (135-137). He used Schrodinger Molecular
Modeling Suite 2009 (Schrodinger LLC, New York, NY) for the docking practice. ABIs
were built and prepared using the Ligprep module, and they were docked into the
colchicine binding site using the Glide module in Schrodinger Suite. The best docking
complexes were subject to restricted molecular dynamics to release any strains by using
Macromodel module with OPLS-2005 force field. The ligand and its surrounding
residues within 15 Ǻ were allowed to move freely, while residues outside the 15-Ǻ radius
were kept rigid.
5.2.10 Tubulin Colchicine Site Binding Assay
Biotin-labeled tubulin (0.5 g/well) (Cytoskeleton, Inc., Denver, CO) was mixed
with [3H]colchicine (0.08 M) (PerkinElmer LLC., Shelton, CT) and various
concentrations of tested compounds in 96-well plates. The mixture was incubated at 37°C
in binding buffer [80 mM PIPES (pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2,
and 1 mM GTP] for 45 min with gentle shaking. At the end of incubation, Streptavidinlabeled SPA beads (80 g/well) (GE-healthcare Bio-Sciences Corp., Piscataway, NJ)
were added. Signals were read using a TopCount NXT scintillation counter (PerkinElmer
LLC, Shelton, CT). IC50 values (concentrations that inhibited 50% of tritiated colchicine
binding) were determined by nonlinear regression analysis with GraphPad Prism
(GraphPad Software, San Diego,CA).
5.2.11 Microtubule Imaging Using Immunofluorescence Microscope
Cellomics Cytoskeleton rearrangement kit (Thermo Scientific, Rockford, IL) was
used to get a visually appreciable proof of ABIs interacting with tubulin inside the cells.
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WM-164 melanoma cells were treated with each compound for 18 h in duplicate using a
collagen-coated 96-well plate (Becton Dickinson Labware, Bedford, MA). Then cells
were fixed with 4% paraformaldehyde (Thermo Scientific, Rockford, IL) and
permeabilized using permeabilization buffer supply from the kit. Primary antibody for
tubulin and fluorescence-labeled secondary antibody were subsequently added to the
cells. Cell nuclei were stained by DAPI. Whole Cell Stain Green was also applied to all
cells. All images were acquired with an Olympus IX71 inverted fluorescence microscope
(Olympus Corp., Tokyo, Japan) with overlays from separate images of tubulin (red),
nuclei (blue), and whole cells (green). For comparison, I also included paclitaxel,
colchicine and ABT-751, along with ABIs.
5.3 Results and Discussion
5.3.1 ABIs Have Great Potency on Melanoma Cell Lines
I tested ABI antiproliferative activity on three melanoma cell lines: A375, B16F1, and WM-164. A375 and WM-164 are malignant human melanoma cell lines. B16-F1
is a pigment-producing mouse melanoma cell line. In order to thoroughly study the SAR
for ABIs and look for the most efficacious compounds in this set, Mr. Jianjun Chen
extensively modified the structure and synthesized 55 imidazole analogs. In this
compound pool, I identified 29 active compounds that have IC50 values less than 10 µM
on the three selected melanoma cell lines. (The synthesis and SAR of ABIs will be
published in another chemistry-oriented article). Twelve very active compounds had IC50
values less than 100 nM. The most active one had IC50s less than 10 nM on A375 and
WM-164 cells. The structure of three representative compounds is shown in Figure 5-1. I
compared our ABIs’ activity with other anticancer drugs such as paclitaxel, vinblastine,
colchicine, bortezomib, and ABT-751 (Table 5-1). Paclitaxel and vinblastine are
clinically used anticancer drugs known to target cell tubulin (138, 139). Although
colchicine is not an FDA-approved drug for cancer treatment, its prodrug, ZD6126, is in
clinical trial for solid tumors (140). Bortezomib is the first therapeutic proteasome
inhibitor and was approved in 2003 by the FDA for use in multiple myeloma (141). ABT751 is known to target the tubulin colchicine binding site. It is a promising drug candidate
in clinical trial for children with relapsed or refractory neuroblastoma(142).
From our results, the three representative ABIs showed great potency on all three
tested melanoma cell lines with IC50s all less than 80 nM. The best compound, ABI-274,
was even more active than paclitaxel and colchicine on A375 and WM-164 cells. Its
potency was very close to that of bortezomib. Compared with ABT-751, ABI-274 was
about 60 times more potent (calculated by IC50 average of three melanoma cell lines).
The great in vitro potency of the ABIs suggests that they are very good candidates for
melanoma treatment.
Besides their great in vitro potency, another important improvement is that ABI270 and ABI-288 do not have a trimethoxy group in their structure but retain good
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Table 5-1. In vitro cytotoxic activity of representative ABI compounds and comparison
with other anticancer drugs.
IC50SEM (nM) (n=3)

Compound
name

A375

B16-F1

WM-164

ABI-270

31±5

63±7

28±3

ABI-274

9±2

46±5

8±2

ABI-288

52±4

73±6

74±9

Paclitaxel

123

172

183

Vinblastine

10

51

10

Colchicine

203

295

102

Bortezomib

81

242

81

ABT-751

1111108

2127351

66156
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activity. The lack of a trimethoxy group differentiated them chemically from previous
SMART compounds and colchicine, thereby overcoming the metabolic instability
drawback of the trimethoxy group.
5.3.2 SAR Studies
5.3.2.1 SAR of Substitutions on the C Ring
Please see Figure 5-1 for the designation of A, B, and C ring in ABI compounds.
A variety of compounds (5aa-5ai) with an un-substituted A-ring and different C ring
substituents generally showed moderate activity (Table 5-2), with IC50 values in the
micromolar range (unless specified, the IC50 value for a specific compound discussed in
the text is referred to as an average of all three cell lines). The most potent compound of
this series was 5aa with an average IC50 value of 160 nM. The removal of one of the
methoxy groups from the 3, 4, 5-trimethoxy on the C ring (5ad, 5ae) led to a significant
loss of activity (IC50>10 μM for 5ae and an IC50 of 3 μM for 5ad). This finding is
consistent with results from SMART compounds in which the 3, 4, 5-trimethoxy
substituted compound was most potent. It should be noted that the compound with 4fluoro on the C ring (5af) also showed relatively good activity (IC50=1 μM), a finding that
has an important implication, because replacing the trimethoxy moiety with a 4-fluoro
group may provide good activity and improved metabolic stability. Interestingly, the
position of the fluorine on the C ring was critical for activity because a shift from 4fluoro to 3-fluoro resulted in a total loss of activity (IC50>10 μM for 5ag compared with 1
μM for 5af). This result suggested that a potential hydrogen bond donor is present close
to the 4-position of this ring. As shown in the molecular modeling studies below, this
hydrogen bond donor is likely to be the thiol group in Cys-241 in loop 7 of the β-subunit
in α/β-tubulin dimer.
Other substituents such as methoxy and methyl at the 3 or 4 position on the C ring
(5ab, 5ac, 5ah, 5ai) were also evaluated, but none showed good activity (IC50>10 μM).
As clearly indicated in Table 5-2, the positions of the A and C rings were critical. A
simple shift of the C ring moiety from position 4 to position 1 in the imidazole ring (B
ring resulted in total loss of activity (IC50>10 μM for 5aba, 5aaa, 3a, 3x, 3j). This result is
consistent with recent reports in which the position of the aryl group was found to be
important for antiproliferative activity (143, 144). Bellina and co-workers reported potent
antitumor activity for a series of 1, 5- and 1, 2-diaryl-1H-imidazole analogs. While the 1,
5-diaryl-imidazole analogs have nanomolar activity, a simple shift of the diaryl
substitution from the 1, 5-position to 1, 2-position resulted in significantly lower activity
down to the micromolar range (143). Similarly, Wang and co-workers reported that 4, 5disubstituted and 1, 5-disubstituted imidazoles are much more active than the
corresponding 1, 2-disubstituted imidazoles (144).
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Table 5-2. In vitro cytotoxic activity of ABI compounds with B and C ring modification.
Structure

IC50SEM (μM) (n=3)
A375
B16-F1
WM-164
200±80
100±12
100±25
nM
nM
nM
>10
>10
>10
>10
>10
>10
3±1
5±1
2±0
>10
>10
>10
1±0
1±0
1±0
>10
>10
>10

ID

R

5aa

3,4,5-(OMe)3

5ab
5ac
5ad
5ae
5af
5ag

4-OMe
3- OMe
3, 5-(OMe)2
3, 4-(OMe)2
4-F
3-F

5ah

4-Me

>10

>10

>10

5ai

3-Me

>10

>10

>10

5aba

4-OMe

>10

>10

>10

>10

>10

>10

5aaa

3,4,5-(OMe)3

3a

H

>10

>10

>10

3x

4-NO2

>10

>10

>10

3j

4-OBn

>10

>10

>10
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5.3.2.2 SAR of Substitutions on the A Ring
Because compounds with 3, 4, 5-trimethoxy and 4-fluoro substitutions on the C
ring showed good activity, a series of compounds was synthesized with fixed
substitutions on the C ring (4-fluoro or 3, 4, 5-trimethoxy) and different substitutions on
the A ring (Table 5-3). These compounds demonstrated excellent antiproliferative
activity with IC50 values as low as 8 nM on WM-164 cell line (5da). In general,
compounds incorporating a single substituent on the para-position of the A ring were
more potent as can be seen from the activities of 5ca, 5cb, 5da, 5db, 5fa, 5fb, 5ga, and
5gb (IC50=8~110 nM). 5db-HCl salt (IC50=172 nM) showed slightly diminished activity
compared with the corresponding free base 5db (IC50=109 nM). Compound 5fb (IC50=64
nM), with a single halogen substituent in the para-position of the A and C rings,
demonstrated potent and was devoid of a methoxy moiety. Compounds with 3, 4, 5trimethoxy substituents on the A ring lost activity completely (IC50>10 μM for 5ea, 5eb),
suggesting very different binding environments near the A ring and C ring. Removal of
the 5-methoxy substituent from the A-ring improved activity significantly (IC50=330 nM
and >10 μM for 5ha, 5ea respectively). Demethylation of the 3, 4, 5-trimethoxy
decreased activity sharply from 43 nM (5fa) to 4 μM (6fa). Similar results were observed
for 6ea, 5ka, 5kb, and 6ha due to the demethylation of subsituents on either the A or C
ring. Electron-donating groups (4-methoxy, 4-dimethylamino, 4-methyl) and electronwithdrawing groups (4-chloro, 2-trifluoromethyl) on the A ring did not show substantial
differences in activity. The introduction of a trifluoromethyl group at the ortho position of
the A ring caused complete loss of activity (IC50>10 μM for 5ia, 5ib). The presence of a
benzoloxy group at the para position of A ring (IC50=75 nM for 5jb) resulted in a 440fold increase in activity when compared with the para-hydroxy compound 5kb (IC50=33
μM). It is worthwhile to note that compound 5jb, with the 4-fluoro in the C ring, has
better activity than does its counterpart 5ja, which has a 3, 4, 5-trimethoxy group in the C
ring (IC50 is 75 nM for 5jb, and 7 μM for 5ja).
5.3.2.3 SAR of Additional Substitutions on the B Ring
To our surprise, some of the compounds with a phenylsulfonyl protection group
attached to the nitrogen of the imidazole ring (4cb, 4db, 4fb, 4ga, 4gb, 4ha, 4jb) were also
very active with IC50 in the nanomolar range (Table 5-4).Generally the activities of these
compounds are comparable to their corresponding unprotected counterparts as
exemplified by comparing the activities of 4cb (43 nM), 4db (111 nM), 4fb (72 nM), 4ga
(285 nM), 4gb (87 nM), 4ha (268 nM), and 4jb (61 nM) with their corresponding
unprotected counterparts 5cb (36 nM), 5db (109 nM), 5fb (64 nM), 5ga (131 nM), 5gb
(72 nM), 5ha (330 nM), and 5jb (75 nM). Other compounds (4ab-4ag, 4ea, 4eb, 4hb, 4ia,
and 4ib, 1-50 μM) were generally much less active, also in line with their counterparts
(5ab-5ag, 5ea, 5eb, 5hb, 5ia, and 5ib, 1-50 μM).
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Table 5-3. In vitro cytotoxic activity of ABI compounds with A ring modification.
Structure

ID

4-F
4-OMe
4-OMe
4-Me
4-Me
5db-HCl
3,4,5-(OMe)3
5ea
3,4,5-(OMe)3
5eb
4-Cl
5fa
4-Cl
5fb
4-Cl
6fa
4-N(Me)2
5ga
4-N(Me)2
5gb
3,4-(OMe)2
5ha
3,4-(OMe)2
5hb
2-CF3
5ia
2-CF3
5ib
3,4,5-(OH)3
6ea
4-OBn
5ja
4-OBn
5jb
4-OH
5ka
4-OH
5kb
3,4-(OH)2
6ha
Colchicine
5ba
5ca
5cb
5da
5db

R1

N

NH

O

R2

R1

R2
3,4,5-(OMe)3
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OH)3
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OH)3
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OH)3
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IC50SEM (nM) (n=3)
A375
B16-F1 WM-164
205±19 320±41
73±8
30±5
108±12
31±4
31±5
63±7
28±3
9±2
46±5
8±2
142±13 222±10 156±19
108±11 297±23
112±9
4800
>10000 >10000
>10000 >10000 >10000
43±5
168±14
26±3
52±4
73±6
74±9
3900
1810
2100
82±9
361±29
80±11
56±7
129±11
62±8
113±14 1400±200 191±18
10000
4210
1400
>10000 >10000 >10000
>10000 >10000 >10000
>10000 >10000 >10000
5200
10000
5500
93±8
117±16
90±12
1600
2400
1800
10000 >10000 >10000
>10000 >10000 >10000
20±3
29±5
10±2

Table 5-4. In vitro cytotoxic activity of ABI compounds with protection on B ring.
Structure

R1

O
Ph S N
O
O

R2

N

ID

R1

4ab
4ac
4ah
4af
4ag
4cb
4db
4ea
4eb
4fb
4ga
4gb
4ha
4hb
4ia
4ib
4jb

H
H
H
H
H
4-OMe
4-Me
3,4,5-(OMe)3
3,4,5-(OMe)3
4-Cl
4-N(Me)2
4-N(Me)2
3,4-(OMe)2
3,4-(OMe)2
2-CF3
2-CF3
4-OBn

R2
4-OMe
3-OMe
4-Me
4-F
3-F
4-F
4-F
3,4,5-(OMe)3
4-F
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
3,4,5-(OMe)3
4-F
4-F
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IC50SEM (nM) (n=3)
A375
B16-F1 WM-164
>10000
>10000
>10000
>10000
>10000
>10000
>10000
>10000
>10000
630±72
946±86
596±61
>10000
>10000
>10000
36±5
71±8
43±6
113±14
287±31
107±14
>10000
>10000
>10000
3840
>10000
>10000
88±9
107±12
70±6
162±13 1200±90
308±32
55±7
242±26
56±4
192±15
970±68
139±15
960±59 2000±400 1400±30
>10000
>10000
>10000
>10000
>10000
>10000
64±7
110±15
48±5

5.3.3 ABIs Overcome Multi-Drug Resistance on Drug Resistant Melanoma Cells
Drug resistance is the major cause of cancer chemotherapy failure. One major
contributor to multi-drug resistance is overexpression of P-glycoprotein (P-gp). This
protein is a clinically important transporter protein belonging to the ATP-binding cassette
family of cell membrane transporters. It can pump substrates including anticancer drugs
out of tumor cells through an ATP-dependent mechanism (145). To test whether our
ABIs could overcome P-gp-mediated multi-drug resistance, Dr. Li obtained one P-gp
overexpressing human melanoma cell line, MDA-MB-435/LCCMDR1, and the matching
sensitive parent cell line from Dr. Robert Clarke at Georgetown University. I then tested
three representative compounds ABI-270, -274, and -288 on these two cell lines together
with colchicine, paclitaxel, and vinblastine. The dose response curves are shown in
Figure 5-2.The IC50 values and calculated resistance index are shown in Table 5-5. Big
distance between two curves for paclitaxel, vinblastine, and colchicine means they were
substrates for P-gp. The two curves of each ABI compound overlapped means they were
not substrates for P-gp and overcame multi-drug resistance.
The results clearly showed that cell line MDA-MB-435/LCCMDR1 was very
resistant to colchicine, paclitaxel, and vinblastine. But our ABIs showed equal potency to
the drug resistant cell line and the sensitive parent cell line. This result strongly suggests
that ABIs are not substrate for P-gp. Thus, they overcame the multi-drug resistance found
in MDA-MB-435/LCCMDR1 cells. Note that ABI-274 has a resistance index of 3,
meaning that MDA-MB-435/LCCMDR1 cells have some resistance to this compound. I
believe that the reason may be that ABI-274 has a trimethoxy-phenyl group, which makes
it partially chemically similar to colchicine.
5.3.4 ABIs Inhibit Melanoma Colony Formation in Soft Agar
Colony formation assay has been generally used to measure the sensitivity of
tumors to anticancer drugs. Results reflect the therapeutic efficacy of a drug (146). To
further measure ABIs’ anti-melanoma efficacy, I tested ABI-270, -274, and -288 on
melanoma colony formation in soft agar. Three different concentrations - 20, 100, 500
nM - were tested. Representative photos are shown in Figure 5-3. Quantified results are
shown in Figure 5-4. After 14 days of incubation, about 130 detectable colonies
(diameter larger than 100µm) were formed in controls (no treatment). Compounds ABI270 and -274 effectively inhibited B16-F1 melanoma colony formation even at the lowest
tested concentration, 20 nM (p<0.05 compared with control). ABI-288 showed effective
inhibition at 100 nM. All three tested compounds showed complete inhibition of colony
formation at 0.5 M, further proving ABIs’ anti-melanoma efficacy.
5.3.5 ABIs Inhibited Melanoma Tumor Growth In Vivo
Encouraged by ABIs’ good activity against melanoma cells and inhibition of
melanoma colony formation in soft agar, in vivo anti-melanoma activity of ABIs was
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Figure 5-2. Dose-response curves showed ABI compounds overcome multi-drug
resistance for melanoma compared with other anticancer drugs.
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Table 5-5. In vitro cytotoxic activity comparison of ABI compounds with other
anticancer drugs on multi-drug resistant melanoma cell line.

Compound
name

IC50SEM (nM) (n=3)

Resistance index
(R)*

MDA-MB-435

MDA-MB-435
/LCC6MDR1

Colchicine

101

65850

66

Paclitaxel

41

27741

69

Vinblastine

400100 pM

111

28

ABI-274

51

152

3

ABI-270

242

304

1

ABI-288

412

382

1

* Resistance indexes were calculated by dividing IC50 values on multi-drug resistant cell
line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive parent cell
line MDA-MB-435.
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Control

ABI-274 20nM

ABI-274 100nM

ABI-274 500nM

Control

ABI-270 20nM

ABI-270 100nM

ABI-270 500nM

Control

ABI-288 20nM

ABI-288 100nM

ABI-288 500nM

Figure 5-3. B16-F1 melanoma colony formation assay in soft agar for ABI compounds.
Compounds ABI-270 and 274 effectively inhibited B16-F1 melanoma colony formation
even at the lowest tested concentration 20 nM (p<0.05 compared with control). ABI-288
showed effective inhibition at 100 nM. All three tested compounds showed complete
inhibition for colony formation at 0.5 M.
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Compound ABI-270

Compound ABI--274
140

*

120

**
*

100

P<0.001
P<0.05

80

**

60
40
20
0

**
0

20

100

Number of Colonies

Number of Colonies

140

120

**

100

P<0.001
P<0.05

80
60
40
20
0

500

**
*

0

Concentration (nM)

20

**

**

100

500

Concentration (nM)

Compound ABI-288
Number of Colonies

140
120

**
*

100
80

P<0.001
P<0.05

**

60
40
20
0

**
0

20

100

500

Concentration (nM)

Figure 5-4. Quantified representation of colony formation assay using colony counter.
*p<0.05 compared with control. **p<0.001 compared with control.
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tested. Compound ABI-288 was chosen because it does not have a trimethoxy group and
its solubility is better than that of the others. Based on our previous study experience, two
dose levels, 15 and 45 mg/kg, were chosen. DTIC at 60 mg/kg was used as a positive
control according to the literature (109). B16-F1 melanoma allograft model on C57BL/6
mice was first chosen for study. After 13 days of treatment (Figure 5-5), ABI-288
inhibited melanoma tumor growth (TGI value) by 32% at 15 mg/kg and 82% at 45 mg/kg.
Student’s t test p value of ABI-288 at 45 mg/kg compared with control was less than
0.001, indicating a significant difference. The t test p value of ABI-288 at 15 mg/kg
compared with control was 0.08, suggesting that this dose was not effective. Comparing
ABI-288 at 45 mg/kg with DTIC at 60 mg/kg, which had a TGI of 51%, the t test p value
was about 0.001, suggesting that ABI-288 had substantially better activity than did DTIC.
I also observed a continuous average body weight loss in the ABI-288 45 mg/kg
treatment group. For the control and ABI-288 15 mg/kg treatment groups, average body
weight increased slightly throughout the experiment period.
To further confirm ABIs’ in vivo activity, A375 human melanoma xenograft
model on SHO mice was used, and ABI-288 at 25 mg/kg was tested. DTIC at a dose of
60 mg/kg was used as a positive control again. After 31 days of treatment (Figure 5-6),
ABI-288 inhibited melanoma tumor growth (TGI value) by 69%, whereas DTIC inhibited
growth by 52%. The t test p value of ABI-288 treatment versus control was less than
0.001, suggesting that ABI-288 significantly inhibited melanoma tumor growth at 25
mg/kg. The t test p value of ABI-288 treatment versus DTIC was less than 0.05,
suggesting again that ABI-288 had better activity than did DTIC. Average body weight of
all groups increased slightly throughout the experiment period. Physical activities for the
mice also looked normal, suggesting that 25 mg/kg was a well tolerated dose for SHO
mice.
5.3.6 ABIs Target Cell Tubulin at the Colchicine Binding Site
The cellular target of ABIs was determined by the following five experiments.
5.3.6.1 Cell Cycle Analysis
After identifying the great anti-melanoma potency of ABIs and their capability
for overcoming multi-drug resistance, our next goal was to determine the cellular target
of this class of compounds. Based on their high potency and behavior similarity with
other tubulin binding agents on melanoma cells, I hypothesized that these compounds
may also target tubulin. If our hypothesis were right, ABIs should arrest cells in the
G2/M phase, so I did a cell cycle analysis. I tested ABI-270, -274, and -288 together with
colchicine as a positive control on A375 cells. Four different concentrations - 10, 50, 200,
and 1000 nM - of each compound were chosen to show the dose effect (Figure 5-7 and
Figure 5-8). For controls (no treatment) without interference, about 16% of A375 cells
were distributed in the G2/M phase. For the colchicine treatment group, as concentration
increased from 10 nM to 50 nM, the percentage of cells distributed in the G2/M phase
117

7000
Control

Tumor volume (mm3)
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DTIC 60mg/kg
ABI-288 15mg/kg
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ABI-288 45 mg/kg
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16
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Days after inoculation
Figure 5-5. In vivo studies on C57BL/6 mice bearing B16-F1 melanoma allograft for
ABI-288.
ABI-288 inhibited melanoma tumor growth in a dose-dependent manner. Each mouse
received 0.5106 cells by s.c. injection into the flank. 30 µL i.p. daily treatments were
started when tumor size reached ~100 mm3. Control, vehicle solution only; points, means;
bars, SD. n=5 per group.
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3000
Tumor volume (mm3)

DTIC 60mg/kg
2500

ABI-288 25mg/kg
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Treatment
1000 starts
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0
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Days after inoculation
Figure 5-6. In vivo studies on SHO nude mice bearing A375 human melanoma xenograft
for ABI-288.
ABI-288 inhibited melanoma tumor growth in a dose-dependent manner. Each mouse
received 2.5106 cells by s.c. injection into the flank. 30 µL i.p. daily treatments were
started when tumor size reached ~150 mm3. Control, vehicle solution only; points, means;
bars, SD. n=5 per group.
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Colchicine (10nM)

Colchicine (50nM)

Colchicine (200nM)

Colchicine (1µM)

ABI-270 (10nM)

ABI-270 (50nM)

ABI-270 (200nM)

ABI-270 (1µM)

ABI-274 (10nM)

ABI-274 (50nM)

ABI-274 (200nM)

ABI-274 (1µM)

ABI-288 (10nM)

ABI-288 (50nM)

ABI-288 (200nM)

ABI-288 (1µM)

Figure 5-7. Cell cycle analysis of A375 cells after incubation with ABI compounds and
colchicine.
Colchicine arrested most cells into G2/M phase starting from 50 nM. ABI-270, 274, and
288 also arrested most cells into G2/M starting from 200, 50, and 200 nM respectively.
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100
Colchicine
ABI-270
Percentage of G2/M Phase

80

ABI-274
ABI-288

60

40

20

0
0

10
50
200
Compound Concentration (nM)

1000

Figure 5-8. Quantified graphic depiction of cell cycle analysis.
ABI-274 showed greater potency than colchicine in arresting cells into G2/M phase.
Although ABI-270 and 288 showed lower potency, they also arrested most cells into
G2/M phase at higher concentration.
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increased from 14% to 85%. ABIs had similar results for A375 cells, in arresting them in
the G2/M phase in a dose-dependent manner. The potency of the different concentrations
in arresting cells in the G2/M phase positively correlated with in vitro activity.
5.3.6.2 In Vitro Tubulin Polymerization Assay
The findings of the cell cycle analysis strongly supported our hypothesis and
guided us to test ABIs’ direct effect on tubulin polymerization. I conducted an in vitro
tubulin polymerization assay by using purified bovine brain tubulin monomer (Figure
5-9). Three tested compounds - ABI-270, -274, and -288 - all showed a strong inhibitory
effect on tubulin polymerization. At a concentration of 10 µM and 15 min of incubation,
the compounds inhibited tubulin polymerization to 17%, 3%, and 22%, respectively,
compared with control (5% DMSO was used in controls as a promoter for tubulin
polymerization and to compensate DMSO usage in compound testing). This microtubule
destabilization effect was similar to that of colchicine and vinblastine but was opposite to
that of paclitaxel. The results not only confirmed that ABIs can directly interact with
tubulin but also suggested that they may share the same binding site with colchicine or
vinblastine. Our next goal was to determine the exact binding site for our compounds.
5.3.6.3 Molecular Modeling
Based on the structure similarity of ABI compounds with colchicine and using
molecular modeling techniques, Dr. Li first tested whether our compounds could bind to
the colchicine binding site on tubulin (147, 148). All three compounds showed excellent
docking scores and their binding poses overlaps with the native ligand very well. As an
example, the binding mode of ABI-288 (stick model) is shown in Figure 5-10. For
comparison, he also displayed the native ligand DAMA-colchicine as a wire model in the
α/β-tubulin heterodimer. The overall structure of ABI-288 and DAMA-colchicine
overlapped very well. The p-Fluoro phenyl moiety overlaps with the trimethoxylpheny
moiety which is interacting with the T7 loop in the β-subunit. Similarly, the p-Chloro
phenyl moiety occupies the other side of the pocket where the seven-member ring of the
DAMA-colchicine is, with the chlorine atom occupying the pocket where the methoxy
moiety interacts. This exciting finding encouraged us to search further for more solid
experimental proof to confirm the binding.
5.3.6.4 Tubulin Colchicine Site Binding Assay
After comparison, rapid [3H]colchicine competition-binding scintillation
proximity assay (SPA) was chosen to confirm the binding site and to measure binding
affinity (131). This method uses SPA technology and requires a close association between
a solid-phase scintillant (the beads) and the radioligand for a signal to be emitted and
subsequently detected. Biotin tubulin was the reagent that brings the radioligand and the
scintillant into close association. When using tritiated colchicine as radioligand, the
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Figure 5-9. Three representative ABI compounds inhibited in vitro tubulin
polymerization at a concentration of 10 μM.
After 15 min incubation, ABI-274, 288, and 270 inhibited tubulin polymerization to 3%,
17%, and 22% respectively compared with control (5% DMSO in general tubulin buffer).
This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of
Pharmacy, the Ohio State University.
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Figure 5-10. Docking of ABI-288 into tubulin crystal structure at the colchicine binding
pocket.
Only the related secondary structures in tubulin are shown; ABT-751 is shown as a wire
model. The overall structure of ABI-288 and ABT-751 overlapped very well in the
binding pocket. The multiple interactions between ABI-288 and tubulin dimer suggested
that this compound may have high binding affinity to this pocket. This experiment was
done by Dr. Wei Li.
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amplitude of signal was proportional to the number of colchicine binding sites that were
occupied by this radioligand. When adding a competitor of radio-labeled colchicine, e.g.,
cold (unlabeled) colchicine, to the mixture, the signal amplitude decreased
proportionately with the concentration of the competitor. This method is very specific for
tubulin colchicine site binding competitors.
The binding graph (Figure 5-11) clearly shows that ABIs can competitively bind
to the tubulin colchicine binding site. As the concentration of the three tested compounds
increased from 0.03 µM to 100 µM, increased tritiated colchicine was competitively
stripped away from tubulin and emitted lower SPA counts. The negative control,
paclitaxel, gave only a flat line, because theoretically it should not bind to the colchicine
binding site on tubulin. Second, ABIs have relatively high binding affinity to the tubulin
colchicine binding site (Table 5-6). GraphPad Prism calculated IC50 values for binding
showed that ABI-274 has the highest binding affinity among the three tested compounds.
Its binding affinity was even higher than that of colchicine. The other two compounds,
ABI-270 and ABI-288, showed a little lower affinity to this site than did the natural
ligand colchicine, but they were still very close. Third, the binding affinity was positively
correlated to in vitro anti-melanoma activity; the higher the binding affinity, the higher
the anti-melanoma activity.
According to the Cheng-Prusoff equation, Ki=IC50/(1+D/Kd), where Ki is the
inhibition constant, D is the concentration of the radioligand, the Kd is the dissociation
constant of the radioligand to tubulin (149). In our experiment, the D value was 0.08 µM,
and the Kd value was around 1 µM according to the literature (131). So the IC50 was very
close to the Ki value. Our result was comparable with the Ki value reported in the
literature for colchicine binding to tubulin.
5.3.6.5 Microtubule Imaging Using Immunofluorescence Microscope
To obtain visual proof of ABIs interacting with tubulin inside the cells, I
examined microtubule arrangement in human melanoma WM-164 cells upon treatment
with different compounds (Figure 5-12). The microtubule images clearly showed that all
five tested compounds resulted in cytoskeleton rearrangement. There was a significant
difference between paclitaxel and the other four compounds (colchicine, ABT-751, ABI270, and 274). Treatment with paclitaxel resulted in a condensation of microtubules
orderly lying around the nuclei compared with controls, consistent with its mechanisms
of action for stabilizing microtubules. On the contrary, treatment with colchicine, ABT751, ABI-270, or 274 had similar effects on microtubules and resulted in some degree of
microtubule fragmentation, consistent with their common mechanism of action for
destabilizing microtubules. These results also confirmed that ABIs shared the same
cellular target with colchicine and induced the same cellular effect.
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Figure 5-11. [3H]colchicine competition-binding assay confirmed ABI compounds
competitively bound to tubulin at the colchicine binding site.
As concentration of these compounds increased from 0.03 µM to 100 µM, more and
more tritiated colchicine were competitively stripped away from tubulin. Thus gave out
lower and lower SPA counts. The negative control paclitaxel just gave out a flat line
because it didn’t bind to the colchicine binding site on tubulin. Each data point represents
an average of three replicates.
Table 5-6. Comparison of tubulin binding affinity and in vitro cytotoxic activity between
ABI compounds and known tubulin interacting drugs.

Compound name
ABI-270
ABI-274
ABI-288
Colchicine
Paclitaxel

IC50SEM (n=3)
For tubulin binding (µM) On A375 (nM)
32
200100 nM
42
21
N/A

N/A: not available
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31±5
9±2
52±4
203
123

Control

Colchicine (0.5µM)

Paclitaxel (0.5µM)

50µm
ABT‐751 (5µM)

ABI‐270 (0.5µM)

ABI‐274 (0.5µM)

Figure 5-12. Microscopic images of immunofluorescence labeled microtubules inside
melanoma cells after compounds treatment.
Treatment with paclitaxel resulted in condensation of microtubules nicely laying around
the nuclei compared with control, consistent with its mechanisms of action for stabilizing
microtubules. On the contrary, treatment with colchicine, ABT-751, ABI-270 or -274 all
had similar effect on microtubules, and resulted in some degree of microtubule
fragmentations, consistent with their common mechanism of action for destabilizing
microtubules.
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5.4 Conclusions
Our team synthesized a set of novel 2-aryl-4-benzoyl-imidazole (ABI) derivatives
that showed potent activity in a number of melanoma cell lines, as well as in a xenograft
model. The compounds inhibited tubulin polymerization by binding to the colchicine
binding site. Structure-activity-relationships were investigated by introducing different
substituents into the A and C rings. Compared with the earlier SMART compounds, ABI
analogs showed two improvements. Firstly, ABI compounds showed much better
resistance index (1) compared with colchicine (66), paclitaxel (69), and vinblastine (28).
The fact that ABIs can overcome multi-drug resistance suggests a promising future
development of more drug-like agents. Secondly, our in vivo study showed that
compound ABI-288 at a dose of 25 mg/kg gave better tumor suppression than that of
DTIC at a dose of 60 mg/kg.
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APPENDIX
Tubulin Ligand (Colchicine) Competition Assay Protocol
The basic approach to the assay is as follows
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

Set-up scintillation plate reader and warm plate in reader to 37°C.
Prepare compounds to 20x strength (1 mM) in G-PEM buffer plus 10% DMSO.
Prepare tritiated colchicine. Assay life 24 h.
Prepare biotin tubulin on ice. Assay life 4 h.
Prepare streptavidin beads. Assay life 24 h.
Prepare bead/tubulin mixture. Assay life 24 h.
Pipette 10 µL of compound into the wells.
Pipette 10 µL of tritiated colchicine into the wells.
Pipette 180 µL of bead/tubulin into the wells.
Incubate for 45 min at 37°C.
Read plate.
Extract the raw data and calculate percent inhibition.

Preparation of compounds
This step is performed before the tubulin is rehydrated because if there is an unforeseen
error or precipitation occurs, then the experiment can be aborted before rehydrating
tubulin. Prepare compound stocks at 20x final concentration (usually 1 mM) in 50%
DMSO, 50% Ethanol or G-PEM plus one of these solvents from 5~50% at room
temperature. The final organic solvent concentration should not exceed 2.5% (v/v).
Solubilizing agents such as SDS or Triton X100 can be used up to 0.1% and 1.0%
respectively. The concentration of compounds may vary depending on the nature of the
screen, 50 µM final concentration is recommended. The necessary controls are zero
compound concentration, 1mM colchicine for competition, and 1mM vinblastine for
noncompetitor.
Preparation of buffers
1.
2.

Reconstitute General Tubulin Buffer (BST01-010) with 100 mL of Milli-Q water
and place at 4°C for storage.
Resuspend GTP vial with 100 µL of water, aliquot into 10x10 µL and freeze at 70°C for storage.
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Preparation of tubulin protein, in 50 assay aliquots
1.
2.
3.
4.
5.
6.

Prepare 1 mL of ice cold G-PEM buffer: On ice, mix 1mL of General Tubulin
Buffer with 10 µL of GTP stock.
Resuspend 500 µg of T333 in 60 µL of ice cold G-PEM and place back on ice.
Microfuge for 5 min at 14,000g at 4°C.
Carefully pipette 55 µL of supernatant (avoiding the location where a very small
pellet might be located) into a clean tube on ice.
Pipette into 10x5 µL aliquots on ice, and drop freeze all of them into liquid
nitrogen.
Store at -70°C, where they are stable for 6 months.

Preparation of beads, enough for 50 assays
This step should be performed just prior to the assays because the change of buffer
decreases the shelf life of the beads to 24 h.
1.
2.
3.
4.
5.

Pipette 4.4 mg of Streptavidin-SPA beads into a 15 mL Falcon tube, centrifuge
3000 rpm for 10 min to pellet the beads.
Carefully pipette off the sup, leaving 100 µL liquid volume above the beads.
Resuspend in 5 mL of General Tubulin Buffer and centrifuge again.
Carefully pipette off the sup, leaving 100 µL liquid volume above the beads.
Resuspend the beads thoroughly in 9.5 mL of General Tubulin Buffer.

Preparation of tubulin-beads, enough for 50 assays
These tubulin loaded beads should be made just prior to assay because they will have a
life time of 24 h at 4°C.
1.
2.
3.
4.

Prepare 1mL of ice cold G-PEM buffer: On ice, mix 1 mL of General Tubulin
Buffer with 10 µL of GTP stock.
Rapidly defrost one vial of biotin tubulin by warming in Milli-Q water for 30
secs, then place on ice.
Dilute the vial of biotin tubulin with 500 µL of G-PEM buffer.
Pipette the entire volume of biotin tubulin into the 9.5 mL of beads, mix
thoroughly incubate on a slow 10 rpm rotator at 4°C for 30 min), then use
immediately, or up to 24 h thereafter if necessary (activity may drop by 40%
during this time). The tubulin-beads must be kept rotating if aliquots are going to
be used continuously over the 24 h period.
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Preparation of tritium colchicine, enough for 50 assays
Dilute 50 µL of [3H]colchicine (specific activity 20~80 Ci/mmole, 1.0 µCi/μL, original
stock concentration 5~10 µM) into 500ul of General Tubulin Buffer and mix well. This
makes a sub-stock of 0.5~1.0 µM and a final concentration in the reaction of 25~50 nM.
If the signal is too low this component can be increased upto fourfold this level, this is
particularly useful for non-HTS applications where more signal is required.
Material and equipment required
Material
Tritiated Colchicine
Streptavidin SPA beads
96-well plates Low PB Corning Costar Inc.
Equipment
Scintillation Counter Packard Instrument Inc. Tel: 1-800-762-4000 Topcount Microtplate
Reader
Scintillation counter plate reader set-up
Measurement type: Top
Sensitivity: Highest.
Read time per well: 10 seconds per read.
Shaking: 5 s medium, orbital.
Plate template: Griener GRE96fb (flat, black).
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Soft Agar Colony Assay Protocol
Preparation of 1.6% agar
1.
2.
3.
4.
5.
6.

Pre-warm 50 mL autoclave-safe glass bottles in a 40°C water bath.
Heat 1800 mL of deionized H2O in a 4 L flask with 2 L calibration to 80~90°C on
a hot plate. Use a glass petri cap to prevent evaporation.
Add 25 g of dry Agar to the flask containing the 80~90°C water. Stir with a glass
rod until lumps disappear.
While the flask is still being heated, adjust the volume to 2000 mL with H2O. Stir
until thoroughly mixed.
Add 40 mL of the 1.6% agar solution to each of the 100 mL bottles previously
held at 40°C. Cap bottles loosely.
Autoclave for 15 min on slow exhaust. Allow bottles to cool for a few minutes
then tighten caps. Store at room temperature or at 4°C.

Preparation of the 0.5% agar growth medium dishes
The directions provided below are for 100 mL of 0.5% Agar Growth Medium—enough
to prepare about 14~60 mm dishes. Volumes may be adjusted for larger sized dishes as
needed.
1.
2.
3.
4.
5.
6.

7.
8.

Prepare the Growth Medium at the desired concentration of FBS, and warm in a
44°C water bath.
Melt 40 mL of 1.6% agar in a microwave oven until just molten, swirling
intermittently. Remove the bottle as soon as the agar solution becomes clear.
Cool the 1.6% agar at room temperature for 2 to 3 min.
Place the bottle containing the agar in the 37°C water bath.
When both the Growth Medium and the 1.25% agar have reached 37°C, mix the
1.6% agar with the Growth Medium to make a 0.5% Agar Growth Medium
solution.
Pipette 6 mL of the 0.5% Agar Growth Medium mixture into each sterile 60 mm
petri dish. Avoid forming bubbles and spread the mixture evenly by slowly
rotating the dish. Note: Reagents such as TPA) or EGF should be added to the
0.5% Agar Growth Medium just before pipetting it into the petri dishes.
Typically, a final concentration of 10 ng/mL TPA or EGF is used. Control plates
to which the solvent (DMSO or water) for the TPA or EGF is added should also
be prepared.
Allow the 0.5% Agar Growth Medium layer to harden for 30 to 40 min at room
temperature in a sterile laminar flow hood.
Store the dishes overnight in a 37°C incubator or seal in a bag and store at 4°C.
The dishes can be stored this way for several days. Note: Refrigerated dishes
should be warmed to 37°C before use.
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Preparation of cell suspension and performing the over-agar assay
1.
2.
3.
4.
5.
6.
7.
8.

9.
10.
11.

Two or three days before the experiment, plate the cells in a screw-cap T-25 or T75 flask in a final volume of 10 to 15 mL of Cell Growth Medium.
Grow the cells in a 37°C, 5% CO2 humidified incubator until the cells are 80 to
90% confluent.
Wash the monolayer of cells in T-25 flask or T-75 flask twice with 1~2 mL of
Ca2+, Mg2+ free PBS, aspirating the PBS after each wash.
Add 1 mL of 0.03% Trypsin.
Incubate in a 37°C, 5% CO2 humidified incubator for 3 to 6 min or until 90% of
the cells are detached.
Add 1 mL of DMEM containing 10% heat-inactivated FBS (DMEM-FBS).
Gently resuspend cells with a sterile pipette three or four times to make a singlecell suspension. Note: Observe a sample of the suspension with a microscope to
confirm that it consists of single cells rather than clumps.
Determine the concentration of cells and adjust the suspension to 1×103 cells/mL
in DMEM-FBS. Note: If the cells are to be plated on the TPA- or EGF-containing
0.5% Agar Growth Medium, then TPA or EGF should be added to the cell
suspension just before transferring them onto the plates. The final concentration
of TPA or EGF should be 10 ng/mL.
Transfer 3 mL of the cell suspension (containing a total of 3×103 cells) to the
0.5% Agar Growth Medium plate and incubate at 37°C, 5% CO2.
Culture the cells on the 0.5% Agar Growth Medium plate for 14 to 21 days,
during which time colonies of transformed cells will form in the TPA- or EGFtreated dishes.
Count the number of cells in each colony and the number of colonies using a
microscope. Note: Each colony should contain more than eight cells.
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Cell Cycle Analysis Protocol
1.
2.
3.
4.
5.
6.
7.
8.

Human melanoma cells A375 were cultured into 10 cm tissue culture dishes till
80% confluence.
Serum starved for 24 h. Media was then replaced with media containing testing
compounds at different concentration or vector only in triplicates.
Cells were incubated with compounds for 6 h, trypsinized, and harvested by
centrifugation.
Cells were then washed with 1×PBS 3 times and resuspended in ice-cold 70%
ethanol at 4°C overnight.
Ethanol was removed by centrifugation and washing with 1×PBS 3 times.
Finally, cells were pelleted out of PBS and resuspended in 1mL PBS buffer
containing 100 µg/mL RNase A. cells were incubated at 37°C for 1 h.
After centrifuging cells and aspirating supernatant, resuspend cells in 500 µL of
propidium iodide (50 µg/mL) in PBS.
Cell cycle was determined using a BD LSR-II (BD Biosciences, San Jose, CA
USA) with a 10,000 cells scored. Data were analyzed and graphs were prepared
using the Modfit 2.0 program (Verity Software House, Topsham, ME).
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Tubulin Imaging Protocol
Solution preparation (per 96-well plate)
1.
2.

3.
4.
5.

6.

7.
8.
9.
10.

1X Wash Buffer: Add 30 mL 10X Wash Buffer to 270 mL ultrapure water. Store
buffer at 4°C for up to 7 days.
Fixation Solution: Add 5 mL of 16% formaldehyde solution to 15 mL of 1X
Wash Buffer and heat to 37°C in a water bath just before use. Pre-warming the
Fixation Solution is critical for maintaining cell integrity. Prepare solution just
before each assay.
1X Permeabilization Buffer: Add 2 mL of 10X Permeabilization Buffer to 18 mL
of the 1X Wash Buffer. Store this buffer at 4°C for up to 7 days.
1X Blocking Buffer: Add 10 mL of the 10X Blocking Buffer to 90 mL of 1X
Wash Buffer. Store buffer at 4°C for up to 7 days.
Primary Probe Solution: Reconstitute DY554-phalloidin (F-actin kits) by adding
110 μL for 10 units (550 μL for 50 units) of pure methanol and gently mixing.
Use the DY554-phalloidin immediately and promptly store any unused portion at
-20°C.
F-actin and tubulin kits (8402401, 8402402): Add 100 μL of DY554-phalloidin
and 6 μL of Tubulin Primary Antibody to 5.9 mL of 1X Blocking Buffer. Prepare
solution just before each assay. F-actin kits (8402501, 8402502): Add 6 μL of
DAPI, 100 μL of DY554-phalloidin to 5.9 mL of the 1X Blocking Buffer. Prepare
solution just before each assay.
For the tubulin kits (8402601, 8402602): Add 6 μL of Tubulin Primary Antibody
to 6 mL of the 1X Blocking Buffer. Prepare solution just before each assay.
Staining Solution (Secondary Antibody): F-actin and tubulin kits (8402401,
8402402): Add 6 μL of DAPI, 6 μL of the DyLight 649 Goat Anti-Mouse to 6 mL
of 1X Blocking Buffer. Prepare solution just before each assay.
For the tubulin kits (8402601, 8402602): Add 6 μL of DAPI and 6 μL of the
DyLight 549 Goat Anti-Rabbit to 6 mL of 1X Blocking Buffer. Prepare solution
just before each assay.
Whole Cell Stain Solution: Just before use, reconstitute the Whole Cell Stain
Green by adding 50 μL of DMSO to the tube and mixing. Add 12 μL of the stain
in DMSO to 12 mL of 1X Wash Buffer. Prepare solution just before each assay.
Use the Whole Cell Stain Solution immediately and discard the unused solution.
Whole Cell Stain Green in DMSO may be stored at -20°C for <1 week.

Protocol for the cytoskeletal rearrangement kit
1.

Dilute the cytochalasin D stock solution (e.g., 3 mM in DMSO) to 30 μM, or
other test compounds to appropriate concentration, in culture medium. Add 50 μL
of culture medium to the control wells. Add 50 μL of cytochalasin D in culture
medium to each treatment well (150 μL final). Incubate for 3 h at 37°C in 5%
CO2.
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2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

Aspirate culture medium and add 100 μL/well of warmed Fixation Solution.
Incubate plate in a fume hood at room temperature for 15 min. Using warm
(37°C) Fixation Solution is critical for maintaining cell integrity.
Aspirate Fixation Solution and wash plate twice with 100 μL/well of 1X Wash
Buffer.
Aspirate Wash Buffer, add 100 μL/well of 1X Permeabilization Buffer and
incubate for 15 min at room temperature.
Aspirate Permeabilization Buffer. Add 100 μL/well of 1X Blocking Buffer.
Incubate at room temperature for 15 min.
Aspirate Blocking Buffer and add 50 μL/well primary probe solutions. Incubate
for 1 h at room temperature. Note: For whole cell stain and F-actin kits, skip step
7 and 8.
Aspirate Primary Probe Solution and then wash twice with 100 μL/well of 1X
Blocking Buffer.
Aspirate Blocking Buffer and add 50 μL/well of Staining Solution (secondary
antibody). Incubate for 30 min protected from light at room temperature.
Aspirate solution and then wash plate three times with 100 μL/well of 1X Wash
Buffer.
Add 100 μL/well of Whole Cell Stain Solution. Incubate for 15 min protected
from light at room temperature.
Aspirate Whole Cell Stain Solution and wash plate three times with 100 μL/well
of 1X Wash Buffer.
Aspirate Wash Buffer and replace with 150 μL/well of 1X Wash Buffer.
Seal plate and evaluate on the ArrayScan HCS Reader. Store plates at 4°C.
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